Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same

Modified ADA2 proteins with enhanced adenosine deaminase activity address the immunosuppressive effects of adenosine, improving immune cell function and treating conditions associated with elevated adenosine levels.

CA3203273CActive Publication Date: 2026-11-10HALOZYME INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CA3203273
Authority / Receiving Office
CA · CA
Patent Type
Patents
Current Assignee / Owner
Priority Date
2014-10-14
Filing Date
2015-10-14
Publication Date
2026-11-10
Estimated Expiration
2035-10-14

AI Technical Summary

Technical Problem

Existing treatments for diseases associated with elevated adenosine levels, such as certain cancers and immune-related conditions, are inadequate due to the immunosuppressive effects of adenosine, which inhibit immune cell function and promote tumor growth.

Method used

Development of variant Adenosine Deaminase 2 (ADA2) proteins with specific amino acid modifications to enhance adenosine deaminase activity, reduce heparin binding, and increase thermal stability, thereby increasing the efficacy of adenosine metabolism and immune cell function.

Benefits of technology

The modified ADA2 proteins exhibit enhanced adenosine deaminase activity, leading to improved immune cell function and potential therapeutic benefits for conditions characterized by elevated adenosine levels, including increased T-cell activation and reduced tumor growth.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided herein are variant adenosine deaminase 2 (ADA2) proteins. Also provided are ADA2 conjugates and compositions containing an ADA2 protein or conjugate. Also provided are methods and uses of the ADA2 proteins or conjugates for treating diseases and conditions, such as a tumor or cancer, and in particular any disease or condition associated with elevated adenosine or other associated marker.
Need to check novelty before this filing date? Find Prior Art

Description

COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING SAME RELATED APPLICATIONS This application is a division of application 3126546, filed October 14, 2015. Benefit of priority is claimed to U.S. provisional application Serial No. 62 / 063,936, filed October 14, 2014, to Christopher Thanos, Lin Wang and H. Michael Shepard, entitled COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING SAME. FIELD OF THE INVENTION Provided are variant adenosine deaminase 2 (ADA2) proteins. Also provided are ADA2 conjugates and compositions containing an ADA2 protein or ADA2 conjugate. Also provided are methods and uses of the ADA2 proteins or conjugates for treating diseases and conditions, such as a tumor or cancer, and in particular any disease or condition associated with elevated adenosine or other associated marker. BACKGROUND Adenosine is a well-known effector of immune function. In T-cells, adenosine decreases T-cell receptor induced activation of NF-kB, and inhibits IL-2, IL-4, and IFN-γ. Adenosine decreases T-cell cytotoxicity, increases T-cell anergy, and increases T-cell differentiation to Fop3+ or Lag-3+ regulatory (T-reg) T-cells. On NK cells, adenosine is known to decrease IFN-y production, and suppress NK cell cytoxicity. Adenosine is known to block neutrophil adhesion and extravasation, decrease phagocytosis, and attenuate levels of superoxide and nitric oxide. Adenosine also decreases the expression of TNF-α, IL-12, and MIP-1α on macrophages, attenuates MHC Class II expression, and increases levels of IL-10 and IL-6. In addition, adenosine decreases phagocytosis and superoxide and nitric oxide levels on macrophages. Through these immune-related activities, and others, aberrant or accumulated levels of adenosine is associated with a number of diseases and conditions, including those in which the adenosine-mediated immunosuppressive effects play a role. Hence, there is a need for treatments of such diseases and conditions. SUMMARY Provided herein are variant Adenosine Deaminase 2 (ADA2) proteins or catalytically active portions thereof that contain a modification(s) in the sequence of amino acids of an unmodified ADA2 protein or a catalytically active portion thereof. In some embodiments, the unmodified ADA2 protein can include the sequence of amino acids set forth in SEQ ID NO:5, or a sequence of amino acids that can exhibit at least 85% sequence identity to the sequence of amino acids set forth in SEQ ID NO:5, or is a catalytically active portion thereof; the amino acid modification(s) are selected from among amino acid replacement(s), deletion(s) and insertion(s); and the variant ADA2, when in dimer form, can exhibit one or more properties selected from among increased adenosine deaminase activity, reduced heparin binding, longer serum half-life, altered pH optimum, increased thermal stability, altered receptor binding and hyperglycosylation compared to the corresponding dimer form of the unmodified ADA2 protein. A variety of amino acid modifications, including replacements, deletions and insertions are provided. It is understood that the discreet modifications that confer a particular activity or property can be combined; as in proteins effects of mutation or modifications generally are additive. Any of the variant ADA2 or catalytically active portion thereof provided herein that contains modifications, including replacements, deletions and insertions, and nucleic acids encoding the variant ADA2 or catalytically active portion thereof, can be used in any of the methods, compositions, conjugates, modified forms, vectors, cells, combinations, uses and compositions for use, and combinations for use, provided herein. In some embodiments, the variant ADA2 protein or catalytically active portion thereof, when in dimer form, exhibits increased adenosine deaminase activity or increased adenosine deaminase activity and reduced heparin binding. In some embodiments, the unmodified ADA2 protein is a homodimer, and the monomer form comprises the sequence of amino acid residues set forth in SEQ ID NO:5. In some embodiments, the variant ADA2 is a catalytically active portion of the variant ADA2 protein as provided herein, wherein the unmodified ADA2 protein is a homodimer of corresponding catalytically active portions of the polypeptide whose sequence is set forth in of SEQ ID NO:5, wherein corresponding portions are determined by alignment. In some embodiment, the ADA2 protein or catalytically active portion thereof does not contain a modification selected from among an amino acid replacement corresponding to H7R, G18A, G18R, G18V, I64T, A80D, H83Q, V90A, C108G, A120V, H121R, W133G, R125C, R140Q, K141R, R142W, P164L, P222L, W235S, H306R, E330G, W333G, V365L, Y424C, F464S or a deletion corresponding to R8- K14del --- , with numbering with reference to amino acid residues set forth in SEQ ID NO:5. In some embodiments, the unmodified ADA2 protein can include a sequence of amino acids that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the sequence of amino acids set forth in SEQ ID NO:5 or is a catalytically active portion thereof. For example, the unmodified ADA2 protein has at least 95% sequence identity with the sequence of amino acids set forth in SEQ ID NO:5 or with the corresponding catalytically active portion thereof. For example, the unmodified ADA2 protein includes the sequence of amino acids set forth in any of SEQ ID NOS:5, 326-334, 340, 375 or 380-383 or is a catalytically active portion thereof, or the unmodified ADA2 protein has a sequence of amino acids set forth in any of SEQ ID NOS:5, 326-334, 340, 375 and 380-383 or is a catalytically active portion thereof. In particular embodiments, the unmodified ADA2 protein includes the sequence of amino acids set forth in SEQ ID NO:5 or is a catalytically active portion thereof. In some embodiments, the catalytically active portion of the ADA2 protein can be an ADA2 protein that lacks all or a portion of the putative receptor binding (PRB) domain. For example, the catalytically active portion of the ADA2 protein can include the sequence of amino acids set forth in SEQ ID NOS:548-550. In some embodiments, the catalytically active portion of the unmodified ADA2 protein has the sequence set forth as residues 77-473 of the protein set forth in SEQ ID NO:5. In some embodiments, the variant ADA2 protein can include up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70 or more amino . acid modifications compared to the unmodified ADA2 protein. In some embodiments the variant ADA2 protein includes up to 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications. In some embodiments, the variant ADA2 protein does not contain the sequence of amino acids set forth in any of SEQ ID NOS:1, 5, 68, 286-302, 326-342 or 374-383 or catalytically active fragment thereof. In some embodiments, the primary amino acid sequence of the ADA2 protein variant is not the sequence of amino acids set forth in any of SEQ ID NOS:1, 5, 68, 286-302, 326-342 or 374-383. In some embodiments, the variant ADA2 protein, when in dimer form, exhibits adenosine deaminase activity to convert adenosine to inosine. In some embodiments herein, the variant ADA2 protein, when in dimer form, can exhibit a catalytic efficiency (<com:Math><semantics>kcat / KM<annotation encoding="application / x-tex">k_{cat} / K_{M}< / annotation>< / semantics>< / com:Math>) that is at least or at least about 5 x 10<com:Sup>3< / com:Sup> M<com:Sup>-1< / com:Sup>s<com:Sup>-1< / com:Sup>, 6 x 10<com:Sup>3< / com:Sup> M <com:Math><semantics>1s−1<annotation encoding="application / x-tex">^{1}\text{s}^{-1}< / annotation>< / semantics>< / com:Math>, 7 x 10<com:Math><semantics>3<annotation encoding="application / x-tex">^{3}< / annotation>< / semantics>< / com:Math> M<com:Math><semantics>−1s−1<annotation encoding="application / x-tex">^{-1}\text{s}^{-1}< / annotation>< / semantics>< / com:Math>, 8 x 10<com:Math><semantics>3<annotation encoding="application / x-tex">^{3}< / annotation>< / semantics>< / com:Math> M<com:Math><semantics>−1s−1<annotation encoding="application / x-tex">^{-1}\text{s}^{-1}< / annotation>< / semantics>< / com:Math>, 9 x 10<com:Math><semantics>3<annotation encoding="application / x-tex">^{3}< / annotation>< / semantics>< / com:Math> M<com:Math><semantics>−1s−1<annotation encoding="application / x-tex">^{-1}\text{s}^{-1}< / annotation>< / semantics>< / com:Math>, 1 x 10<com:Math><semantics>4<annotation encoding="application / x-tex">^{4}< / annotation>< / semantics>< / com:Math> M<com:Math><semantics>−1s−1<annotation encoding="application / x-tex">^{-1}\text{s}^{-1}< / annotation>< / semantics>< / com:Math>, 2 x 10<com:Math><semantics>4<annotation encoding="application / x-tex">^{4}< / annotation>< / semantics>< / com:Math> M<com:Math><semantics>−1s−1<annotation encoding="application / x-tex">^{-1}\text{s}^{-1}< / annotation>< / semantics>< / com:Math>, 3 x 10<com:Math><semantics>4<annotation encoding="application / x-tex">^{4}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>M−1s−1<annotation encoding="application / x-tex">M^{-1}s^{-1}< / annotation>< / semantics>< / com:Math>, 4 x 10<com:Sup>4< / com:Sup> <com:Math><semantics>M−1s−1<annotation encoding="application / x-tex">M^{-1}s^{-1}< / annotation>< / semantics>< / com:Math>, 5 x 10<com:Sup>4< / com:Sup> <com:Math><semantics>M−1s−1<annotation encoding="application / x-tex">M^{-1}s^{-1}< / annotation>< / semantics>< / com:Math>, 6 x 10<com:Sup>4< / com:Sup> <com:Math><semantics>M−1s−1<annotation encoding="application / x-tex">M^{-1}s^{-1}< / annotation>< / semantics>< / com:Math>, 7 x 10<com:Sup>4< / com:Sup> <com:Math><semantics>M−1s−1<annotation encoding="application / x-tex">M^{-1}s^{-1}< / annotation>< / semantics>< / com:Math>, 8 x 10<com:Sup>4< / com:Sup> <com:Math><semantics>M−1s−1<annotation encoding="application / x-tex">M^{-1}s^{-1}< / annotation>< / semantics>< / com:Math>, 9 x <com:Math><semantics>104M−1s−1<annotation encoding="application / x-tex">10^4 \,\mathrm{M}^{-1}\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>1×105M−1s−1<annotation encoding="application / x-tex">1 \times 10^5 \,\mathrm{M}^{-1}\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>2×105M−1s−1<annotation encoding="application / x-tex">2 \times 10^5 \,\mathrm{M}^{-1}\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>3×105M−1s−1<annotation encoding="application / x-tex">3 \times 10^5 \,\mathrm{M}^{-1}\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>4×105M−1s−1<annotation encoding="application / x-tex">4 \times 10^5 \,\mathrm{M}^{-1}\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>5×105M−1s−1<annotation encoding="application / x-tex">5 \times 10^5 \,\mathrm{M}^{-1}\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math> or greater. In some embodiments, the variant ADA2 protein, when in dimer form, can exhibit a thermal stability with a melting temperature (Tm) of at least 58°C. For example, the Tm of the ADA2 protein is at least 59°C, 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 68°C, 69°C, 70°C, 71°C, 72°C or greater. In some embodiments, the variant ADA2 protein can contain a modification(s) that is an amino acid replacement(s); and the variant ADA2 protein includes one or more amino acid replacement(s) at an amino acid position corresponding to amino acid residue 11, 13, 20, 22, 26, 86, 179, 217, 219, 221, 258, 262, 264, 266, 267, 277, 283, 296, 309, 317, 321, 352, 366, 371, 372, 373, 374, 403, 404, 405, 406, 441, 444, 452, 461, 469 or 470, with reference to amino acid positions set forth in SEQ ID NO:5. For example, the amino acid replacement(s) are positions corresponding to amino acid residue 11, 20, 219, 221, 262, 264, 366, 371, 372 or 452, with reference to amino acid positions set forth in SEQ ID NO:5. In some embodiments, the variant ADA2 protein can include one or more amino acid replacement(s) selected from among K11A, K11D, K11E, K13A, K13D, K13E, R20A, R20D, R20E, R20N, V22S, K26A, K26D, K26E, D86A, D86C, D86E, D86F, D86G, D86H, D86I, D86K, D86L, D86M, D86N, D86P, D86Q, D86R, D86S, D86T, D86V, D86W, D86Y, E179A, E179C, E179D, E179F, E179G, E179H, E179I, E179K, E179L, E179M, E179N, E179P, E179Q, E179R, E179S, E179T, E179V, E179W, E179Y, R217A, R217D, R217E, R219A, R219C, R219D, R219E, R219F, R219G, R219H, R219I, R219K, R219L, R219M, R219N, R219P, R219Q, R219S, R219T, R219V, R219W, R219Y, L221A, L221C, L221D, L221E, L221F, L221G, L221H, L221I, L221K, L221M, L221N, L221P, L221Q, L221R, L221S, L221T, L221V, L221W, L221Y, K258A, K258D, K258E, S262A, S262C, S262D, S262E, S262F, S262G, S262H, S262I, S262K, S262L, S262M, S262N, S262P, S262Q, S262R, S262T, S262V, S262W, S262Y, H264A, H264C, H264D, H264E, H264F, H264G, H264I, H264K, H264L, H264M, H264N, H264P, H264Q, H264R, H264S, H264T, H264V, H264W, H264Y, S266A, S266C, S266D, S266E, S266F, S266G, S266H, S266I, S266K, S266L, S266M, S266N, S266P, S266Q, S266R, S266T, S266V, S266W, S266Y, K267A, K267C, K267D, K267E, K267F, K267G, K267H, K267I, K267L, K267M, K267N, K267P, K267Q, K267R, K267S, K267T, K267V, K267W, K267Y, R277A, R277D, R277E, R283A, R283D, R283E, V296A, V296C, V296D, V296E, V296F, V296G, V296H, V296I, V296K, V296L, V296M, V296N, V296P, V296Q, V296R, V296S, V296T, V296W, V296Y, K309A, K309D, K309E, K317A, K317D, K317E, K321A, K321D, K321E, R352A, R352D, R352E, R366A, R366D, R366E, K371A, K371D, K371E, K371N, K372A, K372D, K372E, K372N, D373S, 1374S, T403N, G404N, H405S, P406S, R441A, R441D, R441E, K444A, K444D, K444E, K452A, K452D, K452E, K461A, K461D, K461E, K469A, K469D, K469E, K470A, K470D, K470E, with reference to amino acid positions set forth in SEQ ID NO:5. For example, the variant ADA2 protein contains one or more amino acid replacement(s) selected from among replacements corresponding to H264A; H264Q; H264N; H264G; R219K; R219Q; R219N; R219A; L221A; L221V; L221G; E179D; E179A; E179S; E179T; E179V; E179G; S262A; S262V; S262M; S262N; D86A; D86C; D86E; D86F; D86G; D86H; D86I; D86K; D86L; D86M; D86N; D86P; D86Q; D86R; D86S; D86T; D86V; D86W; D86Y; E179C; E179F; E179H; E179I; E179K; E179L; E179M; E179N; E179P; E179Q; E179R; E179W; E179Y; R219C; R219D; R219E; R219F; R219G; R219H; R219I; R219L; R219M; R219P; R219S; R219T; R219V; R219W; R219Y; L221C; L221D; L221E; L221F; L221H; L221I; L221K; L221M; L221N; L221P; L221Q; L221R; L221S; L221T; L221W; L221Y; S262C; S262D; S262E; S262F; S262G; S262H; S262I; S262K; S262L; S262P; S262Q; S262R; S262T; S262W; S262Y; H264C; H264D; H264E; H264F; H264I; H264K; H264L; H264M; H264P; H264R; H264S; H264T; H264V; H264W; H264Y; S266A; S266C; S266D; S266E; S266F; S266G; S266H; S266I; S266K; S266L; S266M; S266N; S266P; S266Q; S266R; S266T; S266V; S266W; S266Y; K267A; K267C; K267D; K267E; K267F; K267G; K267H; K267I; K267L; K267M; K267N; K267P; K267Q; K267R; K267S; K267T; K267V; K267W; K267Y; V296A; V296C; V296D; V296E; V296F; V296G; V296H; V296I; V296K; V296L; V296M; V296N; V296P; V296Q; V296R; V296S; V296T; V296W; and V296Y. In some embodiments, the variant ADA2 protein contains an amino acid replacement at one or both of positions corresponding to amino acid residue 219 and 262, with reference to amino acid positions set forth in SEQ ID NO:5. For Example, the variant ADA2 protein or catalytically active portion thereof contains the replacement corresponding to S262N or S262Q. In some embodiments, the variant ADA2 contains the replacement corresponding to S262N. In some embodiments, the variant ADA2 contains the replacement corresponding to R219K, R219Q, R219N or R219A. In other embodiments, the variant ADA2 contains the replacement corresponding to R219Q or the replacements R219Q / R20E. In other embodiments, the variant ADA2 contains the replacement corresponding to R219Q / S262N. For example, the variant ADA2 protein or catalytically active portion thereof contains modification(s) selected from among any of R219Q / S262N / --<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>N1 / --<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>A2 / --<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>S3, R219Q / S262N / R20N / V22S, R219Q / S262N / K371N / D373S, R219Q / S262N / K372N / I374S, R219Q / S262N / T403N / H405S, <com:Math><semantics>R219Q / S262N / G404N / P406S<annotation encoding="application / x-tex">R219Q / S262N / G404N / P406S< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R219Q / S262N / C105−T147del→(Gly)15<annotation encoding="application / x-tex">R219Q / S262N / C105-T147del \rightarrow (Gly)_{15}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R219Q / S262N / C105−T147del→(Gly)10,R219Q / S262N / C105−T147del→(Gly)7,<annotation encoding="application / x-tex">R219Q / S262N / C105-T147del \rightarrow (Gly)_{10}, R219Q / S262N / C105-T147del \rightarrow (Gly)_{7},< / annotation>< / semantics>< / com:Math> <com:Math><semantics>R219Q / S262N / C105−T147del→(Gly)5,R219Q / S262N / C105−T147del→(Gly)3,<annotation encoding="application / x-tex">R219Q / S262N / C105-T147del \rightarrow (Gly)_5, R219Q / S262N / C105-T147del \rightarrow (Gly)_3,< / annotation>< / semantics>< / com:Math> R219Q / S262N / R125N / P126A, R219Q / S262N / S127N / K129S, R219Q / S262N / P126N / E128T, R219Q / S262N / R112N / I114T, R219Q / S262N / I134N / L135C / L136T, R219Q / S262N / I134N / L135S / L136T, R219Q / S262N / R142N / Q144S, R219Q / S262N / E137N / Y139T, R219Q / S262N / P111N / G113S, R219Q / S262N / F119S, R219Q / S262N / F119K, R219Q / S262N / Y224R, R219Q / S262N / Y224N, R219Q / S262N / Y191S, 7 [Image disponible dans le document PDF, Image available in the PDF document] 3 8 [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 52F, R219Q / S262N / V296Y. In some embodiments, the variant ADA2 protein comprises the modifications selected from among R219Q / K11A / R20A, R219Q / K11A / R20A / K371A, R219Q / R20A / K371A, 219Q / K11A / K371A, S262N / K11A / R20A, S262N / K11A / R20A / K371A, S262N / R20A / K371A, <com:Math><semantics>S262N / K11A / K371A<annotation encoding="application / x-tex">S262N / K11A / K371A< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R219Q / C105−T147del→(Gly)n<annotation encoding="application / x-tex">R219Q / C105-T147del \rightarrow (Gly)n< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R219Q / V99−V99−V99−V99−V99−V99−V99−V99−V99−V99<annotation encoding="application / x-tex">R219Q / V99-V99-V99-V99-V99-V99-V99-V99-V99-V99< / annotation>< / semantics>< / com:Math> Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, R219Q / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, R219Q / N98-N156del, R219Q / C105-E148del, R219Q / C105-T147del, R219Q / V99-Q144del, S262N / C105- <com:Math><semantics>T147del→(Gly)n<annotation encoding="application / x-tex">T147del \rightarrow (Gly)n< / annotation>< / semantics>< / com:Math>, S262N / V99-Q144del<com:Math><semantics>→(GGGGS)n<annotation encoding="application / x-tex">\rightarrow (GGGGS)n< / annotation>< / semantics>< / com:Math>, S262N / C105- <com:Math><semantics>T147del→(GGGGS)n<annotation encoding="application / x-tex">T147del \rightarrow (GGGGS)n< / annotation>< / semantics>< / com:Math>, S262N / N98-N156del, S262N / C105-E148del, S262N / C105- T147del and S262N / V99-Q144del. In some embodiments, the variant ADA2 protein, when in dimer form, can exhibit increased adenosine deaminase activity. For example, the variant ADA2 protein, when in dimer form, can exhibit at least 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 225%, 250%, 300%, 350%, 400%, 450%, 500%, 600%, 700%, 800% or more activity of the corresponding dimer form of the unmodified ADA2 protein, wherein adenosine deaminase activity is assessed under the same conditions. In some embodiments, the variant ADA2 protein, when in dimer form, can exhibit a catalytic efficiency <com:Math><semantics>(kcat / KM)<annotation encoding="application / x-tex">(k_{cat} / K_M)< / annotation>< / semantics>< / com:Math> that is at least or at least about 1.2- fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2.0-fold, 2.2- fold, 2.5-fold, 3.0-fold, 3.5-fold, 4-fold, 4.5-fold, 5.0-fold, 6.0-fold, 7.0-fold, 8.0-fold, 9.0-fold, 10.0-fold or more compared to the catalytic efficiency (<com:Math><semantics>kcat / KM<annotation encoding="application / x-tex">k_{\text{cat}} / K_{\text{M}}< / annotation>< / semantics>< / com:Math>) of the corresponding dimer form of the unmodified ADA2 protein, wherein catalytic efficiency of adenosine deaminase activity is assessed under the same conditions. For example, the variant ADA2 protein, when in dimer form, can exhibit a catalytic efficiency (<com:Math><semantics>kcat / KM<annotation encoding="application / x-tex">k_{\text{cat}} / K_{\text{M}}< / annotation>< / semantics>< / com:Math>) that is at least or at least about 2 x 10<com:Sup>4< / com:Sup> M<com:Sup>-1< / com:Sup> s<com:Sup>-1< / com:Sup>, 3 x 10<com:Sup>4< / com:Sup> M<com:Sup>-1< / com:Sup> s<com:Sup>-1< / com:Sup>, 4 x <com:Math><semantics>104M−1s−1<annotation encoding="application / x-tex">10^4 \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, 5 x <com:Math><semantics>104M−1s−1<annotation encoding="application / x-tex">10^4 \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, 6 x <com:Math><semantics>104M−1s−1<annotation encoding="application / x-tex">10^4 \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, 7 x <com:Math><semantics>104M−1s−1<annotation encoding="application / x-tex">10^4 \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, 8 x <com:Math><semantics>104M−1s−1<annotation encoding="application / x-tex">10^4 \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, 9 x <com:Math><semantics>104M−1<annotation encoding="application / x-tex">10^4 \,\mathrm{M}^{-1}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>s−1<annotation encoding="application / x-tex">s^{-1}< / annotation>< / semantics>< / com:Math>, 1 x 10<com:Sup>5< / com:Sup> <com:Math><semantics>M−1<annotation encoding="application / x-tex">M^{-1}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>s−1<annotation encoding="application / x-tex">s^{-1}< / annotation>< / semantics>< / com:Math>, 2 x 10<com:Sup>5< / com:Sup> <com:Math><semantics>M−1<annotation encoding="application / x-tex">M^{-1}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>s−1<annotation encoding="application / x-tex">s^{-1}< / annotation>< / semantics>< / com:Math>, 3 x 10<com:Sup>5< / com:Sup> <com:Math><semantics>M−1<annotation encoding="application / x-tex">M^{-1}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>s−1<annotation encoding="application / x-tex">s^{-1}< / annotation>< / semantics>< / com:Math>, 4 x 10<com:Sup>5< / com:Sup> <com:Math><semantics>M−1<annotation encoding="application / x-tex">M^{-1}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>s−1<annotation encoding="application / x-tex">s^{-1}< / annotation>< / semantics>< / com:Math>, 5 x 10<com:Sup>5< / com:Sup> <com:Math><semantics>M−1<annotation encoding="application / x-tex">M^{-1}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>s−1<annotation encoding="application / x-tex">s^{-1}< / annotation>< / semantics>< / com:Math> or greater. In some embodiments, the variant ADA2 protein or catalytically active portion thereof contains the modifications selected from among K371D / V99- <com:Math><semantics>Q144del→(GGGGS)1,K371D / V99−Q144del→(GGGGS)2,<annotation encoding="application / x-tex">Q144del \rightarrow (GGGGS)_1, K371D / V99-Q144del \rightarrow (GGGGS)_2,< / annotation>< / semantics>< / com:Math> <com:Math><semantics>K371D / V99−Q144del→(GGGGS)3,K371D / C105−T147del→(GGGGS)1,<annotation encoding="application / x-tex">K371D / V99-Q144del \rightarrow (GGGGS)_3, K371D / C105-T147del \rightarrow (GGGGS)_1,< / annotation>< / semantics>< / com:Math> <com:Math><semantics>K371D / C105−T147del→(GGGGS)2,K371D / C105−T147del→(GGGGS)3,<annotation encoding="application / x-tex">K371D / C105-T147del \rightarrow (GGGGS)_2, K371D / C105-T147del \rightarrow (GGGGS)_3,< / annotation>< / semantics>< / com:Math> <com:Math><semantics>R219Q / S262N / −−→N1 / −−→A2 / −−→S3<annotation encoding="application / x-tex">R219Q / S262N / --\rightarrow N1 / --\rightarrow A2 / --\rightarrow S3< / annotation>< / semantics>< / com:Math>, K371D / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)n, <com:Math><semantics>K371D / C105−T147del→(Gly)15,K371D / C105−T147del→(Gly)10,K371D / C105−<annotation encoding="application / x-tex">K371D / C105-T147del \rightarrow (Gly)_{15}, K371D / C105-T147del \rightarrow (Gly)_{10}, K371D / C105-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>T147del→(Gly)7<annotation encoding="application / x-tex">T147del \rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math>, K371D / C105-T147del<com:Math><semantics>→(Gly)5<annotation encoding="application / x-tex">\rightarrow (Gly)_5< / annotation>< / semantics>< / com:Math>, K371D / C105-T147del<com:Math><semantics>→(Gly)3<annotation encoding="application / x-tex">\rightarrow (Gly)_3< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>K371D / V99−Q144del→(GGGGS)n,K371D / C105−T147del→(GGGGS)n,<annotation encoding="application / x-tex">K371D / V99-Q144del \rightarrow (GGGGS)n, K371D / C105-T147del \rightarrow (GGGGS)n,< / annotation>< / semantics>< / com:Math> K371D / N98-N156del, K371D / C105-E148del, K371D / C105-T147del and K371D / V99-Q144del. In some embodiments, the variant ADA2 protein or catalytically active portion thereof contains modifications selected from among R125N / P126A, S127N / K129S, P126N / E128T, R112N / I114T, I134N / L135C / L136T, I134N / L135S / L136T, R142N / Q144S, E137N / Y139T, P111N / G113S, F119S, F119K, Y224R, Y224N, Y191S, Y191D, F183K, Y191D / Y224R, F109S, F109A, R118D, R118A, Y139T, Y139A, W133S, W133T, P124A, P124S, V99-Q144del, V99- <com:Math><semantics>Q144del→(GGGGS)n,C105−T147del→(GGGGS)n,V99−Q144del→(GGGGS)1,<annotation encoding="application / x-tex">Q144del \rightarrow (GGGGS)n, C105-T147del \rightarrow (GGGGS)n, V99-Q144del \rightarrow (GGGGS)_1,< / annotation>< / semantics>< / com:Math> <com:Math><semantics>V99−Q144del→(GGGGS)2,V99−Q144del→(GGGGS)3,C105−T147del→(GGGGS)1,<annotation encoding="application / x-tex">V99-Q144del \rightarrow (GGGGS)_2, V99-Q144del \rightarrow (GGGGS)_3, C105-T147del \rightarrow (GGGGS)_1,< / annotation>< / semantics>< / com:Math> C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)<com:Sub>2< / com:Sub>, and C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)<com:Sub>3< / com:Sub>. In some embodiments, the variant ADA2 protein or catalytically active portion thereof contains modifications selected from among R125N / P126A, S127N / K129S, P126N / E128T, R112N / I114T, I134N / L135C / L136T, I134N / L135S / L136T, R142N / Q144S, E137N / Y139T, P111N / G113S, F119S, F119K, Y224R, Y224N, Y191S, Y191D, F183K, Y191D / Y224R, F109S, F109A, R118D, R118A, Y139T, Y139A, W133S, W133T, P124A, P124S, V99-Q144del, V99-Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, <com:Math><semantics>C105−T147del→(GGGGS)n,V99−Q144del→(GGGGS)1,V99−Q144del→(GGGGS)2,<annotation encoding="application / x-tex">C105-T147del \rightarrow (GGGGS)n, V99-Q144del \rightarrow (GGGGS)_1, V99-Q144del \rightarrow (GGGGS)_2,< / annotation>< / semantics>< / com:Math> <com:Math><semantics>V99−Q144del→(GGGGS)3,C105−T147del→(GGGGS)1,C105−T147del→(GGGGS)2<annotation encoding="application / x-tex">V99-Q144del \rightarrow (GGGGS)_3, C105-T147del \rightarrow (GGGGS)_1, C105-T147del \rightarrow (GGGGS)_2< / annotation>< / semantics>< / com:Math> and C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)<com:Sub>3< / com:Sub>. For example, among such variant ADA2 proteins are any that include one or more amino acid replacement(s) at an amino acid position corresponding to amino acid residue 11, 20, 219, 221, 262, 264, 366, 371, 372 or 452, with reference to amino acid positions set forth in SEQ ID NO:5. For example, the variant ADA2 protein can include one or more amino acid replacement(s) selected from among K11A, K11E, R20A, R20E, R219K, R219Q, L221A, L221V, L221G, S262N, H264Q, H264G, R366E, K371A, K371D, K371E, K372D, K372E, K452D and K452E, with reference to amino acid positions set forth in SEQ ID NO:5. In some embodiments, the variant ADA2 protein can include amino acid replacements selected from among K11A / R20A, K11A / R20A / K371A, R20A / K371A, K11A / K371A, S262N / K371D, S262N / K371E, S262N / R20E, S262N / R20E / K371D, S262N / R20E / K371E, R219Q / K371E, R219Q / K371D, R219Q / R20E, R219Q / K371E / R20E, R219Q / K371D / R20E, R219Q / S262N / K371E, R219Q / S262N / K371D, R219Q / S262N / R20E, R219Q / S262N / K371E / R20E, R219Q / S262N / K371D / R20E and R219Q / S262N, with reference to amino acid positions set forth in SEQ ID NO:5. In some embodiments, the variant ADA2 protein, when in dimer form, can exhibit reduced heparin binding. For example, the variant ADA2 protein, when in dimer form, can exhibit no more than 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% of the heparin binding of the corresponding dimer form of the unmodified ADA2 protein, wherein heparin binding is assessed under the same conditions. For example, among such the variant ADA2 proteins are any that include one or more amino acid replacement(s) at an amino acid position corresponding to amino acid residue 20, 262, 366, 371, 372, or 452, with reference to amino acid positions set forth in SEQ ID NO:5. For example, the variant ADA2 protein can include one or more amino acid replacement(s) selected from among R20A, R20D, R20E, S262N, R366A, R366D, R366E, K371A, K371D, K371E, K372A, K372D, K372E and K452E, with reference to amino acid positions set forth in SEQ ID NO:5. In some embodiments, the variant ADA2 protein can include amino acid replacements selected from among K11A / R20A, K11A / R20A / K371A, R20A / K371A, K11A / K371A, S262N / K371D, S262N / K371E, S262N / R20E, S262N / R20E / K371D and S262N / R20E / K371E, with reference to amino acid positions set forth in SEQ ID NO:5. In some embodiments, the variant ADA2 protein or catalytically active portion thereof contains one or more amino acid replacement(s) corresponding to K11A; K11D; K11E; K13A; K13D; K13E; K371A; K371D; K371E; K372A; K372D; K372E; K452A; K452D; K452E; R20A; R20D; R20E; R366A; R366D; R366E; K26A; K26D; K26E; R217A; R217D; R217E; K258A; K258D; K258E; R277A; R277D; R277E; R283A; R283D; R283E; K309A; K309D; K309E; K317A; K317D; K317E; K321A; K321D; K321E; R352A; R352D; R352E; R441A; R441D; R441E; K444A; K444D; K444E; K461A; K461D; K461E; K469A; K469D; K469E; K470A; K470D; and K470E. In some embodiments, the variant ADA2 protein, when in dimer form, can exhibit a longer serum half-life <com:Math><semantics>(t1 / 2)<annotation encoding="application / x-tex">(t_{1 / 2})< / annotation>< / semantics>< / com:Math>. For example, the variant ADA2, when in dimer form, can exhibit a half-life that is at least or at least about 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 225%, 250%, 300%, 350%, 400%, 450%, 500%, 600%, 700%, 800% or more longer than the half-life of the corresponding dimer form of the unmodified ADA2 protein, wherein half-life is assessed under the same conditions. In some embodiments, the variant ADA2 protein, when in dimer form, can exhibit increased thermal stability. For example, the variant ADA2 protein, when in dimer form, can exhibit thermal stability with a melting temperature (Tm) that is increased at least or at least about 0.5°C, 1.0°C, 2.0°C, 3.0°C, 4.0°C, 5.0°C, 6.0°C, 7.0°C, 8.0°C, 9.0°C, 10.0°C or more compared to the Tm of the corresponding dimer form of the unmodified ADA2 protein, wherein Tm is assessed under the same conditions. For example, the variant ADA2 protein can have a melting temperature (Tm) of at least or at least about 67.6°C, 67.8°C, 68.0°C, 68.2°C, 68.4°C, 68.6°C, 68.8°C, 69.0°C, 69.2°C, 69.4°C, 69.6°C, 69.8°C, 70.0°C, 70.2°C, 70.4°C, 70.6°C, 70.8°C, 71.0°C, 71.2°C, 71.4°C, 71.6°C, 71.8°C or higher. In examples of any of the variant ADA2 proteins provided herein, the adenosine deaminase activity of the variant ADA2 protein can be assessed or exhibited at or about pH <com:Math><semantics>6.5±0.2<annotation encoding="application / x-tex">6.5 \pm 0.2< / annotation>< / semantics>< / com:Math>. In some examples, the variant ADA2 protein, when in dimer form, can exhibit an altered pH optimum for adenosine deaminase activity. For example, the variant ADA2 protein, when in dimer form, can exhibit a pH optimum for adenosine deaminase activity that is at a higher pH compared to the pH optimum of the corresponding dimer form of the unmodified ADA2 protein. For example, the variant ADA2 protein, when in dimer form, can have a pH optimum with a pH that is at least or at least about 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5 or higher. In other examples, the variant ADA2 protein, when in dimer form, can exhibit a pH optimum for adenosine deaminase activity that is at a lower pH compared to the pH optimum of the corresponding dimer form of the unmodified ADA2 protein. For example, the variant ADA2 protein, when in dimer form, can have a pH optimum with a pH that is less than or less than about 6.5, 6.4, 6.3, 6.3, 6.2, 6.1, 6.0 or less. In some embodiments, the variant ADA2 protein can include a modification of one or more amino acids in the putative receptor binding (PRB) domain, wherein the modification is an amino acid deletion, insertion or replacement. In any of such examples, the variant ADA2 protein does not contain a modification that is an amino acid replacement corresponding to amino acid replacement C108G, A120V, H121R, R125C, R140Q, K141R or R142W, with reference to amino acid positions set forth in SEQ ID NO:5. In some embodiments, the variant ADA2 protein or catalytically active portion thereof lacks all or a portion of the putative receptor binding (PRB) domain or has a modification of the PRB, whereby any receptor binding or growth factor activity is reduced or eliminated or other activity of ADA2 other than deaminase activity is reduced or eliminated or interaction with the ADA domain is reduced or eliminated and the PRB domain corresponds to residues 98 to 156 set forth in SEQ ID NO:5. In some embodiments, the variant ADA2 lacks residues 105-148 or 105 to 147 or 99 to 144, with reference to amino acid positions set forth in SEQ ID NO:5. In some examples, the variant ADA2 protein or catalytically active portion thereof contains the sequence of amino acids set forth in any of SEQ ID NOS:548-550 and 579. In some embodiments, variant ADA2 protein or catalytically active portion thereof contains a deletion of all or a portion of the PRB domain and optionally an insertion of peptide linker. In some examples, the variant ADA2 protein can have a deletion of one or more contiguous amino acid residues corresponding to any one or more contiguous amino acid residues between or between about amino acid residues 98 and 156 or amino acid residues 105 and 148, inclusive, with reference to amino acid positions set forth in SEQ ID NO:5. In any of such examples, the variant of the ADA2 polypeptide can further include substitution of the deleted region with a peptide linker. For example, the peptide linker can be selected from among (Gly)n (SEQ ID NO:368), where n is 2 to 20; (GGGGS)n (SEQ ID NO:343), where n is 1 to 6; (SSSSG)n (SEQ ID NO:344), where n is 1 to 6; (AlaAlaProAla)n (SEQ ID NO:350), where n is 1 to 6; GKSSGSGSESKS (SEQ ID NO:345); GGSTSGSGKSSEGKG (SEQ ID NO:346); GSTSGSGKSSSEGSGSTKG (SEQ ID NO:347); GSTSGSGKPGSGEGSTKG (SEQ ID NO:348); and EGKSSGSGSESKEF (SEQ ID NO:349). For example, the peptide linker can be selected from among GGG (SEQ ID NO:369); GGGGG (SEQ ID NO:360); GGGGGGG (SEQ ID NO:370); GGGGGGGGGG (SEQ ID NO:371); and GGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG In some embodiments, the variant ADA2 can contain the variant ADA2 polypeptide that can include a modification in the PRB domain that corresponds to C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>n< / com:Sub>, where n is 2 to 20, such as C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>15< / com:Sub>, C105- <com:Math><semantics>T147del→(Gly)10,C105−T147del→(Gly)7,C105−T147del→(Gly)5 or C105−<annotation encoding="application / x-tex">T147del \rightarrow (Gly)_{10}, C105-T147del \rightarrow (Gly)_7, C105-T147del \rightarrow (Gly)_5 \text{ or } C105-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>T147del→(Gly)3<annotation encoding="application / x-tex">T147del \rightarrow (Gly)_3< / annotation>< / semantics>< / com:Math> with reference to amino acid positions set forth in SEQ ID NO:5. In some embodiments, the variant ADA2 can include modification in the PRB domain that corresponds to C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)n, where n = 2 to 20; C105- <com:Math><semantics>T147del→(Gly)15<annotation encoding="application / x-tex">T147del \rightarrow (Gly)_{15}< / annotation>< / semantics>< / com:Math>; C105-T147del <com:Math><semantics>→(Gly)10<annotation encoding="application / x-tex">\rightarrow (Gly)_{10}< / annotation>< / semantics>< / com:Math>; C105-T147del <com:Math><semantics>→(Gly)7<annotation encoding="application / x-tex">\rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math>; C105- <com:Math><semantics>T147del→(Gly)5<annotation encoding="application / x-tex">T147del \rightarrow (Gly)_5< / annotation>< / semantics>< / com:Math>; C105-T147del <com:Math><semantics>→(Gly)3<annotation encoding="application / x-tex">\rightarrow (Gly)_3< / annotation>< / semantics>< / com:Math>; N98-N156del; C105-E148del; C105- T147del; V99-Q144del; V99-Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, where n = 1 to 5; C105- <com:Math><semantics>T147del→(GGGGS)n<annotation encoding="application / x-tex">T147del \rightarrow (GGGGS)n< / annotation>< / semantics>< / com:Math>, where <com:Math><semantics>n=1<annotation encoding="application / x-tex">n = 1< / annotation>< / semantics>< / com:Math> to 5; V99-Q144del<com:Math><semantics>→(GGGGS)1<annotation encoding="application / x-tex">\rightarrow (GGGGS)_1< / annotation>< / semantics>< / com:Math>; V99- <com:Math><semantics>Q144del→(GGGGS)2;V99−Q144del→(GGGGS)3;C105−T147del→(GGGGS)1;<annotation encoding="application / x-tex">Q144del \rightarrow (GGGGS)_2; V99-Q144del \rightarrow (GGGGS)_3; C105-T147del \rightarrow (GGGGS)_1;< / annotation>< / semantics>< / com:Math> C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)<com:Sub>2< / com:Sub>; and C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)<com:Sub>3< / com:Sub>, with reference to amino acid positions set forth in SEQ ID NO:5. In some embodiments, the variant ADA2 protein or catalytically active portion thereof contains one or more amino acid replacement(s) selected from among replacements corresponding to F119S; F119K; Y224R; Y224N; Y191S; Y191D; F183K; Y191D / Y224R; F109S; F109A; R118D; R118A; Y139T; Y139A; W133S; W133T; P124A; and P124S, with reference to amino acid positions set forth in SEQ ID NO:5. In some embodiments, the variant ADA2 protein or catalytically active portion thereof contains amino acid replacements selected from among replacements corresponding to R219Q / S262N / F119S; R219Q / S262N / F119K; R219Q / S262N / Y224R; R219Q / S262N / Y224N; R219Q / S262N / Y191S; R219Q / S262N / Y191D; R219Q / S262N / F183K; R219Q / S262N / Y191D / Y224R; R219Q / S262N / F109S; R219Q / S262N / F109A; R219Q / S262N / R118D; R219Q / S262N / R118A; R219Q / S262N / Y139T; R219Q / S262N / Y139A; R219Q / S262N / W133S; R219Q / S262N / W133T; R219Q / S262N / P124A; and R219Q / S262N / P124S. In some embodiments, the variant ADA2 contains modifications selected from among <com:Math><semantics>K371D / V99−Q144del→(GGGGS)1;K371D / V99−Q144del→(GGGGS)2;<annotation encoding="application / x-tex">K371D / V99-Q144del \rightarrow (GGGGS)_1; K371D / V99-Q144del \rightarrow (GGGGS)_2;< / annotation>< / semantics>< / com:Math> <com:Math><semantics>K371D / V99−Q144del→(GGGGS)3;K371D / C105−T147del→(GGGGS)1;<annotation encoding="application / x-tex">K371D / V99-Q144del \rightarrow (GGGGS)_3; K371D / C105-T147del \rightarrow (GGGGS)_1;< / annotation>< / semantics>< / com:Math> <com:Math><semantics>K371D / C105−T147del→(GGGGS)2;K371D / C105−T147del→(GGGGS)3;<annotation encoding="application / x-tex">K371D / C105-T147del \rightarrow (GGGGS)_2; K371D / C105-T147del \rightarrow (GGGGS)_3;< / annotation>< / semantics>< / com:Math> <com:Math><semantics>R219Q / S262N / C105−T147del→(Gly)15;R219Q / S262N / C105−T147del→(Gly)10;<annotation encoding="application / x-tex">R219Q / S262N / C105-T147del \rightarrow (Gly)_{15}; R219Q / S262N / C105-T147del \rightarrow (Gly)_{10};< / annotation>< / semantics>< / com:Math> <com:Math><semantics>R219Q / S262N / C105−T147del→(Gly)7<annotation encoding="application / x-tex">R219Q / S262N / C105-T147del \rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R219Q / S262N / C105−T147del→(Gly)5<annotation encoding="application / x-tex">R219Q / S262N / C105-T147del \rightarrow (Gly)_5< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R219Q / S262N / C105−T147del→(Gly)3;R219Q / S262N / V99−Q144del→(GGGGS)1;<annotation encoding="application / x-tex">R219Q / S262N / C105-T147del \rightarrow (Gly)_3; R219Q / S262N / V99-Q144del \rightarrow (GGGGS)_1;< / annotation>< / semantics>< / com:Math> <com:Math><semantics>R219Q / S262N / V99−Q144del→(GGGGS)2;R219Q / S262N / V99−<annotation encoding="application / x-tex">R219Q / S262N / V99-Q144del \rightarrow (GGGGS)_2; R219Q / S262N / V99-< / annotation>< / semantics>< / com:Math> Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)<com:Sub>3< / com:Sub>; R219Q / S262N / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)<com:Sub>1< / com:Sub>; <com:Math><semantics>R219Q / S262N / C105−T147del→(GGGGS)2;R219Q / S262N / C105−<annotation encoding="application / x-tex">R219Q / S262N / C105-T147del \rightarrow (GGGGS)_2; R219Q / S262N / C105-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>T147del→(GGGGS)3<annotation encoding="application / x-tex">T147del \rightarrow (GGGGS)_3< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R219Q / S262N / K371D / V99−Q144del→(GGGGS)1<annotation encoding="application / x-tex">R219Q / S262N / K371D / V99-Q144del \rightarrow (GGGGS)_1< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R219Q / S262N / K371D / V99−Q144del→(GGGGS)2;R219Q / S262N / K371D / V99−<annotation encoding="application / x-tex">R219Q / S262N / K371D / V99-Q144del \rightarrow (GGGGS)_2; R219Q / S262N / K371D / V99-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>Q144del→(GGGGS)3<annotation encoding="application / x-tex">Q144del \rightarrow (GGGGS)_3< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R219Q / S262N / K371D / C105−T147del→(GGGGS)1<annotation encoding="application / x-tex">R219Q / S262N / K371D / C105-T147del \rightarrow (GGGGS)_1< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R219Q / S262N / K371D / C105−T147del→(GGGGS)2;R219Q / S262N / K371D / C105−<annotation encoding="application / x-tex">R219Q / S262N / K371D / C105-T147del \rightarrow (GGGGS)_2; R219Q / S262N / K371D / C105-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>T147del→(GGGGS)3<annotation encoding="application / x-tex">T147del \rightarrow (GGGGS)_3< / annotation>< / semantics>< / com:Math>; K371D / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)n, where n = 2 to 20; <com:Math><semantics>K371D / C105−T147del→(Gly)15<annotation encoding="application / x-tex">K371D / C105-T147del \rightarrow (Gly)_{15}< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>K371D / C105−T147del→(Gly)10<annotation encoding="application / x-tex">K371D / C105-T147del \rightarrow (Gly)_{10}< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>K371D / C105−<annotation encoding="application / x-tex">K371D / C105-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>T147del→(Gly)7<annotation encoding="application / x-tex">T147del \rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math>; K371D / C105-T147del<com:Math><semantics>→(Gly)5<annotation encoding="application / x-tex">\rightarrow (Gly)_5< / annotation>< / semantics>< / com:Math>; K371D / C105-T147del<com:Math><semantics>→(Gly)3<annotation encoding="application / x-tex">\rightarrow (Gly)_3< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>K371D / V99−Q144del→(GGGGS)n<annotation encoding="application / x-tex">K371D / V99-Q144del \rightarrow (GGGGS)n< / annotation>< / semantics>< / com:Math>, where n = 1 to 5; <com:Math><semantics>K371D / C105<annotation encoding="application / x-tex">K371D / C105< / annotation>< / semantics>< / com:Math>- <com:Math><semantics>T147del→(GGGGS)n<annotation encoding="application / x-tex">T147del \rightarrow (GGGGS)n< / annotation>< / semantics>< / com:Math>, where <com:Math><semantics>n=1<annotation encoding="application / x-tex">n = 1< / annotation>< / semantics>< / com:Math> to 5; K371D / N98-N156del; K371D / C105- E148del; K371D / C105-T147del; K371D / V99-Q144del; R219Q / S262N / C105- <com:Math><semantics>T147del→(Gly)n<annotation encoding="application / x-tex">T147del \rightarrow (Gly)n< / annotation>< / semantics>< / com:Math>, where <com:Math><semantics>n=2<annotation encoding="application / x-tex">n = 2< / annotation>< / semantics>< / com:Math> to 20; <com:Math><semantics>R219Q / S262N / V99−Q144del→(GGGGS)n<annotation encoding="application / x-tex">R219Q / S262N / V99-Q144del \rightarrow (GGGGS)n< / annotation>< / semantics>< / com:Math>, where <com:Math><semantics>n=1<annotation encoding="application / x-tex">n = 1< / annotation>< / semantics>< / com:Math> to 5; R219Q / S262N / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, where <com:Math><semantics>n=1<annotation encoding="application / x-tex">n = 1< / annotation>< / semantics>< / com:Math> to 5; R219Q / S262N / N98-N156del; R219Q / S262N / C105-E148del; R219Q / S262N / C105- T147del; R219Q / S262N / V99-Q144del; R219Q / S262N / K371D / C105- <com:Math><semantics>T147del→(Gly)n<annotation encoding="application / x-tex">T147del \rightarrow (Gly)n< / annotation>< / semantics>< / com:Math>, where n = 2 to 20; R219Q / S262N / K371D / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>15< / com:Sub>; <com:Math><semantics>R219Q / S262N / K371D / C105−T147del→(Gly)10<annotation encoding="application / x-tex">R219Q / S262N / K371D / C105-T147del \rightarrow (Gly)_{10}< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R219Q / S262N / K371D / C105−<annotation encoding="application / x-tex">R219Q / S262N / K371D / C105-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>T147del→(Gly)7<annotation encoding="application / x-tex">T147del \rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math>; R219Q / S262N / K371D / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>5< / com:Sub>; <com:Math><semantics>R219Q / S262N / K371D / C105−T147del→(Gly)3;R219Q / S262N / K371D / V99−<annotation encoding="application / x-tex">R219Q / S262N / K371D / C105-T147del \rightarrow (Gly)_3; R219Q / S262N / K371D / V99-< / annotation>< / semantics>< / com:Math> Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, where n = 1 to 5; R219Q / S262N / K371D / C105- <com:Math><semantics>T147del→(GGGGS)n<annotation encoding="application / x-tex">T147del \rightarrow (GGGGS)n< / annotation>< / semantics>< / com:Math>, where <com:Math><semantics>n=1<annotation encoding="application / x-tex">n = 1< / annotation>< / semantics>< / com:Math> to 5; R219Q / S262N / K371D / N98-N156del; R219Q / S262N / K371D / C105-E148del; R219Q / S262N / K371D / C105-T147del; R219Q / S262N / K371D / V99-Q144del; R219Q / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)n, where n = 2 to 20; R219Q / V99-Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, where n = 1 to 5; R219Q / C105- <com:Math><semantics>T147del→(GGGGS)n<annotation encoding="application / x-tex">T147del \rightarrow (GGGGS)n< / annotation>< / semantics>< / com:Math>, where <com:Math><semantics>n=1<annotation encoding="application / x-tex">n = 1< / annotation>< / semantics>< / com:Math> to 5; R219Q / N98-N156del; R219Q / C105- E148del; R219Q / C105-T147del; R219Q / V99-Q144del; S262N / C105- <com:Math><semantics>T147del→(Gly)n<annotation encoding="application / x-tex">T147del \rightarrow (Gly)n< / annotation>< / semantics>< / com:Math>, where <com:Math><semantics>n=2<annotation encoding="application / x-tex">n = 2< / annotation>< / semantics>< / com:Math> to 20; <com:Math><semantics>S262N / V99−Q144del→(GGGGS)n<annotation encoding="application / x-tex">S262N / V99-Q144del \rightarrow (GGGGS)n< / annotation>< / semantics>< / com:Math>, where <com:Math><semantics>n=1<annotation encoding="application / x-tex">n = 1< / annotation>< / semantics>< / com:Math> to 5; S262N / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, where n = 1 to 5; S262N / N98-N156del; and S262N / C105-E148del; S262N / C105-T147del; and S262N / V99-Q144del. In some embodiments of a variant ADA2 protein, including examples containing a modified PRB domain, the variant ADA2 protein, when in dimer form, can exhibit reduced binding to any one or more adenosine receptor (ADR) selected from among A<com:Sub>1< / com:Sub>, A<com:Sub>2A< / com:Sub>, A<com:Sub>2B< / com:Sub> and A<com:Sub>3< / com:Sub> compared to binding of the unmodified ADA2 protein to the same receptor when assessed under the same conditions. For example, the variant ADA2 protein has a binding that is reduced at least or at least about 0.5- fold, 1-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10- fold or more. In some embodiments of the variant ADA2 provided herein, the variant ADA2 can be glycosylated, for example, at a native or a non-native glycosylation site. In some embodiments, the variant ADA2 protein can include a modification(s) that alters glycosylation by introduction of a non-native glycosylation site, whereby, when expressed in a cell capable of glycosylation, the variant ADA2 protein is hyperglycosylated compared to the unmodified ADA2 polypeptide. For example, the non-native glycosylation site is introduced by amino acid replacement(s) or insertion of one, two or three amino acids. For example, the modifications are selected from among modifications corresponding to <com:Math><semantics>−−→N1 / −−→A2 / −−→S3<annotation encoding="application / x-tex">--\rightarrow N1 / --\rightarrow A2 / --\rightarrow S3< / annotation>< / semantics>< / com:Math>, R20N / V22S, K371N / D373S, K372N / I374S, T403N / H405S and G404N / P406S, with reference to amino acid positions set forth in SEQ ID NO:5. In some embodiments, the variant ADA2 or catalytically active portion thereof contains modifications corresponding to <com:Math><semantics>R219Q / S262N / −−→N1 / −−→A2 / −−→S3<annotation encoding="application / x-tex">R219Q / S262N / --\rightarrow N1 / --\rightarrow A2 / --\rightarrow S3< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R219Q / S262N / R20N / V22S<annotation encoding="application / x-tex">R219Q / S262N / R20N / V22S< / annotation>< / semantics>< / com:Math>; R219Q / S262N / K371N / D373S; R219Q / S262N / K372N / I374S; R219Q / S262N / T403N / H405S; or R219Q / S262N / G404N / P406S. In some embodiments, the variant ADA2 protein or catalytically active portion thereof contains a modification in the putative receptor binding domain (PRB) corresponding to one or more of the modifications selected from among: R125N / P126A; S127N / K129S; P126N / E128T; R112N / I114T; I134N / L135C / L136T; I134N / L135S / L136T; R142N / Q144S; E137N / Y139T; and P111N / G113S. In some embodiments, the variant ADA2 protein or catalytically active portion thereof contains amino acid replacements corresponding to R219Q / S262N / R125N / P126A; R219Q / S262N / S127N / K129S; R219Q / S262N / P126N / E128T; R219Q / S262N / R112N / I114T; R219Q / S262N / I134N / L135C / L136T; R219Q / S262N / I134N / L135S / L136T; R219Q / S262N / R142N / Q144S; R219Q / S262N / E137N / Y139T; or R219Q / S262N / P111N / G113S. In some embodiments, the variant ADA2 protein can be a human ADA2. In some embodiments, the variant ADA2 protein can be isolated or purified. In some embodiments, the variant ADA2 protein can contain a polypeptide that exhibits at least 65% sequence identity to SEQ ID NO:5 or a catalytically active portion thereof. For example, the variant ADA2 protein can contain a polypeptide that exhibits at least 70%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:5 or a catalytically active portion thereof. For example, the variant ADA2 protein contains a polypeptide that has the sequence of amino acids set forth in any of SEQ ID NOS:13-63 or 71-285 or a catalytically active portion thereof. In some embodiments, the variant ADA2 protein or catalytically active portion thereof contains the sequence of amino acids set forth in any of SEQ ID NOS: 551-579 or 581-993 or a catalytically active portion thereof. In some embodiments, the variant ADA2 protein or a catalytically active portion thereof can contain amino acid replacements selected from among replacements corresponding to K11A / R20A; K11A / R20A / K371A; R20A / K371A; K11A / K371A; S262N / K371D; S262N / K371E; S262N / R20E; S262N / R20E / K371D; S262N / R20E / K371E; R219Q / K371E; R219Q / K371D; R219Q / R20E; R219Q / K371E / R20E; R219Q / K371D / R20E; R219Q / S262N / K371E; R219Q / S262N / K371D; R219Q / S262N / R20E; R219Q / S262N / K371E / R20E; R219Q / S262N / K371D / R20E; R219Q / S262N; R219Q / S262N / K11A; R219Q / S262N / K11D; R219Q / S262N / K11E; R219Q / S262N / K13A; R219Q / S262N / K13D; R219Q / S262N / K13E; R219Q / S262N / K371A; [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 21 R219Q / S262N / K267Y; R219Q / S262N / V296A; R219Q / S262N / V296C; R219Q / S262N / V296D; R219Q / S262N / V296E; R219Q / S262N / V296F; R219Q / S262N / V296G; R219Q / S262N / V296H; R219Q / S262N / V296I; R219Q / S262N / V296K; R219Q / S262N / V296L; R219Q / S262N / V296M; R219Q / S262N / V296N; R219Q / S262N / V296P; R219Q / S262N / V296Q; R219Q / S262N / V296R; R219Q / S262N / V296S; R219Q / S262N / V296T; R219Q / S262N / V296W; R219Q / S262N / V296Y; R219Q / K11A / R20A; R219Q / K11A / R20A / K371A; R219Q / R20A / K371A; R219Q / K11A / K371A; S262N / K11A / R20A; S262N / K11A / R20A / K371A; S262N / R20A / K371A; and S262N / K11A / K371A, with reference to SEQ ID NO:5. The variant ADA2 protein can be a monomer or a dimer. In particular, among variant ADA2 proteins provided herein are dimers of a variant ADA2 protein, that can include any of the variant ADA2 proteins provided. In some examples, the dimer can be a homodimer. In other examples, the dimer can be a heterodimer. Provided are nucleic acid molecules encoding the variant ADA2 proteins provided herein. Also provided herein is a vector that includes the nucleic acid encoding any of the variant ADA2 proteins provided herein. The vector can be a eukaryotic or a prokaryotic vector, such as a mammalian vector or a viral vector. For example, the vector is an adenovirus vector, an adeno-associated-virus vector, a retrovirus vector, a herpes virus vector, a lentivirus vector, a poxvirus vector, or a cytomegalovirus vector. In some embodiments, the vector is an oncolytic vector. In some embodiments, the vector can also encode a soluble hyaluronidase. Also provided herein are cells containing any of the vectors provided herein. The cell can be a eukaryotic cell, such as a mammalian cell. If human, the cells are isolated or are provided as a cell culture. For example, the cell is a mammalian cell, such as a Chinese Hamster Ovary (CHO) cell. In some embodiments, the cell can expresses the variant ADA2 protein, such as a dimer. Also provided herein are variant ADA2 proteins, such as variant ADA2 dimers, that are produced by the cell provided herein. In some embodiments, the cell is an isolated cell or a cell culture, such as a eukaryotic cell, a non-human cell, a mammalian cell, or a cell that is not a human stem cell. In some embodiments, the cell is an immune cell, such as a T cell, a tumor-infiltrating lymphocyte (TIL), a cytotoxic T lymphocyte (CTL), a natural killer (NK) cell or a lymphokine-activated killer (LAK) cell. In some embodiments, the cell is a T cell that encodes and expresses chimeric antigen receptor (CAR) and the variant ADA2 protein or dimer. In some examples, the CAR is specific for a tumor cell antigen, and the tumor antigen is selected from among HER2, CD19, HERV-K, CD20, CD22, ROR1, mesothelin, CD33 / IL3Ra, c-Met, PSMA, Glycolipid F77, EGFRvIII, GD-2, NY- ESO-1 TCR, MAGE A3 TCR and GD2 and combinations thereof. Provided herein are conjugates include a variant ADA2 protein or a catalytically active portion of any ADA2 protein provided herein, such as a variant ADA2 dimer provided in any examples herein, linked directly or indirectly via a linker to a heterologous moiety, such as a toxin or therapeutic drug. Also provided herein are conjugates that include an ADA2 protein linked directly or indirectly via a linker to a heterologous moiety. In any of the conjugates, the ADA2 protein can be a monomer or a dimer. In some examples, the dimer is a homodimer; in other it is a heterodimer. In any of the conjugates in the examples herein, the heterologous moiety is conjugated to one or both subunits in the dimer. The heterologous moiety, for example, can be selected from among a peptide, small molecule, nucleic acid, carbohydrate and polymer. In some embodiments of the conjugates provided herein, the heterologous moiety is a half-life extending moiety. For example, the half-life extending moiety is selected from among biocompatible fatty acids and derivatives thereof, hydroxy alkyl starch (HAS), polyethylene glycol (PEG), Poly (Gly<com:Sub>x< / com:Sub>- Ser<com:Sub>y< / com:Sub>)<com:Sub>n< / com:Sub>, homo-amino-acid polymers (HAP), hyaluronic acid (HA), heparosan polymers (HEP), phosphorylcholine-based polymers (PC polymer), Fleximers, dextran, polysialic acids (PSA), Fc domain, Transferrin, Albumin, elastin-like peptides, XTEN sequences, albumin binding peptides, a CTP peptide, and any combination thereof. In some examples, the half-life extending moiety is a PEG and the ADA2 protein is PEGylated. For example, the PEG can be selected from among methoxy- polyethylene glycols (mPEG), PEG-glycidyl ethers (Epox-PEG), PEG- oxycarbonylimidazole (CDI-PEG), branched PEGs and polyethylene oxide (PEO). In some examples, the PEG has a molecular weight of from or from about 1 kDa to about 100 kDa. The PEG can be linear or branched. In some embodiments of conjugates provided herein, the PEG moieties result from reaction with a PEG reagent selected from among mPEG-Succinimidyl Propionates (mPEG-SPA), mPEG Succinimidyl Carboxymethyl Ester (mPEG-SCM), mPEG-Succinimidyl Butanoates (mPEG-SBA), mPEG2-N-Hydroxylsuccinimide, mPEG-succinimidyl butanoate (mPEG-SBA), mPEG-succinimidyl α-methylbutanoate (mPEG-SMB), mPEG- butyrldehyde, PEG-p-nitrophenyl-carbonate and PEG-propionaldehyde. For example, the PEG moieities result from reaction with a PEG reagent selected from among mPEG-SCM (20kDa), mPEG-SCM (30kDa), mPEG-SBA (5kDa), mPEG-SBA (20kDa), mPEG-SBA (30kDa), mPEG-SMB (20kDa), mPEG-SMB (30kDa), mPEG- butyrldehyde (30kDa), mPEG-SPA (20kDa), mPEG-SPA (30kDa), mPEG2-NHS (10kDa branched), mPEG2-NHS (20kDa branched), mPEG2-NHS (40kDa branched), mPEG2-NHS (60kDa branched), PEG-NHS-biotin (5kDa biotinylated), PEG-p- nitrophenyl-carbonate (30kDa) and PEG-propionaldehyde (30kDa). In embodiments of the conjugates provided herein, the ADA2 protein can contain the sequence of amino acids set forth in any of SEQ ID NOS:5, 326-334, 340, 375 or 380-383, a sequence that exhibits at least 85% sequence identity to the sequence of amino acids set forth in any of SEQ ID NOS:5, 326-334, 340, 375 or 380-383 or a catalytically form thereof. For example, the ADA2 protein can contain a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the sequence of amino acids set forth in any of SEQ ID NOS:5, 326-334, 340, 375 or 380-383 or a catalytically active portion thereof. For example, the ADA2 protein can contain a sequence of amino acids that exhibits at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the sequence of amino acids set forth in SEQ ID NOS:5 or a catalytically active portion thereof. In another example, the ADA2 protein can include a polypeptide having the sequence of amino acids set forth in SEQ ID NO:5 or a catalytically active portion thereof. In embodiments of conjugates provided herein, the ADA2 protein is a variant ADA2 protein that contains a sequence of amino acids that includes a modification(s) in the sequence of amino acids of an unmodified ADA2 protein or a catalytically active portion thereof, where the unmodified ADA2 protein contains the sequence of amino acids set forth in SEQ ID NO:5, or a sequence of amino acids that exhibits at least 85% sequence identity to the sequence of amino acids set forth in SEQ ID NO:5, or is a catalytically active portion thereof. In any of such examples, the amino acid modification(s) are selected from among amino acid replacement(s), deletion(s) and insertion(s); and the variant ADA2 protein, when in dimer form, can exhibit adenosine deaminase activity to convert adenosine to inosine. In any of the conjugates provided herein, the ADA2 protein, when in dimer form, can exhibit a catalytic efficiency <com:Math><semantics>(kcat / KM)<annotation encoding="application / x-tex">(k_{cat} / K_{M})< / annotation>< / semantics>< / com:Math> that is at least or at least about 5 x 10<com:Sup>3< / com:Sup> M<com:Sup>-1< / com:Sup> s<com:Sup>-1< / com:Sup>, 6 x 10<com:Sup>3< / com:Sup> M<com:Sup>-1< / com:Sup> s<com:Sup>-1< / com:Sup>, 7 x 10<com:Sup>3< / com:Sup> M<com:Sup>-1< / com:Sup> s<com:Sup>-1< / com:Sup>, <com:Math><semantics>8×103M−1s−1<annotation encoding="application / x-tex">8 \times 10^{3} \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>9×103M−1s−1<annotation encoding="application / x-tex">9 \times 10^{3} \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>1×104M−1s−1<annotation encoding="application / x-tex">1 \times 10^{4} \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>2×104M−1s−1<annotation encoding="application / x-tex">2 \times 10^{4} \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>3×104M−1s−1<annotation encoding="application / x-tex">3 \times 10^{4} \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>4×104M−1s−1<annotation encoding="application / x-tex">4 \times 10^{4} \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>M−1<annotation encoding="application / x-tex">M^{-1}< / annotation>< / semantics>< / com:Math> s<com:Sup>-1< / com:Sup>, 5 x 10<com:Sup>4< / com:Sup> <com:Math><semantics>M−1<annotation encoding="application / x-tex">M^{-1}< / annotation>< / semantics>< / com:Math> s<com:Sup>-1< / com:Sup>, 6 x 10<com:Sup>4< / com:Sup> <com:Math><semantics>M−1<annotation encoding="application / x-tex">M^{-1}< / annotation>< / semantics>< / com:Math> s<com:Sup>-1< / com:Sup>, 7 x 10<com:Sup>4< / com:Sup> <com:Math><semantics>M−1<annotation encoding="application / x-tex">M^{-1}< / annotation>< / semantics>< / com:Math> s<com:Sup>-1< / com:Sup>, 8 x 10<com:Sup>4< / com:Sup> <com:Math><semantics>M−1<annotation encoding="application / x-tex">M^{-1}< / annotation>< / semantics>< / com:Math> s<com:Sup>-1< / com:Sup>, 9 x 10<com:Sup>4< / com:Sup> <com:Math><semantics>M−1<annotation encoding="application / x-tex">M^{-1}< / annotation>< / semantics>< / com:Math> s<com:Sup>-1< / com:Sup>, <com:Math><semantics>1×105 M−1 s−1<annotation encoding="application / x-tex">1 \times 10^{5} \text{ M}^{-1} \text{ s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>2×105 M−1 s−1<annotation encoding="application / x-tex">2 \times 10^{5} \text{ M}^{-1} \text{ s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>3×105 M−1 s−1<annotation encoding="application / x-tex">3 \times 10^{5} \text{ M}^{-1} \text{ s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>4×105 M−1 s−1<annotation encoding="application / x-tex">4 \times 10^{5} \text{ M}^{-1} \text{ s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>5×105 M−1 s−1<annotation encoding="application / x-tex">5 \times 10^{5} \text{ M}^{-1} \text{ s}^{-1}< / annotation>< / semantics>< / com:Math> or greater. In any of the embodiments of conjugates provided herein, the modification(s) of the ADA2 protein can be an amino acid replacement(s); and the variant ADA2 protein can include one or more amino acid replacement(s) at an amino acid position corresponding to amino acid residue 11, 13, 20, 22, 26, 86, 179, 217, 219, 221, 258, 262, 264, 266, 267, 277, 283, 296, 309, 317, 321, 352, 366, 371, 372, 373, 374, 403, 404, 405, 406, 441, 444, 452, 461, 469 or 470, with reference to amino acid positions set forth in SEQ ID NO:5. For example, in some embodiments of conjugates provided herein, the variant ADA2 protein can include one or more amino acid replacement(s) selected from among K11A, K11D, K11E, K13A, K13D, K13E, R20A, R20D, R20E, R20N, V22S, K26A, K26D, K26E, D86A, D86C, D86E, D86F, D86G, D86H, D86I, D86K, D86L, D86M, D86N, D86P, D86Q, D86R, D86S, D86T, D86V, D86W, D86Y, E179A, E179C, E179D, E179F, E179G, E179H, E179I, E179K, E179L, E179M, E179N, E179P, E179Q, E179R, E179S, E179T, E179V, E179W, E179Y, R217A, R217D, R217E, R219A, R219C, R219D, R219E, R219F, R219G, R219H, R219I, R219K, R219L, R219M, R219N, R219P, R219Q, R219S, R219T, R219V, R219W, R219Y, L221A, L221C, L221D, L221E, L221F, L221G, L221H, L221I, L221K, L221M, L221N, L221P, L221Q, L221R, L221S, L221T, L221V, L221W, L221Y, K258A, K258D, K258E, S262A, S262C, S262D, S262E, S262F, S262G, S262H, S262I, S262K, S262L, S262M, S262N, S262P, S262Q, S262R, S262T, S262V, S262W, S262Y, H264A, H264C, H264D, H264E, H264F, H264G, H264I, H264K, H264L, H264M, H264N, H264P, H264Q, H264R, H264S, H264T, H264V, H264W, H264Y, S266A, S266C, S266D, S266E, S266F, S266G, S266H, S266I, S266K, S266L, S266M, S266N, S266P, S266Q, S266R, S266T, S266V, S266W, S266Y, K267A, K267C, K267D, K267E, K267F, K267G, K267H, K267I, K267L, K267M, K267N, K267P, K267Q, K267R, K267S, K267T, K267V, K267W, K267Y, R277A, R277D, R277E, R283A, R283D, R283E, V296A, V296C, V296D, V296E, V296F, V296G, V296H, V296I, V296K, V296L, V296M, V296N, V296P, V296Q, V296R, V296S, V296T, V296W, V296Y, K309A, K309D, K309E, K317A, K317D, K317E, K321A, K321D, K321E, R352A, R352D, R352E, R366A, R366D, R366E, K371A, K371D, K371E, K371N, K372A, K372D, K372E, K372N, D373S, I374S, T403N, G404N, H405S, P406S, R441A, R441D, R441E, K444A, K444D, K444E, K452A, K452D, K452E, K461A, K461D, K461E, K469A, K469D, K469E, K470A, K470D, K470E, with reference to amino acid positions set forth in SEQ ID NO:5. For example, the variant ADA2 protien can include one or more amino acid replacement(s) selected from among K11A, K11E, R20A, R20D, R20E, R219K, R219Q, L221A, L221V, L221G, S262N, H264Q, H264G, R366A, R366D, R366E, K371A, K371D, K371E, K372A, K372D, K372E, K452D and K452E, with reference to amino acid positions set forth in SEQ ID NO:5. In some examples, the variant ADA2 protein can include amino acid replacements selected from among K11A / R20A, K11A / R20A / K371A, R20A / K371A, K11A / K371A, S262N / K371D, S262N / K371E, S262N / R20E, S262N / R20E / K371D, S262N / R20E / K371E, R219Q / K371E, R219Q / K371D, R219Q / R20E, R219Q / K371E / R20E, R219Q / K371D / R20E, R219Q / S262N / K371E, R219Q / S262N / K371D, R219Q / S262N / R20E, R219Q / S262N / K371E / R20E, R219Q / S262N / K371D / R20E and R219Q / S262N, with reference to amino acid positions set forth in SEQ ID NO:5. In some embodiments of conjugates provided herein, the variant ADA2 protein can include a modification of one or more amino acids in the putative receptor binding (PRB) domain that is an amino acid deletion, insertion or replacement. For example, in some embodiments of conjugates provided herein, the variant ADA2 protein can include deletion of one or more contiguous amino acid residues corresponding to any one or more contiguous amino acid residues between or between about amino acid residues 98 and 156 or amino acid residues 105 and 148, inclusive, with reference to amino acid positions set forth in SEQ ID NO:5. In some examples, the variant ADA2 protein in the conjugate can further include substitution of the deleted region with a peptide linker. For example, the peptide linker can be selected from among (Gly)n (SEQ ID NO:368), where n is 2 to 20; (GGGGS)n (SEQ ID NO:343), where n is 1 to 6; (SSSSG)n (SEQ ID NO:344), where n is 1 to 6; (AlaAlaProAla)n (SEQ ID NO:350), where n is 1 to 6; GKSSGSGSESKS (SEQ ID NO:345); GGSTSGSGKSSEGKG (SEQ ID NO:346); GSTSGSGKSSSEGSGSTKG (SEQ ID NO:347); GSTSGSGKPGSGEGSTKG (SEQ ID NO:348); and EGKSSGSGSESKEF (SEQ ID NO:349). In some examples, the peptide linker is selected from among GGG (SEQ ID NO:369); GGGGG (SEQ ID NO:360); GGGGGGG (SEQ ID NO:370); GGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG ID NO:372). For example, the modification in the PRB domain can correspond to C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>n< / com:Sub>, where n is 2 to 20, such as, C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>15< / com:Sub>, C105- <com:Math><semantics>T148del→(Gly)10<annotation encoding="application / x-tex">T148del \rightarrow (Gly)_{10}< / annotation>< / semantics>< / com:Math>, C105-T147del <com:Math><semantics>→(Gly)7<annotation encoding="application / x-tex">\rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math>, C105-T147del <com:Math><semantics>→(Gly)5<annotation encoding="application / x-tex">\rightarrow (Gly)_5< / annotation>< / semantics>< / com:Math> or C105- T147del→(Gly)<com:Sub>3< / com:Sub>, with reference to amino acid positions set forth in SEQ ID NO:5. In some embodiments of conjugates provided herein, the ADA2 protein in the conjugate can be glycosylated at one or more native or non-native glycosylation site. For example, in some embodiments of conjugates provided herein containing a variant ADA2 protein, the variant ADA2 protein in the conjugate can include a modification(s) that alters glycosylation by introduction of a non-native glycosylation site. The non-native glycosylation site can be introduced by creating the canonical glycosylation sequence (NXT / S, where X is not Pro for N-linked carbohydrates, S / T for O-linked) by introducing amino acid replacement(s), insertions or deletions of one, two or three amino acids. For example, the modifications that alter glycosylation are selected from among modifications corresponding to <com:Math><semantics>−−→N1 / −−→A2 / −−→S3<annotation encoding="application / x-tex">--\rightarrow N1 / --\rightarrow A2 / --\rightarrow S3< / annotation>< / semantics>< / com:Math>, R20N / V22S, K371N / D373S, K372N / I374S, T403N / H405S and G404N / P406S, with reference to amino acid positions set forth in SEQ ID NO:5. In some embodiments of conjugates provided herein, the variant ADA2 protein in the conjugate can have the sequence of amino acid set forth in any of SEQ ID NOS:13-63 or 71-285 or a catalytically active portion thereof. In some embodiments of conjugates containing an ADA2 or variant ADA2 protein provided herein, the conjugate retains the adenosine deaminase activity compared to the ADA2 protein that is not conjugated. For example, the conjugate can exhibit from or from about 50% to 500%, 50% to 200%, 50% to 100%, 50% to 80%, 80% to 500%, 80% to 200%, 80% to 100%, 100% to 500% or 100% to 200%, each inclusive, of the adenosine deaminase activity of the ADA2 protein that is not conjugated, such as at least 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, 300%, 400%, 500% or more the adenosine deaminase activity of the ADA2 protein that is not conjugated. In some embodiments of conjugates provided herein, the ADA2 in the conjugate can exhibit a catalytic efficiency (<com:Math><semantics>kcat / KM<annotation encoding="application / x-tex">k_{cat} / K_{M}< / annotation>< / semantics>< / com:Math>) that is at least or at least about 5 x 10<com:Sup>3< / com:Sup> M<com:Sup>-1< / com:Sup> s<com:Sup>-1< / com:Sup>, 6 x 10<com:Sup>3< / com:Sup> M <com:Math><semantics>1<annotation encoding="application / x-tex">^{1}< / annotation>< / semantics>< / com:Math> s<com:Sup>-1< / com:Sup>, 7 x 10<com:Sup>3< / com:Sup> M<com:Sup>-1< / com:Sup> s<com:Sup>-1< / com:Sup>, 8 x 10<com:Sup>3< / com:Sup> M<com:Sup>-1< / com:Sup> s<com:Sup>-1< / com:Sup>, 9 x 10<com:Sup>3< / com:Sup> M<com:Sup>-1< / com:Sup> s<com:Sup>-1< / com:Sup>, 1 x 10<com:Sup>4< / com:Sup> M<com:Sup>-1< / com:Sup> s<com:Sup>-1< / com:Sup>, 2 x 10<com:Sup>4< / com:Sup> M<com:Sup>-1< / com:Sup> s<com:Sup>-1< / com:Sup>, 3 x <com:Math><semantics>104M−1s−1<annotation encoding="application / x-tex">10^4 \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>4×104M−1s−1<annotation encoding="application / x-tex">4 \times 10^4 \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>5×104M−1s−1<annotation encoding="application / x-tex">5 \times 10^4 \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>6×104M−1s−1<annotation encoding="application / x-tex">6 \times 10^4 \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>7×104M−1s−1<annotation encoding="application / x-tex">7 \times 10^4 \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>8×104M−1<annotation encoding="application / x-tex">8 \times 10^4 \,\mathrm{M}^{-1}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>s−1<annotation encoding="application / x-tex">s^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>9×104M−1s−1<annotation encoding="application / x-tex">9 \times 10^4 M^{-1} s^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>1×105M−1s−1<annotation encoding="application / x-tex">1 \times 10^5 M^{-1} s^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>2×105M−1s−1<annotation encoding="application / x-tex">2 \times 10^5 M^{-1} s^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>3×105M−1s−1<annotation encoding="application / x-tex">3 \times 10^5 M^{-1} s^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>4×105M−1s−1<annotation encoding="application / x-tex">4 \times 10^5 M^{-1} s^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>5×105M−1s−1<annotation encoding="application / x-tex">5 \times 10^5 M^{-1} s^{-1}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>105M−1s−1<annotation encoding="application / x-tex">10^5 \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math> or greater. Provided herein are combinations containing any of the variant ADA2 proteins or a catalytically active portion thereof provided herein, any variant ADA2 dimer provided herein or any conjugate of any of the examples provided herein, and a therapeutic agent. Also provided herein are combinations containing any ADA2 protein; and a therapeutic agent. In any examples of the combination provided herein, the ADA2 protein can be a monomer or a dimer. For example, the ADA2 protein can be a dimer, such as a homodimer. In some embodiments of combinations provided herein, the therapeutic agent can be selected from among an antibody, cytotoxic agent, chemotherapeutic agents, cytokine, growth inhibitory agent, anti-hormonal agent, kinase inhibitor, anti- angiogenic agent, cardioprotectant, immunostimulatory agent, immunosuppressive agent, immune checkpoint inhibitor, antibiotic and angiogenesis inhibitor. For example, the therapeutic agent can be an anti-cancer agent. In some embodiments of combinations provided herein, the anti-cancer agent can be an anti-cancer antibody, a chemotherapeutic agent, a radioimmunotherapeutic, an anti-angiogenic agent or an immune checkpoint inhibitor. For example, the anti-cancer agent can be an immune checkpoint inhibitor; and the target of the immune checkpoint inhibitor can be selected from among . . CTLA4, PD-1, and PD-L1. In some embodiments of combinations provided herein, the immune checkpoint inhibitor can be an antibody, a fusion protein, an aptamer, or an immune checkpoint protein-binding fragment thereof. For example, the immune checkpoint inhibitor is an anti-immune checkpoint protein antibody or antigen- binding fragment thereof. In particular examples, the immune checkpoint inhibitor is selected from among: an anti-CTLA4 antibody, derivative thereof, or antigen-binding fragment thereof; an anti-PD-L1 antibody, derivative thereof, or antigen-binding fragment thereof; and an anti-PD-1 antibody, derivative thereof, or antigen-binding fragment thereof. For example, the immune checkpoint inhibitor can be selected from among: Ipilimumab, a derivative thereof, or an antigen-binding fragment thereof; Tremelimumab, a derivative thereof, or an antigen-binding fragment thereof; Nivolumab, a derivative thereof, or an antigen-binding fragment thereof; and Pidilizumab, a derivative thereof, or an antigen-binding fragment thereof. In some embodiments of combinations provided herein, the therapeutic agent can be an anti-hyaluronan agent. For example, the anti-hyaluronan agent can be a soluble hyaluronidase. In some embodiments of combinations provided herein, the soluble hyaluronidase can exhibit hyaluronidase activity at neutral pH. In particular, the soluble hyaluronidase can be selected from among bovine, ovine or a C-terminal truncated human PH20 that lacks all or a portion of the glycosylphosphatidylinositol (GPI) anchor attachment sequence. For example, the soluble hyaluronidase is a C- terminally truncated human PH20 that lacks all or a portion of the GPI anchor attachment sequence, such as those set forth in any of SEQ ID NOS:481-488, 493- 514, or 526-532, or that has a sequence of amino acids that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to a sequence of amino acids set forth in any of SEQ ID NOS:481-488, 493- 514, or 526-532 and is soluble and retains hyaluronidase activity. In some embodiments of combinations provided herein, the anti-hyaluronan agent or soluble hyaluronidase can be conjugated to a polymer, such as a PEG moiety. In some embodiments of combinations provided herein, the ADA2 protein can include a polypeptide having the sequence of amino acids set forth in any of SEQ ID NOS:5, 326-334, 340, 375 or 380-383, a sequence that can exhibit at least 85% sequence identity to the sequence of amino acids set forth in SEQ ID NOS:5, 326-334, 340, 375 or 380-383 or a catalytically active form thereof. For example, the ADA2 , protein can include a protein having a sequence of amino acids that can exhibit at least 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the sequence of amino acids set forth in SEQ ID NOS:5, 326-334, 340, 375 or 380-383 or a catalytically active portion thereof. In particular examples, the ADA2 protein can contain a sequence of amino acids that can exhibit at least 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the sequence of amino acids set forth in SEQ ID NO:5. For example, the ADA2 protein can contain the sequence of amino acids set forth in SEQ ID NO:5. In some embodiments of combinations provided herein, the ADA2 protein is a variant ADA2 protein having a sequence of amino acids that includes a modification(s) in the sequence of amino acids of an unmodified ADA2 polypeptide or a catalytically active portion thereof. In any of such examples, the unmodified ADA2 protein can include the sequence of amino acids set forth in SEQ ID NO:5, or a sequence of amino acids that can exhibit at least 85% sequence identity to the sequence of amino acids set forth in SEQ ID NO:5, or is a catalytically active portion thereof; the amino acid modification(s) are selected from among amino acid replacement(s), deletion(s) and insertion(s); and the variant ADA2 protein, when in dimer form, can exhibit adenosine deaminase activity to convert adenosine to inosine. In some embodiments of combinations provided herein, the ADA2 protein, when in dimer form, can exhibit a catalytic efficiency <com:Math><semantics>(kcat / KM)<annotation encoding="application / x-tex">(k_{cat} / K_M)< / annotation>< / semantics>< / com:Math> that is at least or at least about <com:Math><semantics>5×103M−1s−1<annotation encoding="application / x-tex">5 \times 10^3 \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>6×103M−1s−1<annotation encoding="application / x-tex">6 \times 10^3 \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>7×103M−1s−1<annotation encoding="application / x-tex">7 \times 10^3 \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>8×103M−1s−1<annotation encoding="application / x-tex">8 \times 10^3 \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>9×103M−1<annotation encoding="application / x-tex">9 \times 10^3 \,\mathrm{M}^{-1}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>s−1<annotation encoding="application / x-tex">s^{-1}< / annotation>< / semantics>< / com:Math>, 1 x 10<com:Sup>4< / com:Sup> M<com:Sup>-1< / com:Sup> <com:Math><semantics>s−1<annotation encoding="application / x-tex">s^{-1}< / annotation>< / semantics>< / com:Math>, 2 x 10<com:Sup>4< / com:Sup> M<com:Sup>-1< / com:Sup> <com:Math><semantics>s−1<annotation encoding="application / x-tex">s^{-1}< / annotation>< / semantics>< / com:Math>, 3 x 10<com:Sup>4< / com:Sup> M<com:Sup>-1< / com:Sup> <com:Math><semantics>s−1<annotation encoding="application / x-tex">s^{-1}< / annotation>< / semantics>< / com:Math>, 4 x 10<com:Sup>4< / com:Sup> M<com:Sup>-1< / com:Sup> <com:Math><semantics>s−1<annotation encoding="application / x-tex">s^{-1}< / annotation>< / semantics>< / com:Math>, 5 x 10<com:Sup>4< / com:Sup> M<com:Sup>-1< / com:Sup> <com:Math><semantics>s−1<annotation encoding="application / x-tex">s^{-1}< / annotation>< / semantics>< / com:Math>, 6 x <com:Math><semantics>104 M−1 s−1<annotation encoding="application / x-tex">10^4 \text{ M}^{-1} \text{ s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>7×104 M−1 s−1<annotation encoding="application / x-tex">7 \times 10^4 \text{ M}^{-1} \text{ s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>8×104 M−1 s−1<annotation encoding="application / x-tex">8 \times 10^4 \text{ M}^{-1} \text{ s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>9×104 M−1 s−1<annotation encoding="application / x-tex">9 \times 10^4 \text{ M}^{-1} \text{ s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>1×105 M−1 s−1<annotation encoding="application / x-tex">1 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>2×105 M−1<annotation encoding="application / x-tex">2 \times 10^5 \text{ M}^{-1}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>s−1<annotation encoding="application / x-tex">s^{-1}< / annotation>< / semantics>< / com:Math>, 3 x 10<com:Sup>5< / com:Sup> M<com:Sup>-1< / com:Sup> <com:Math><semantics>s−1<annotation encoding="application / x-tex">s^{-1}< / annotation>< / semantics>< / com:Math>, 4 x 10<com:Sup>5< / com:Sup> M<com:Sup>-1< / com:Sup> <com:Math><semantics>s−1<annotation encoding="application / x-tex">s^{-1}< / annotation>< / semantics>< / com:Math>, 5 x 10<com:Sup>5< / com:Sup> M<com:Sup>-1< / com:Sup> <com:Math><semantics>s−1<annotation encoding="application / x-tex">s^{-1}< / annotation>< / semantics>< / com:Math> or greater. In some embodiments of combinations provided herein, the modification(s) in the sequence of amino acids of an unmodified ADA2 protein can include an amino acid replacement(s); and the variant ADA2 protein can include one or more amino acid replacement(s) at an amino acid position corresponding to amino acid residue 11, 13, 20, 22, 26, 86, 179, 217, 219, 221, 258, 262, 264, 266, 267, 277, 283, 296, 309, 317, 321, 352, 366, 371, 372, 373, 374, 403, 404, 405, 406, 441, 444, 452, 461, 469 or 470, with reference to amino acid positions set forth in SEQ ID NO:5. For example, the variant ADA2 protein can include one or more amino acid replacement(s) selected from among K11A, K11D, K11E, K13A, K13D, K13E, R20A, R20D, R20E, R20N, V22S, K26A, K26D, K26E, D86A, D86C, D86E, D86F, D86G, D86H, D86I, D86K, D86L, D86M, D86N, D86P, D86Q, D86R, D86S, D86T, D86V, D86W, D86Y, E179A, E179C, E179D, E179F, E179G, E179H, E179I, E179K, E179L, E179M, E179N, E179P, E179Q, E179R, E179S, E179T, E179V, E179W, E179Y, R217A, R217D, R217E, R219A, R219C, R219D, R219E, R219F, R219G, R219H, R219I, R219K, R219L, R219M, R219N, R219P, R219Q, R219S, R219T, R219V, R219W, R219Y, L221A, L221C, L221D, L221E, L221F, L221G, L221H, L221I, L221K, L221M, L221N, L221P, L221Q, L221R, L221S, L221T, L221V, L221W, L221Y, K258A, K258D, K258E, S262A, S262C, S262D, S262E, S262F, S262G, S262H, S262I, S262K, S262L, S262M, S262N, S262P, S262Q, S262R, S262T, S262V, S262W, S262Y, H264A, H264C, H264D, H264E, H264F, H264G, H264I, H264K, H264L, H264M, H264N, H264P, H264Q, H264R, H264S, H264T, H264V, H264W, H264Y, S266A, S266C, S266D, S266E, S266F, S266G, S266H, S266I, S266K, S266L, S266M, S266N, S266P, S266Q, S266R, S266T, S266V, S266W, S266Y, K267A, K267C, K267D, K267E, K267F, K267G, K267H, K267I, K267L, K267M, K267N, K267P, K267Q, K267R, K267S, K267T, K267V, K267W, K267Y, R277A, R277D, R277E, R283A, R283D, R283E, V296A, V296C, V296D, V296E, V296F, V296G, V296H, V296I, V296K, V296L, V296M, V296N, V296P, V296Q, V296R, V296S, V296T, V296W, V296Y, K309A, K309D, K309E, K317A, K317D, K317E, K321A, K321D, K321E, R352A, R352D, R352E, R366A, R366D, R366E, K371A, K371D, K371E, K371N, K372A, K372D, K372E, K372N, D373S, I374S, T403N, G404N, H405S, P406S, R441A, R441D, R441E, K444A, K444D, K444E, K452A, K452D, K452E, K461A, K461D, K461E, K469A, K469D, K469E, K470A, K470D, and K470E, with reference to amino acid positions set forth in SEQ ID NO:5. In particular examples, the variant ADA2 protein can include one or more amino acid replacement(s) selected from among K11A, K11E, R20A, R20D, R20E, R219K, R219Q, L221A, L221V, L221G, S262N, H264Q, H264G, R366A, R366D, R366E, K371A, K371D, K371E, K372A, K372D, K372E, K452D and K452E, with reference to amino acid positions set forth in SEQ ID NO:5. In some examples of the combinations provided herein, the variant ADA2 protein can include amino acid replacements selected from among K11A / R20A, K11A / R20A / K371A, R20A / K371A, K11A / K371A, S262N / K371D, S262N / K371E, S262N / R20E, S262N / R20E / K371D, $262N / R20E / K371E, R219Q / K371E, R219Q / K371D, R219Q / R20E, R219O / K371E / R20E, R219Q / K371D / R20E, R219Q / S262N / K371E, R219Q / S262N / K371D, R219Q / S262N / R20E, R219Q / S262N / K371E / R20E, R219Q / S262N / K371D / R20E and R219Q / S262N, with reference to amino acid positions set forth in SEQ ID NO:5. In some embodiments of combinations provided herein, the variant ADA2 protein can include a modification of one or more amino acids in the putative receptor binding (PRB) domain, wherein the modification is an amino acid deletion, insertion or replacement. For example, the variant ADA2 can include deletion of one or more contiguous amino acid residues corresponding to any one or more contiguous amino acid residues between or between about amino acid residues 98 and 156 or amino acid residues 105 and 148, inclusive, with reference to amino acid positions set forth in SEQ ID NO:5. In some embodiments, the variant of ADA2 polypeptide can further include substitution of the deleted region with a peptide linker. For example, the peptide linker can be selected from among (Gly)n (SEQ ID NO:368), where n is 2 to 20; (GGGGS)n (SEQ ID NO:343), where n is 1 to 6; (SSSSG)n (SEQ ID NO:344), * where n is 1 to 6; (AlaAlaProAla)n (SEQ ID NO:350), where n is 1 to 6; GKSSGSGSESKS (SEQ ID NO:345); GGSTSGSGKSSEGKG (SEQ ID NO:346); GSTSGSGKSSSEGSGSTKG (SEQ ID NO:347); GSTSGSGKPGSGEGSTKG (SEQ ID NO:348); and EGKSSGSGSESKEF (SEQ ID NO:349). In particular examples, the peptide linker is selected from among GGG (SEQ ID NO:369); GGGGG (SEQ ID NO:360); GGGGGGG (SEQ ID NO:370); GGGGGGGGGG (SEQ ID NO:371); and GGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG combinations provided herein, the modification in the PRB domain of the variant ADA2 polypeptide corresponds to C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>n< / com:Sub>, where n is 2 to 20, such as <com:Math><semantics>C105−T147del→(Gly)15<annotation encoding="application / x-tex">C105-T147del \rightarrow (Gly)_{15}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C105−T147del→(Gly)10<annotation encoding="application / x-tex">C105-T147del \rightarrow (Gly)_{10}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C105−T147del→(Gly)7<annotation encoding="application / x-tex">C105-T147del \rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C105−T147del→(Gly)7<annotation encoding="application / x-tex">C105-T147del \rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C105−T147del→(Gly)7<annotation encoding="application / x-tex">C105-T147del \rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C105−T147del→(Gly)7<annotation encoding="application / x-tex">C105-T147del \rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C105−T147del→(Gly)7<annotation encoding="application / x-tex">C105-T147del \rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C105−T147del→(Gly)7<annotation encoding="application / x-tex">C105-T147del \rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C105−T<annotation encoding="application / x-tex">C105-T< / annotation>< / semantics>< / com:Math> T147del→(Gly)<com:Sub>5< / com:Sub> or C105-T147del→(Gly)<com:Sub>3< / com:Sub>, with reference to amino acid positions set forth in SEQ ID NO:5. In some embodiments of combinations provided herein, the ADA2 protein in the combination can be glycosylated at one or more native or non-native glycosylation site. For example, in some embodiments of combinations provided herein containing a variant ADA2 protein, the variant ADA2 protein in the combination include a modification(s) that alters glycosylation by introduction of a non-native glycosylation site. The non-native glycosylation site is introduced by amino acid replacement(s) or insertion of one, two or three amino acids. For example, the modifications that alter hyperglycosylation can be selected from among modifications corresponding to -- <com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>N1 / --<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>A2 / --<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>S3, R20N / V22S, K371N / D373S, K372N / I374S, T403N / H405S and G404N / P406S, with reference to amino acid positions set forth in SEQ ID NO:5. In some embodiments of combinations provided herein, the variant ADA2 polypeptide has the sequence of amino acids set forth in any of SEQ ID NOS:13-63 or 71-285 or a catalytically active portion thereof. Provided herein are pharmaceutical compositions that can include any of the variant ADA2 proteins or a catalytically active portion thereof provided herein, any variant ADA2 dimer provided herein or any conjugate provided herein, in a pharmaceutically acceptable vehicle. In some embodiments, the pharmaceutical composition can be formulated for local or systemic administration. For example, the pharmaceutical composition is formulated for intravenous administration. Provided herein are methods of treating a tumor or cancer in a subject, that can include administering to the subject any of the variant ADA2 proteins or a catalytically active portion thereof provided herein, any variant ADA2 dimer provided herein, any conjugate provided herein, or any combination provided herein. Also provided are medical uses or pharmaceutical compositions for use of any of the variant ADA2 proteins or a catalytically active portion thereof provided herein, any variant ADA2 dimer provided herein or any conjugate provided herein for treating a tumor or a cancer in a subject. Also provided are combinations for use of any of the combinations provided herein for use in treating a tumor or cancer. Also provided herein are methods of treating a tumor or cancer in a subject that can include administering to the subject any ADA2 protein. Also provided are medical uses of an ADA2 protein or pharmaceutical composition for use containing an ADA2 protein for treating a tumor or a cancer. Also provided are combinations for use containing an ADA2 protein and a therapeutic agent for treating a tumor or cancer. In some embodiments of methods, uses, pharmaceutical compositions for use or uses provided herein, the tumor can be a solid tumor or a metastatic tumor. In particular examples, the tumor can be a carcinoma, gliomas, sarcoma, adenocarcinoma, adenosarcoma, or adenoma. In some embodiments, the tumor can be a tumor of the breast, heart, lung, small intestine, colon, spleen, kidney, bladder, head and neck, ovary, prostate, brain, pancreas, skin, bone, bone marrow, blood, thymus, uterus, testicles, cervix or liver. In some embodiments of methods provided herein, the subject can be selected for treatment based on elevated levels of plasma adenosine, tumor-associated expression of adenosine receptor (ADR) or tumor-associated expression of a nucleotidase. In particular examples, the ADR is A2A or A2B. In particular examples, the nucleotidase is CD39 or CD73. In some embodiments of methods provided herein, the elevated level is at least 0.5-fold, 1-fold, 2-fold, 3-fold, 4-fold, 5- fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, 150-fold, 200-fold, 500-fold, 1000-fold or more, compared to the predetermined level or predetermined amount or control sample. In some embodiments of methods provided herein, the method of treating a tumor or cancer in a subject can further include administration of one or more anticancer agents or treatments. For example, the anti-cancer agent can be selected from among an anti-cancer antibody, a chemotherapeutic agent, a radioimmunotherapeutic, an anti-angiogenic agent and an immune checkpoint inhibitor. Provided herein are methods of treating a disease or condition in a subject, that can include administering to the subject any of the variant ADA2 proteins or a catalytically active portion thereof provided herein, any variant ADA2 dimer provided herein, any conjugate provided herein, or any combination provided herein for treating a disease or condition that is a non-cancer hyperproliferative disease, a fibrotic disease, an infectious disease, a vasculopathy or Severe Combined Immunodeficiency (SCID). Also provided are medical uses or pharmaceutical compositions for use of any of the variant ADA2 proteins or a catalytically active portion thereof provided herein, any variant ADA2 dimer provided herein or any conjugate provided herein for treating a non-cancer hyperproliferative disease, a fibrotic disease, an infectious disease, a vasculopathy or Severe Combined Immunodeficiency (SCID) in a subject. Also provided are combinations for use of any of the combinations provided herein for use in treating a non-cancer hyperproliferative disease, a fibrotic disease, an infectious disease, a vasculopathy or Severe Combined Immunodeficiency (SCID). Also provided herein are methods of treating a disease or condition in a subject, that can include administering to the subject any ADA2 protein, for treating a disease or condition that is a non-cancer hyperproliferative disease, a fibrotic disease, an infectious disease, a vasculopathy or Severe Combined Immunodeficiency (SCID). Also provided are medical uses of an ADA2 protein or pharmaceutical compositions for use containing an ADA2 protein for treating a disease or condition that is a non-cancer hyperproliferative disease, a fibrotic disease, an infectious disease, a vasculopathy or Severe Combined Immunodeficiency (SCID). Also provided are combinations for use containing an ADA2 protein and a therapeutic agent for treating a disease or condition that is a non- cancer hyperproliferative disease, a fibrotic disease, an infectious disease, a vasculopathy or Severe Combined Immunodeficiency (SCID) In some embodiments of methods, uses, pharmaceutical compositions for use or uses provided herein, the ADA2 protein can be a monomer or a dimer. For example, the ADA2 protein can be a dimer, in particular, a homodimer. In some embodiments of methods, uses, pharmaceutical compositions for use or combinations for use provided herein, the ADA2 protein can contain the sequence of amino acids set forth in any of SEQ ID NOS:5, 326-334, 340, 375 or 380-383, a sequence that can exhibit at least 85% sequence identity to the sequence of amino acids set forth in SEQ ID NOS:5, 326-334, 340; 375 or 380-383 or a catalytically active form thereof. For example, the ADA2 protein can contain a sequence of amino acids that can exhibit at least 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the sequence of amino acids set forth in SEQ ID NOS:5, 326-334, 340, 375 or 380-383 or a catalytically active portion thereof. In particular examples, the ADA2 protein can contain a sequence of amino acids that can exhibit at least 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the sequence of amino acids set forth in SEQ ID NOS:5 or a catalytically active portion thereof. For example, the ADA2 protein can contain the sequence of amino acids set forth in SEQ ID NO:5. In some embodiments of methods, uses, pharmaceutical compositions for use, or combinations for use provided herein, the ADA2 protein is a variant ADA2 protein that includes modification(s) in the sequence of amino acids of an unmodified ADA2 polypeptide or a catalytically active portion thereof. In any of such examples, the unmodified ADA2 protein can include the sequence of amino acids set forth in SEQ ID NO:5, or a sequence of amino acids that can exhibit at least 85% sequence identity to the sequence of amino acids set forth in SEQ ID NO:5, or is a catalytically active portion thereof; the amino acid modification(s) are selected from among amino acid replacement(s), deletion(s) and insertion(s); and the variant ADA2 protein, when in dimer form, can exhibit adenosine deaminase activity to convert adenosine to inosine. In some embodiments of methods, uses, pharmaceutical compositions for use or combinations for use provided herein, the ADA2 protein, when in dimer form, can exhibit a catalytic efficiency (<com:Math><semantics>kcat / KM<annotation encoding="application / x-tex">k_{cat} / K_{M}< / annotation>< / semantics>< / com:Math>) that is at least or at least about 5 x 10<com:Sup>3< / com:Sup> M<com:Sup>-1< / com:Sup> s<com:Sup>-1< / com:Sup>, 6 <com:Math><semantics>×103M−1s−1<annotation encoding="application / x-tex">\times 10^{3} \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>7×103M−1s−1<annotation encoding="application / x-tex">7 \times 10^{3} \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>8×103M−1s−1<annotation encoding="application / x-tex">8 \times 10^{3} \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>9×103M−1s−1<annotation encoding="application / x-tex">9 \times 10^{3} \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>1×104M−1s−1<annotation encoding="application / x-tex">1 \times 10^{4} \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>2×104M−1s−1<annotation encoding="application / x-tex">2 \times 10^{4} \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>1<annotation encoding="application / x-tex">^{1}< / annotation>< / semantics>< / com:Math> s<com:Sup>-1< / com:Sup>, 3 x 10<com:Sup>4< / com:Sup> M<com:Sup>-1< / com:Sup> s<com:Sup>-1< / com:Sup>, 4 x 10<com:Sup>4< / com:Sup> M<com:Sup>-1< / com:Sup> s<com:Sup>-1< / com:Sup>, 5 x 10<com:Sup>4< / com:Sup> M<com:Sup>-1< / com:Sup> s<com:Sup>-1< / com:Sup>, 6 x 10<com:Sup>4< / com:Sup> M<com:Sup>-1< / com:Sup> s<com:Sup>-1< / com:Sup>, 7 x 10<com:Sup>4< / com:Sup> M<com:Sup>-1< / com:Sup> s<com:Sup>-1< / com:Sup>, 8 x <com:Math><semantics>104M−1s−1<annotation encoding="application / x-tex">10^4 \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>9×104M−1s−1<annotation encoding="application / x-tex">9 \times 10^4 \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>1×105M−1s−1<annotation encoding="application / x-tex">1 \times 10^5 \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>2×105M−1s−1<annotation encoding="application / x-tex">2 \times 10^5 \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>3×105M−1s−1<annotation encoding="application / x-tex">3 \times 10^5 \,\mathrm{M}^{-1} \,\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>4×105M−1<annotation encoding="application / x-tex">4 \times 10^5 \,\mathrm{M}^{-1}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>s−1<annotation encoding="application / x-tex">s^{-1}< / annotation>< / semantics>< / com:Math>, 5 x 10<com:Sup>5< / com:Sup> M<com:Sup>-1< / com:Sup> s<com:Sup>-1< / com:Sup> or greater. In some embodiments of methods, uses, pharmaceutical compositions for use, or combinations for use provided herein, the modification(s) in the sequence of amino acids of an unmodified ADA2 polypeptide can include an amino acid replacement(s); and the variant ADA2 protein can include one or more amino acid replacement(s) at an amino acid position corresponding to amino acid residue 11, 13, 20, 22, 26, 86, 179, 217, 219, 221, 258, 262, 264, 266, 267, 277, 283, 296, 309, 317, 321, 352, 366, 371, 372, 373, 374, 403, 404, 405, 406, 441, 444, 452, 461, 469 or 470, with reference to amino acid positions set forth in SEQ ID NO:5. For example, the variant ADA2 protein can include one or more amino acid replacement selected from among K11A, K11D, K11E, K13A, K13D, K13E, R20A, R20D, R20E, R20N, V22S, K26A, K26D, K26E, D86A, D86C, D86E, D86F, D86G, D86H, D86I, D86K, D86L, D86M, D86N, D86P, D86Q, D86R, D86S, D86T, D86V, D86W, D86Y, E179A, E179C, E179D, E179F, E179G, E179H, E179I, E179K, E179L, E179M, E179N, E179P, E179Q, E179R, E179S, E179T, E179V, E179W, E179Y, R217A, R217D, R217E, R219A, R219C, R219D, R219E, R219F, R219G, R219H, R219I, R219K, R219L, R219M, R219N, R219P, R219Q, R219S, R219T, R219V, R219W, R219Y, L221A, L221C, L221D, L221E, L221F, L221G, L221H, L221I, L221K, L221M, L221N, L221P, L221Q, L221R, L221S, L221T, L221V, L221W, L221Y, K258A, K258D, K258E, S262A, S262C, S262D, S262E, S262F, S262G, S262H, S262I, S262K, S262L, S262M, S262N, S262P, S262Q, S262R, S262T, S262V, S262W, S262Y, H264A, H264C, H264D, H264E, H264F, H264G, H264I, H264K, H264L, H264M, H264N, H264P, H264Q, H264R, H654S, H264T, H264V, H264W, H264Y, S266A, S266C, S266D, S266E, S266F, S266G, S266H, S266I, S266K, S266L, S266M, S266N, S266P, S266Q, S266R, S266T, S266V, S266W, S266Y, K267A, K267C, K267D, K267E, K267F, K267G, K267H, K267I, K267L, K267M, K267N, K267P, K267Q, K267R, K267S, K267T, K267V, K267W, K267Y, R277A, R277D, R277E, R283A, R283D, R283E, V296A, V296C, V296D, V296E, V296F, V296G, V296H, V296I, V296K, V296L, V296M, V296N, V296P, V296Q, V296R, V296S, V296T, V296W, V296Y, K309A, K309D, K309E, K317A, K317D, K317E, K321A, K321D, K321E, R352A, R352D, R352E, R366A, R366D, R366E, K371A, K371D, K371E, K371N, K372A, K372D, K372E, K372N, D373S, I374S, T403N, G404N, H405S, P406S, R441A, R441D, R441E, K444A, K444D, K444E, K452A, K452D, K452E, K461A, K461D, K461E, K469A, K469D, K469E, K470A, K470D, and K470E, with reference to amino acid positions set forth in SEQ ID NO:5. In particular examples, the variant ADA2 protein can include one or more amino acid replacement(s) selected from among K11A, K11E, R20A, R20D, R20E, R219K, R219Q, L221A, L221V, L221G, S262N, H264Q, H264G, R366A, R366D, R366E, K371A, K371D, K371E, K372A, K372D, K372E, K452D and K452E, with reference to amino acid positions set forth in SEQ ID NO:5. In some embodiments of methods, uses, pharmaceutical compositions for use or combinations for use provided herein, the variant ADA2 protein can include amino acid replacements selected from among K11A / R20A, K11A / R20A / K371A, R20A / K371A, K11A / K371A, 30 $262N / K371D, $262N / K371E, $262N / R20E, $262N / R20E / K371D, S262N / R20E / K371E, R219Q / K371E, R219Q / K371D, R219Q / R20E, R219Q / K371E / R20E, R219Q / K371D / R20E, R219Q / S262N / K371E, R219Q / S262N / K371D, R219Q / S262N / R20E, R219Q / S262N / K371E / R20E, R219Q / S262N / K371D / R20E and R219Q / S262N, with reference to amino acid positions set forth in SEQ ID NO:5. In some embodiments of methods, uses, pharmaceutical compositions for use or combinations for use provided herein, the variant ADA2 protein can include a modification of one or more amino acids in the putative receptor binding (PRB) domain, such as an amino acid deletion, insertion or replacement. For example, the variant ADA2 can include deletion of one or more contiguous amino acid residues corresponding to any one or more contiguous amino acid residues between or between about amino acid residues 98 and 156 or amino acid residues 105 and 148, inclusive, with reference to amino acid positions set forth in SEQ ID NO:5. In any of such examples of methods, uses, pharmaceutical compositions for use or combinations for use provided herein, the variant of ADA2 protein can further include substitution of the deleted region with a peptide linker. For example, the peptide linker is selected from among (Gly)n (SEQ ID NO:368), where n is 2 to 20; (GGGGS)n (SEQ ID NO:343), where n is 1 to 6; (SSSSG)n (SEQ ID NO:344), where n is 1 to 6; (AlaAlaProAla)n (SEQ ID NO:350), where n is 1 to 6; GKSSGSGSESKS (SEQ ID NO:345); GGSTSGSGKSSEGKG (SEQ ID NO:346); GSTSGSGKSSSEGSGSTKG (SEQ ID NO:347); GSTSGSGKPGSGEGSTKG (SEQ ID NO:348); and EGKSSGSGSESKEF (SEQ ID NO:349). In particular examples the peptide linker is selected from among GGG (SEQ ID NO:369); GGGGG (SEQ ID NO:360); GGGGGGG (SEQ ID NO:370); GGGGGGGGGG (SEQ ID NO:371); and GGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG For example, the modification in the PRB domain of the ADA2 protein corresponds to C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>n< / com:Sub>, where n is 2 to 20, such as C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>15< / com:Sub>, C105- <com:Math><semantics>T147del→(Gly)10<annotation encoding="application / x-tex">T147del \rightarrow (Gly)_{10}< / annotation>< / semantics>< / com:Math> C105-T147del <com:Math><semantics>→(Gly)7<annotation encoding="application / x-tex">\rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math>, C105-T147del <com:Math><semantics>→(Gly)5<annotation encoding="application / x-tex">\rightarrow (Gly)_5< / annotation>< / semantics>< / com:Math> or C105- T147del→(Gly)<com:Sub>3< / com:Sub>, with reference to amino acid positions set forth in SEQ ID NO:5. In some embodiments of methods, uses, pharmaceutical compositions for use or combinations for use provided herein, the ADA2 protein can be glycosylated at one or more native or non-native glycosylation sites. For example, in some embodiments provided herein containing a variant ADA2 protein, the variant ADA2 protein includes a modification(s) that alters glycosylation by introduction of a non-native glycosylation site. For example, the non-native glycosylation site is introduced by amino acid replacement(s) or insertion of one, two or three amino acids. In particular examples, the modifications that alter glycosylation are selected from among modifications corresponding to <com:Math><semantics>−−→N1 / −−→S3<annotation encoding="application / x-tex">--\rightarrow N1 / --\rightarrow S3< / annotation>< / semantics>< / com:Math>, R20N / V22S, K371N / D373S, K372N / I374S, T403N / H405S and G404N / P406S, with reference to amino acid positions set forth in SEQ ID NO:5. In some embodiments of methods, uses, pharmaceutical compositions for use or combinations for use provided herein, the variant ADA2 can include a polypeptide that has the sequence of amino acids set forth in any of SEQ ID NOS:13-63 or 71-285 or a catalytically active portion thereof. In some embodiments of methods, uses, pharmaceutical compositions for use or uses provided herein, the subject can be a mammal, in particular a human. In some embodiments of methods provided herein, the pharmaceutical composition can be administered parenterally, locally, or systemically. For example, the pharmaceutical composition can be administered intranasally, intramuscularly, intradermally, intraperitoneally, intravenously, subcutaneously, orally, or by pulmonary administration. In some embodiments, in the variant ADA2 protein or catalytically active portion thereof provided herein, the variant ADA2 protein in the methods, compositions, conjugates, modified forms, vectors, cells, combinations, uses and compositions for use, and the nucleic acids encoding the variant ADA2 provided herein and vectors that include the nucleic acids, the modifications can be from any one or more of the following amino acid replacement(s), insertion(s), deletion(s), and any combination thereof. The modification(s) listed below are with reference to mature numbering, as set forth in the amino acid positions set forth in SEQ ID NO:5. Exemplary of ADA2 variants provided herein are the following; it is understood that the different types of mutants (amino acid modifications) can be combined to exploit the properties of each type of mutation. It is understood by those of skill in the art that, in general, the effects of mutations in proteins are at least additive, and can be synergistic. 1. Heparin binding mutants The following modifications can confer reduced heparin binding. Binding to heparin can deplete circulating levels of administered ADA2. Thus, the following ADA2 variants can increase the bioavailability and pharmacokinetics of the administered ADA2: K11A; K11D; K11E; K13A; K13D; K13E; K371A; K371D; K371E; K372A; K372D; K372E; K452A; K452D; K452E; R20A; R20D; R20E; R366A; R366D; R366E; K26A; K26D; K26E; R217A; R217D; R217E; K258A; K258D; K258E; R277A; R277D; R277E; R283A; R283D; R283E; K309A; K309D; K309E; K317A; K317D; K317E; K321A; K321D; K321E; R352A; R352D; R352E; R441A; R441D; R441E; K444A; K444D; K444E; K461A; K461D; K461E; K469A; K469D; K469E; K470A; K470D; and K470E. Examples of heparin binding mutants containing these replacements. K11A (SEQ ID NO:13); K11D (SEQ ID NO:14); K11E (SEQ ID NO:15); K13A (SEQ ID NO:16); K13D (SEQ ID NO:17); K13E (SEQ ID NO:18); K371A (SEQ ID NO:19); K371D (SEQ ID NO:20); K371E (SEQ ID NO:21); K372A (SEQ ID NO:22); K372D (SEQ ID NO:23); K372E (SEQ ID NO:24); K452A (SEQ ID NO:25); K452D (SEQ ID NO:26); K452E (SEQ ID NO:27); R20A (SEQ ID NO:28); R20D (SEQ ID NO:29); R20E (SEQ ID NO:30); R366A (SEQ ID NO:31); R366D (SEQ ID NO:32); R366E (SEQ ID NO:33); K26A (SEQ ID NO:71); K26D (SEQ ID NO:72); K26E (SEQ ID NO:73); R217A (SEQ ID NO:74); R217D (SEQ ID NO:75); R217E (SEQ ID NO:76); K258A (SEQ ID NO:77); K258D (SEQ ID NO:78); K258E (SEQ ID NO:79); R277A (SEQ ID NO:80); R277D (SEQ ID NO:81); R277E (SEQ ID NO:82); R283A (SEQ ID NO:83); R283D (SEQ ID NO:84); R283E (SEQ ID NO:85); K309A (SEQ ID NO:86); K309D (SEQ ID NO:87); K309E (SEQ ID NO:88); K317A (SEQ ID NO:89); K317D (SEQ ID NO:90); K317E (SEQ ID NO:91); K321A (SEQ ID NO:92); K321D (SEQ ID NO:93); K321E (SEQ ID NO:94); R352A (SEQ ID NO:95); R352D (SEQ ID NO:96); R352E (SEQ ID NO:97); R441A (SEQ ID NO:98); R441D (SEQ ID NO:99); R441E (SEQ ID NO:100); K444A (SEQ ID NO:101); K444D (SEQ ID NO:102); K444E (SEQ ID NO:103); K461A (SEQ ID NO:104); K461D (SEQ ID NO:105); K461E (SEQ ID NO:106); K469A (SEQ ID NO:107); K469D (SEQ ID NO:108); K469E (SEQ ID NO:109); K470A (SEQ ID NO:110); K470D (SEQ ID NO:111); and K470E (SEQ ID NO:112). 2. Active site mutants The following modifications can confer increased catalytic efficiency. The modifications are in select residues of the active site, and can effect improved catalytic efficiency <com:Math><semantics>(kcat / Km)<annotation encoding="application / x-tex">(k_{cat} / K_m)< / annotation>< / semantics>< / com:Math> for adenosine. Binding to heparin can deplete circulating levels of administered ADA2. Thus, the following ADA2 variants can confer increased adenosine deaminase activity: H264A; H264Q; H264N; H264G; R219K; R219Q; R219N; R219A; L221A; L221V; L221G; E179D; E179A; E179S; E179T; E179V; E179G; S262A; S262V; S262M; S262N; D86A; D86C; D86E; D86F; D86G; D86H; D86I; D86K; D86L; D86M; D86N; D86P; D86Q; D86R; D86S; D86T; D86V; D86W; D86Y; E179C; E179F; E179H; E179I; E179K; E179L; E179M; E179N; E179P; E179Q; E179R; E179W; E179Y; R219C; R219D; R219E; R219F; R219G; R219H; R219I; R219L; R219M; R219P; R219S; R219T; R219V; R219W; R219Y; L221C; L221D; L221E; L221F; L221H; L221I; L221K; L221M; L221N; L221P; L221Q; L221R; L221S; L221T; L221W; L221Y; S262C; S262D; S262E; S262F; S262G; S262H; S262I; S262K; S262L; S262P; S262Q; S262R; S262T; S262W; S262Y; H264C; H264D; H264E; H264F; H264I; H264K; H264L; H264M; H264P; H264R; H264S; H264T; H264V; H264W; H264Y; S266A; S266C; S266D; S266E; S266F; S266G; S266H; S266I; S266K; S266L; S266M; S266N; S266P; S266Q; S266R; S266T; S266V; S266W; S266Y; K267A; K267C; K267D; K267E; K267F; K267G; K267H; K267I; K267L; K267M; K267N; K267P; K267Q; K267R; K267S; K267T; K267V; K267W; K267Y; V296A; V296C; V296D; V296E; V296F; V296G; V296H; V296I; V296K; V296L; V296M; V296N; V296P; V296Q; V296R; V296S; V296T; V296W; and V296Y. Examples of Active site mutants containing these replacements: H264A (SEQ ID NO:34); H264Q (SEQ ID NO:35); H264N (SEQ ID NO:36); H264G (SEQ ID NO:37); R219K (SEQ ID NO:38); R219Q (SEQ ID NO:39); R219N (SEQ ID NO:40); R219A (SEQ ID NO:41); L221A (SEQ ID NO:42); L221V (SEQ ID NO:43); L221G (SEQ ID NO:44); E179D (SEQ ID NO:45); E179A (SEQ ID NO:46); E179S (SEQ ID NO:47); E179T (SEQ ID NO:48); E179V (SEQ ID NO:49); E179G [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 3. Hyperglycosylation mutants The following modifications introduce a non-native glycosylation site in ADA2. Introduction of non-native glycosylation sites, such as N-linked glycosylation sites, can confer an increase in stability and pharmacokinetic profiles. Thus, the following ADA2 variants can effect hyperglycosylation of ADA2, and increase the stability and pharmacokinetic profiles of the administered ADA2: <com:Math><semantics>→<annotation encoding="application / x-tex">\longrightarrow< / annotation>< / semantics>< / com:Math> N1 / --->A2 / --->S3; R20N / V22S; K371N / D373S; K372N / I374S; T403N / H405S; and G404N / P406S. Examples of Hyperglycosylation mutants containing these replacements: <com:Math><semantics>→<annotation encoding="application / x-tex">\longrightarrow< / annotation>< / semantics>< / com:Math> N1 / ---> A2 / ---> S3 (SEQ ID NO:274); R20N / V22S (SEQ ID NO:275); K371N / D373S (SEQ ID NO:276); K372N / I374S (SEQ ID NO:277); T403N / H405S (SEQ ID NO:278); and G404N / P406S (SEQ ID NO:279). 4. PRB deletion and replacement mutants The following variants contain a modified PRB domain. The modifications of the PRB domain can include deletion of all or a portion of the PRB domain (i.e. deletion of one or more residues of the PRB domain), insertion of one or more amino acid residues into the PRB domain, amino acid replacement of one or more residues of the PRB domain or a combination thereof. Deletion and / or substitution of the PRB domain can confer altered activity, e.g., reduction in binding to a receptor and / or the activity mediated by the receptor. C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)n, where n = 2 to 20; C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>15< / com:Sub>; C105- <com:Math><semantics>T147del→(Gly)10<annotation encoding="application / x-tex">T147del \rightarrow (Gly)10< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>C105−T147del→(Gly)7<annotation encoding="application / x-tex">C105-T147del \rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>C105−T147del→(Gly)5<annotation encoding="application / x-tex">C105-T147del \rightarrow (Gly)_5< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>C105−T147del→(Gly)7<annotation encoding="application / x-tex">C105-T147del \rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>C105−T147del→(Gly)7<annotation encoding="application / x-tex">C105-T147del \rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>C105−T147del→(Gly)7<annotation encoding="application / x-tex">C105-T147del \rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>C105−T147del→(Gly)7<annotation encoding="application / x-tex">C105-T147del \rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>C105−T147del→(Gly)7<annotation encoding="application / x-tex">C105-T147del \rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>C105−T147del→(G<annotation encoding="application / x-tex">C105-T147del \rightarrow (G< / annotation>< / semantics>< / com:Math> <com:Math><semantics>T147del→(Gly)3<annotation encoding="application / x-tex">T147del \rightarrow (Gly)_3< / annotation>< / semantics>< / com:Math>; N98-N156del; C105-E148del; C105-T147del; V99-Q144del; V99- Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, where n = 1 to 5; C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, where n = 1 to 5; V99-Q144del→(GGGGS)<com:Sub>1< / com:Sub>; V99-Q144del→(GGGGS)<com:Sub>2< / com:Sub>; V99- Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)<com:Sub>3< / com:Sub>; C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)<com:Sub>1< / com:Sub>; C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)<com:Sub>2< / com:Sub>; and <com:Math><semantics>C105−T147del→(GGGGS)3<annotation encoding="application / x-tex">C105-T147del \rightarrow (GGGGS)_3< / annotation>< / semantics>< / com:Math> Examples of PRB deletion and replacement mutants containing these replacements: C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)n (SEQ ID NO:280); C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>15< / com:Sub> (SEQ ID NO:281); C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>10< / com:Sub> (SEQ ID NO:282); C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>7< / com:Sub> (SEQ ID NO:283); C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>5< / com:Sub> (SEQ ID NO:284); C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>3< / com:Sub> (SEQ ID NO:285); N98-N156del (SEQ ID NO:548); C105-E148del (SEQ ID NO:549); C105-T147del (SEQ ID NO:550); V99-Q144del (SEQ ID NO:579); V99- Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, where n = 1 to 5 (SEQ ID NO:581); C105- T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, where n = 1 to 5 (SEQ ID NO:582); V99- Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)<com:Sub>1< / com:Sub> (SEQ ID NO:583); V99-Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)<com:Sub>2< / com:Sub> (SEQ ID NO:584); V99-Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)<com:Sub>3< / com:Sub> (SEQ ID NO:585); C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)<com:Sub>1< / com:Sub> (SEQ ID NO:586); C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)<com:Sub>2< / com:Sub> (SEQ ID NO:587); and C105- <com:Math><semantics>T147del→(GGGGS)3(SEQIDNO:588)<annotation encoding="application / x-tex">T147del \rightarrow (GGGGS)_3 (SEQ ID NO:588)< / annotation>< / semantics>< / com:Math> 5. PRB hyperglycosylation mutants The following modifications can introduce a non-native glycosylation site in the PRB domain. Introduction of non-native glycosylation sites, such as N-linked glycosylation sites, in the PRB domain can confer an increase in stability and pharmacokinetic profiles and / or other activities, e.g., reduction in binding to a receptor. Thus, the following ADA2 variants can effect hyperglycosylation of the ADA2 in the PRB domain, reduce receptor binding, and increase the stability and pharmacokinetic profiles of the administered ADA2: R125N / P126A; S127N / K129S; P126N / E128T; R112N / I114T; I134N / L135C / L136T; I134N / L135S / L136T; R142N / Q144S; E137N / Y139T; and P111N / G113S. Examples of PRB hyperglycosylation mutants containing these replacements: R125N / P126A (SEQ ID NO:552); S127N / K129S (SEQ ID NO:553); P126N / E128T (SEQ ID NO:554); R112N / I114T (SEQ ID NO:555); I134N / L135C / L136T (SEQ ID NO:556); I134N / L135S / L136T (SEQ ID NO:557); R142N / Q144S (SEQ ID NO:558); E137N / Y139T (SEQ ID NO:559); and P111N / G113S (SEQ ID NO:560). 6. PRB-ADA domain interaction mutants The following modifications can confer altered interaction between the PRB domain and the rest of ADA2 (e.g., the adenosine deaminase (ADA) domain). Altering the interaction between the PRB domain and the rest of ADA2, such as the ADA domain, can confer an activity, e.g., an increase in the adenosine deaminse activity and a reduction in receptor binding: F119S; F119K; Y224R; Y224N; Y191S; Y191D; F183K; Y191D / Y224R; F109S; F109A; R118D; R118A; Y139T; Y139A; W133S; W133T; P124A; and P124S. Examples of PRB-ADA domain interaction mutants containing these replacements: F119S (SEQ ID NO:561); F119K (SEQ ID NO:562); Y224R (SEQ ID NO:563); Y224N (SEQ ID NO:564); Y191S (SEQ ID NO:565); Y191D (SEQ ID NO:566); F183K (SEQ ID NO:567); Y191D / Y224R (SEQ ID NO:568); F109S (SEQ ID NO:569); F109A (SEQ ID NO:570); R118D (SEQ ID NO:571); R118A (SEQ ID NO:572); Y139T (SEQ ID NO:573); Y139A (SEQ ID NO:574); W133S (SEQ ID NO:575); W133T (SEQ'ID NO:576); P124A (SEQ ID NO:577); and P124S (SEQ ID NO:578). 7. Combinations of mutations with hyperglycosylation mutants The following variants combine modifications that effect improved catalytic efficiency <com:Math><semantics>(kcat / Km)<annotation encoding="application / x-tex">(k_{cat} / K_m)< / annotation>< / semantics>< / com:Math> for adenosine, such as R219Q and / or S262N, with modifications that introduce non-native glycosylation sites: <com:Math><semantics>R219Q / S262N / −−→N1 / −−→A2 / −−→S3<annotation encoding="application / x-tex">R219Q / S262N / --\rightarrow N1 / --\rightarrow A2 / --\rightarrow S3< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R219Q / S262N / R20N / V22S<annotation encoding="application / x-tex">R219Q / S262N / R20N / V22S< / annotation>< / semantics>< / com:Math>; R219Q / S262N / K371N / D373S; R219Q / S262N / K372N / I374S; R219Q / S262N / T403N / H405S; and R219Q / S262N / G404N / P406S. Combination with hyperglycosylation mutants containing these replacements: <com:Math><semantics>R219Q / S262N / −−→N1 / −−→A2 / −−→S3<annotation encoding="application / x-tex">R219Q / S262N / --\rightarrow N1 / --\rightarrow A2 / --\rightarrow S3< / annotation>< / semantics>< / com:Math> (SEQ ID NO:596); R219Q / S262N / R20N / V22S (SEQ ID NO:597); R219Q / S262N / K371N / D373S (SEQ ID NO:598); R219Q / S262N / K372N / I374S (SEQ ID NO:599); R219Q / S262N / T403N / H405S (SEQ ID NO:600); and R219Q / S262N / G404N / P406S (SEQ ID NO:601). 8. Combinations of muations with PRB hyperglycosylation mutants The following variants combine modifications that effect improved catalytic efficiency <com:Math><semantics>(kcat / Km)<annotation encoding="application / x-tex">(k_{cat} / K_m)< / annotation>< / semantics>< / com:Math> for adenosine, such as R219Q and / or S262N, with modifications that introduce non-native glycosylation sites in the PRB domain: R219Q / S262N / R125N / P126A; R219Q / S262N / S127N / K129S; R219Q / S262N / P126N / E128T; R219Q / S262N / R112N / I114T; R219Q / S262N / I134N / L135C / L136T; R219Q / S262N / I134N / L135S / L136T; R219Q / S262N / R142N / Q144S; R219Q / S262N / E137N / Y139T; and R219Q / S262N / P111N / G113S. Examples of combinations with PRB hyperglycosylation mutants containing these replacements: R219Q / S262N / R125N / P126A (SEQ ID NO:607); R219Q / S262N / S127N / K129S (SEQ ID NO:608); R219Q / S262N / P126N / E128T (SEQ ID NO:609); R219Q / S262N / R112N / I114T (SEQ ID NO:610); R219Q / S262N / I134N / L135C / L136T (SEQ ID NO:611); R219Q / S262N / I134N / L135S / L136T (SEQ ID NO:612); R219Q / S262N / R142N / Q144S (SEQ ID NO:613); R219Q / S262N / E137N / Y139T (SEQ ID NO:614); and R219Q / S262N / P111N / G113S (SEQ ID NO:615). 9. Combinations with PRB-ADA domain interaction mutants The following variants combine modifications that effect improved catalytic efficiency <com:Math><semantics>(kcat / Km)<annotation encoding="application / x-tex">(k_{cat} / K_m)< / annotation>< / semantics>< / com:Math> for adenosine, such as R219Q and / or S262N, with modifications that alter the interaction between the PRB domain and the rest of ADA2 (e.g., the adenosine deaminase (ADA) domain): R219Q / S262N / F119S; R219Q / S262N / F119K; R219Q / S262N / Y224R; R219Q / S262N / Y224N; R219Q / S262N / Y191S; R219Q / S262N / Y191D; R219Q / S262N / F183K; R219Q / S262N / Y191D / Y224R; R219Q / S262N / F109S; R219Q / S262N / F109A; R219Q / S262N / R118D; R219Q / S262N / R118A; R219Q / S262N / Y139T; R219Q / S262N / Y139A; R219Q / S262N / W133S; R219Q / S262N / W133T; R219Q / S262N / P124A; and R219Q / S262N / P124S. Combinations with PRB-ADA domain interaction mutants containing these replacements: R219Q / S262N / F119S (SEQ ID NO:616); R219Q / S262N / F119K (SEQ ID NO:617); R219Q / S262N / Y224R (SEQ ID NO:618); R219Q / S262N / Y224N (SEQ ID NO:619); R219Q / S262N / Y191S (SEQ ID NO:620); R219Q / S262N / Y191D (SEQ ID NO:621); R219Q / S262N / F183K (SEQ ID NO:622); R219Q / S262N / Y191D / Y224R (SEQ ID NO:623); R219Q / S262N / F109S (SEQ ID NO:624); R219Q / S262N / F109A (SEQ ID NO:625); R219Q / S262N / R118D (SEQ ID NO:626); R219Q / S262N / R118A (SEQ ID NO:627); R219Q / S262N / Y139T (SEQ ID NO:628); R219Q / S262N / Y139A (SEQ ID NO:629); R219Q / S262N / W133S (SEQ ID NO:630); R219Q / S262N / W133T (SEQ ID NO:631); R219Q / S262N / P124A (SEQ ID NO:632); and R219Q / S262N / P124S (SEQ ID NO:633). 10. Combinations with PRB deletion mutants The following variants combine modifications that effect improved catalytic efficiency <com:Math><semantics>(kcat / Km)<annotation encoding="application / x-tex">(k_{cat} / K_m)< / annotation>< / semantics>< / com:Math> for adenosine, such as R219Q and / or S262N, and / or modifications that confer reduced heparin binding, such as K371D, with modifications, e.g., deletions, insertions, substitutions, and / or replacements, in the PRB domain: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>R219Q / S262N / C105−T147del→(Gly)15<annotation encoding="application / x-tex">R219Q / S262N / C105-T147del \rightarrow (Gly)_{15}< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R219Q / S262N / C105−T147del→(Gly)10<annotation encoding="application / x-tex">R219Q / S262N / C105-T147del \rightarrow (Gly)_{10}< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R219Q / S262N / C105−T147del→(Gly)7<annotation encoding="application / x-tex">R219Q / S262N / C105-T147del \rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R219Q / S262N / C105−T147del→(Gly)5<annotation encoding="application / x-tex">R219Q / S262N / C105-T147del \rightarrow (Gly)_5< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R219Q / S262N / C105−T147del→(Gly)3;R219Q / S262N / V99−Q144del→(GGGGS)1;<annotation encoding="application / x-tex">R219Q / S262N / C105-T147del \rightarrow (Gly)_3; R219Q / S262N / V99-Q144del \rightarrow (GGGGS)_1;< / annotation>< / semantics>< / com:Math> <com:Math><semantics>R219Q / S262N / V99−Q144del→(GGGGS)2;R219Q / S262N / V99−<annotation encoding="application / x-tex">R219Q / S262N / V99-Q144del \rightarrow (GGGGS)_2; R219Q / S262N / V99-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>Q144del→(GGGGS)3<annotation encoding="application / x-tex">Q144del \rightarrow (GGGGS)_3< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R219Q / S262N / C105−T147del→(GGGGS)1<annotation encoding="application / x-tex">R219Q / S262N / C105-T147del \rightarrow (GGGGS)_1< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R219Q / S262N / C105−T147del→(GGGGS)2;R219Q / S262N / C105−<annotation encoding="application / x-tex">R219Q / S262N / C105-T147del \rightarrow (GGGGS)_2; R219Q / S262N / C105-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>T147del→(GGGGS)3<annotation encoding="application / x-tex">T147del \rightarrow (GGGGS)_3< / annotation>< / semantics>< / com:Math>; R219Q / S262N / K371D / V99-Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)<com:Sub>1< / com:Sub>; <com:Math><semantics>R219Q / S262N / K371D / V99−Q144del→(GGGGS)2;R219Q / S262N / K371D / V99−<annotation encoding="application / x-tex">R219Q / S262N / K371D / V99-Q144del \rightarrow (GGGGS)_2; R219Q / S262N / K371D / V99-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>Q144del→(GGGGS)3<annotation encoding="application / x-tex">Q144del \rightarrow (GGGGS)_3< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R219Q / S262N / K371D / C105−T147del→(GGGGS)1<annotation encoding="application / x-tex">R219Q / S262N / K371D / C105-T147del \rightarrow (GGGGS)_1< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R219Q / S262N / K371D / C105−T147del→(GGGGS)2;R219Q / S262N / K371D / C105−<annotation encoding="application / x-tex">R219Q / S262N / K371D / C105-T147del \rightarrow (GGGGS)_2; R219Q / S262N / K371D / C105-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>T147del→(GGGGS)3<annotation encoding="application / x-tex">T147del \rightarrow (GGGGS)_3< / annotation>< / semantics>< / com:Math>; K371D / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)n, where n = 2 to 20; <com:Math><semantics>K371D / C105−T147del→(Gly)15;K371D / C105−T147del→(Gly)10;K371D / C105−<annotation encoding="application / x-tex">K371D / C105-T147del \rightarrow (Gly)_{15}; K371D / C105-T147del \rightarrow (Gly)_{10}; K371D / C105-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>T147del→(Gly)7<annotation encoding="application / x-tex">T147del \rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math>; K371D / C105-T147del<com:Math><semantics>→(Gly)5<annotation encoding="application / x-tex">\rightarrow (Gly)_5< / annotation>< / semantics>< / com:Math>; K371D / C105-T147del<com:Math><semantics>→(Gly)3<annotation encoding="application / x-tex">\rightarrow (Gly)_3< / annotation>< / semantics>< / com:Math>; K371D / V99-Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, where n = 1 to 5; K371D / C105- <com:Math><semantics>T147del→(GGGGS)n<annotation encoding="application / x-tex">T147del \rightarrow (GGGGS)n< / annotation>< / semantics>< / com:Math>, where <com:Math><semantics>n=1<annotation encoding="application / x-tex">n = 1< / annotation>< / semantics>< / com:Math> to 5; K371D / N98-N156del; K371D / C105- E148del; K371D / C105-T147del; K371D / V99-Q144del; R219Q / S262N / C105- T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)n, where n = 2 to 20; R219Q / S262N / V99-Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, where <com:Math><semantics>n=1<annotation encoding="application / x-tex">n = 1< / annotation>< / semantics>< / com:Math> to 5; R219Q / S262N / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, where <com:Math><semantics>n=1<annotation encoding="application / x-tex">n = 1< / annotation>< / semantics>< / com:Math> to 5; R219Q / S262N / N98-N156del; R219Q / S262N / C105-E148del; R219Q / S262N / C105- T147del; R219Q / S262N / V99-Q144del; R219Q / S262N / K371D / C105- <com:Math><semantics>T147del→(Gly)n<annotation encoding="application / x-tex">T147del \rightarrow (Gly)n< / annotation>< / semantics>< / com:Math>, where n = 2 to 20; R219Q / S262N / K371D / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>15< / com:Sub>; <com:Math><semantics>R219Q / S262N / K371D / C105−T147del→(Gly)10<annotation encoding="application / x-tex">R219Q / S262N / K371D / C105-T147del \rightarrow (Gly)_{10}< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>R219Q / S262N / K371D / C105−<annotation encoding="application / x-tex">R219Q / S262N / K371D / C105-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>T147del→(Gly)7<annotation encoding="application / x-tex">T147del \rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math>; R219Q / S262N / K371D / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>5< / com:Sub>; <com:Math><semantics>R219Q / S262N / K371D / C105−T147del→(Gly)3;R219Q / S262N / K371D / V99−<annotation encoding="application / x-tex">R219Q / S262N / K371D / C105-T147del \rightarrow (Gly)_3; R219Q / S262N / K371D / V99-< / annotation>< / semantics>< / com:Math> Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, where n = 1 to 5; R219Q / S262N / K371D / C105- <com:Math><semantics>T147del→(GGGGS)n<annotation encoding="application / x-tex">T147del \rightarrow (GGGGS)n< / annotation>< / semantics>< / com:Math>, where <com:Math><semantics>n=1<annotation encoding="application / x-tex">n = 1< / annotation>< / semantics>< / com:Math> to 5; <com:Math><semantics>R219Q / S262N / K371D / N98−N156del<annotation encoding="application / x-tex">R219Q / S262N / K371D / N98-N156del< / annotation>< / semantics>< / com:Math>; R219Q / S262N / K371D / C105-E148del; R219Q / S262N / K371D / C105-T147del; R219Q / S262N / K371D / V99-Q144del; R219Q / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)n, where n = 2 to 20; R219Q / V99-Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, where n = 1 to 5; R219Q / C105- <com:Math><semantics>T147del→(GGGGS)n<annotation encoding="application / x-tex">T147del \rightarrow (GGGGS)n< / annotation>< / semantics>< / com:Math>, where n = 1 to 5; R219Q / N98-N156del; R219Q / C105- E148del; R219Q / C105-T147del; R219Q / V99-Q144del; S262N / C105- <com:Math><semantics>T147del→(Gly)n<annotation encoding="application / x-tex">T147del \rightarrow (Gly)n< / annotation>< / semantics>< / com:Math>, where <com:Math><semantics>n=2<annotation encoding="application / x-tex">n = 2< / annotation>< / semantics>< / com:Math> to 20; <com:Math><semantics>S262N / V99−Q144del→(GGGGS)n<annotation encoding="application / x-tex">S262N / V99-Q144del \rightarrow (GGGGS)n< / annotation>< / semantics>< / com:Math>, where <com:Math><semantics>n=1<annotation encoding="application / x-tex">n = 1< / annotation>< / semantics>< / com:Math> to 5; S262N / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, where n = 1 to 5; S262N / N98-N156del; and S262N / C105-E148del; S262N / C105-T147del; and S262N / V99-Q144del. Examples of combination with PRB deletion mutants containing these replacements: <com:Math><semantics>K371D / V99−Q144del→(GGGGS)1<annotation encoding="application / x-tex">K371D / V99-Q144del \rightarrow (GGGGS)_1< / annotation>< / semantics>< / com:Math> (SEQ ID NO:589); <com:Math><semantics>K371D / V99−<annotation encoding="application / x-tex">K371D / V99-< / annotation>< / semantics>< / com:Math> Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)<com:Sub>2< / com:Sub> (SEQ ID NO:590); K371D / V99-Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)<com:Sub>3< / com:Sub> (SEQ ID NO:591); K371D / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)<com:Sub>1< / com:Sub> (SEQ ID NO:592); K371D / C105- <com:Math><semantics>T147del→(GGGGS)2<annotation encoding="application / x-tex">T147del \rightarrow (GGGGS)_2< / annotation>< / semantics>< / com:Math> (SEQ ID NO:593); K371D / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math> (GGGGS)<com:Sub>3< / com:Sub> (SEQ ID NO:594); R219Q / S262N / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>15< / com:Sub> (SEQ ID NO:602); R219Q / S262N / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>10< / com:Sub> (SEQ ID NO:603); R219Q / S262N / C105- <com:Math><semantics>T147del→(Gly)7<annotation encoding="application / x-tex">T147del \rightarrow (Gly)_7< / annotation>< / semantics>< / com:Math> (SEQ ID NO:604); R219Q / S262N / C105-T147del <com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math> (Gly)<com:Sub>5< / com:Sub> (SEQ ID NO:605); R219Q / S262N / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>3< / com:Sub> (SEQ ID NO:606); <com:Math><semantics>R219Q / S262N / V99−Q144del→(GGGGS)1(SEQIDNO:634);R219Q / S262N / V99−<annotation encoding="application / x-tex">R219Q / S262N / V99-Q144del \rightarrow (GGGGS)_1 (SEQ ID NO:634); R219Q / S262N / V99-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>Q144del→(GGGGS)2<annotation encoding="application / x-tex">Q144del \rightarrow (GGGGS)_2< / annotation>< / semantics>< / com:Math> (SEQ ID NO:635); R219Q / S262N / V99-Q144del<com:Math><semantics>→(GGGGS)3<annotation encoding="application / x-tex">\rightarrow (GGGGS)_3< / annotation>< / semantics>< / com:Math> (SEQ ID NO:636); R219Q / S262N / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)<com:Sub>1< / com:Sub> (SEQ ID NO:637); <com:Math><semantics>R219Q / S262N / C105−T147del→(GGGGS)2(SEQIDNO:638);R219Q / S262N / C105−<annotation encoding="application / x-tex">R219Q / S262N / C105-T147del \rightarrow (GGGGS)_2 (SEQ ID NO:638); R219Q / S262N / C105-< / annotation>< / semantics>< / com:Math> <com:Math><semantics>T147del→(GGGGS)3<annotation encoding="application / x-tex">T147del \rightarrow (GGGGS)_3< / annotation>< / semantics>< / com:Math> (SEQ ID NO:639); R219Q / S262N / K371D / V99- <com:Math><semantics>Q144del→(GGGGS)1<annotation encoding="application / x-tex">Q144del \rightarrow (GGGGS)_1< / annotation>< / semantics>< / com:Math> (SEQ ID NO:640); R219Q / S262N / K371D / V99- Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)<com:Sub>2< / com:Sub> (SEQ ID NO:641); R219Q / S262N / K371D / V99- Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)<com:Sub>3< / com:Sub> (SEQ ID NO:642); R219Q / S262N / K371D / C105- <com:Math><semantics>T147del→(GGGGS)1<annotation encoding="application / x-tex">T147del \rightarrow (GGGGS)_1< / annotation>< / semantics>< / com:Math> (SEQ ID NO:643); R219Q / S262N / K371D / C105- <com:Math><semantics>T147del→(GGGGS)2<annotation encoding="application / x-tex">T147del \rightarrow (GGGGS)_2< / annotation>< / semantics>< / com:Math> (SEQ ID NO:644); R219Q / S262N / K371D / C105- <com:Math><semantics>T147del→(GGGGS)3<annotation encoding="application / x-tex">T147del \rightarrow (GGGGS)_3< / annotation>< / semantics>< / com:Math> (SEQ ID NO:645); K371D / C105-T147del <com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math> (Gly)n, where n = 2 to 20 (SEQ ID NO:646); K371D / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>15< / com:Sub> (SEQ ID NO:647); <com:Math><semantics>K371D / C105−T147del→(Gly)10<annotation encoding="application / x-tex">K371D / C105-T147del \rightarrow (Gly)_{10}< / annotation>< / semantics>< / com:Math> (SEQ ID NO:648); <com:Math><semantics>K371D / C105−T147del→(Gly)7<annotation encoding="application / x-tex">K371D / C105-T147del \rightarrow (Gly)_{7}< / annotation>< / semantics>< / com:Math> (SEQ ID NO:649); K371D / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>5< / com:Sub> (SEQ ID NO:650); K371D / C105- <com:Math><semantics>T147del→(Gly)3<annotation encoding="application / x-tex">T147del \rightarrow (Gly)_3< / annotation>< / semantics>< / com:Math> (SEQ ID NO:651); K371D / V99-Q144del <com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math> (GGGGS)n, where n = 1 to 5 (SEQ ID NO:652); K371D / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math> (GGGGS)n, where n = 1 to 5 (SEQ ID NO:653); K371D / N98-N156del (SEQ ID NO:654); K371D / C105-E148del (SEQ ID NO:655); K371D / C105-T147del (SEQ ID NO:656); K371D / V99-Q144del (SEQ ID NO:657); R219Q / S262N / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)n, where n = 2 to 20 (SEQ ID NO:658); R219Q / S262N / V99-Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, where n = 1 to 5 (SEQ ID NO:664); R219Q / S262N / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, where n = 1 to 5 (SEQ ID NO:665); R219Q / S262N / N98-N156del (SEQ ID NO:666); R219Q / S262N / C105- E148del (SEQ ID NO:667); R219Q / S262N / C105-T147del (SEQ ID NO:668); R219Q / S262N / V99-Q144del (SEQ ID NO:669); R219Q / S262N / K371D / C105- <com:Math><semantics>T147del→(Gly)n<annotation encoding="application / x-tex">T147del \rightarrow (Gly)n< / annotation>< / semantics>< / com:Math>, where n = 2 to 20 (SEQ ID NO:670); R219Q / S262N / K371D / C105- <com:Math><semantics>T147del→(Gly)15<annotation encoding="application / x-tex">T147del \rightarrow (Gly)_{15}< / annotation>< / semantics>< / com:Math> (SEQ ID NO:671); R219Q / S262N / K371D / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>10< / com:Sub> (SEQ ID NO:672); R219Q / S262N / K371D / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>7< / com:Sub> (SEQ ID NO:673); <com:Math><semantics>R219Q / S262N / K371D / C105−T147del→(Gly)5(SEQIDNO:674);<annotation encoding="application / x-tex">R219Q / S262N / K371D / C105-T147del \rightarrow (Gly)_5 (SEQ ID NO:674);< / annotation>< / semantics>< / com:Math> R219Q / S262N / K371D / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(Gly)<com:Sub>3< / com:Sub> (SEQ ID NO:675); R219Q / S262N / K371D / V99-Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, where n = 1 to 5 (SEQ ID NO:676); R219Q / S262N / K371D / C105-T147del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, where n = 1 to 5 (SEQ ID NO:677); R219Q / S262N / K371D / N98-N156del (SEQ ID NO:678); R219Q / S262N / K371D / C105-E148del (SEQ ID NO:679); R219Q / S262N / K371D / C105-T147del (SEQ ID NO:680); R219Q / S262N / K371D / V99-Q144del (SEQ ID NO:681); R219Q / C105- <com:Math><semantics>T147del→(Gly)n<annotation encoding="application / x-tex">T147del \rightarrow (Gly)n< / annotation>< / semantics>< / com:Math>, where n = 2 to 20 (SEQ ID NO:918); R219Q / V99- Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, where n = 1 to 5 (SEQ ID NO:919); R219Q / C105- <com:Math><semantics>T147del→(GGGGS)n<annotation encoding="application / x-tex">T147del \rightarrow (GGGGS)n< / annotation>< / semantics>< / com:Math>, where <com:Math><semantics>n=1<annotation encoding="application / x-tex">n = 1< / annotation>< / semantics>< / com:Math> to 5 (SEQ ID NO:920); R219Q / N98-N156del (SEQ ID NO:921); R219Q / C105-E148del (SEQ ID NO:922); R219Q / C105-T147del (SEQ ID NO:923); R219Q / V99-Q144del (SEQ ID NO:924); S262N / C105- <com:Math><semantics>T147del→(Gly)n<annotation encoding="application / x-tex">T147del \rightarrow (Gly)n< / annotation>< / semantics>< / com:Math>, where n = 2 to 20 (SEQ ID NO:925); S262N / V99- Q144del<com:Math><semantics>→<annotation encoding="application / x-tex">\rightarrow< / annotation>< / semantics>< / com:Math>(GGGGS)n, where n = 1 to 5 (SEQ ID NO:926); S262N / C105- <com:Math><semantics>T147del→(GGGGS)n<annotation encoding="application / x-tex">T147del \rightarrow (GGGGS)n< / annotation>< / semantics>< / com:Math>, where <com:Math><semantics>n=1<annotation encoding="application / x-tex">n = 1< / annotation>< / semantics>< / com:Math> to 5 (SEQ ID NO:927); S262N / N98-N156del (SEQ ID NO:928); S262N / C105-E148del (SEQ ID NO:929); S262N / C105-T147del (SEQ ID NO:930); and S262N / V99-Q144del (SEQ ID NO:931). 11. Other combination mutants The following variants combine various modifications, such as modifications that effect improved catalytic efficiency <com:Math><semantics>(kcat / Km)<annotation encoding="application / x-tex">(k_{cat} / K_m)< / annotation>< / semantics>< / com:Math> for adenosine, such as R219Q and / or S262N, modifications that confer reduced heparin binding, such as K371D, and other modifications: K11A / R20A; K11A / R20A / K371A; R20A / K371A; K11A / K371A; S262N / K371D; S262N / K371E; S262N / R20E; S262N / R20E / K371D; [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] R219Q / S262N / K267A; R219Q / S262N / K267C; R219Q / S262N / K267D; R219Q / S262N / K267E; R219Q / S262N / K267F; R219Q / S262N / K267G; R219Q / S262N / K267H; R219Q / S262N / K267I; R219Q / S262N / K267L; R219Q / S262N / K267M; R219Q / S262N / K267N; R219Q / S262N / K267P; R219Q / S262N / K267Q; R219Q / S262N / K267R; R219Q / S262N / K267S; R219Q / S262N / K267T; R219Q / S262N / K267V; R219Q / S262N / K267W; R219Q / S262N / K267Y; R219Q / S262N / V296A; R219Q / S262N / V296C; R219Q / S262N / V296D; R219Q / S262N / V296E; R219Q / S262N / V296F; R219Q / S262N / V296G; R219Q / S262N / V296H; R219Q / S262N / V296I; R219Q / S262N / V296K; R219Q / S262N / V296L; R219Q / S262N / V296M; R219Q / S262N / V296N; R219Q / S262N / V296P; R219Q / S262N / V296Q; R219Q / S262N / V296R; R219Q / S262N / V296S; R219Q / S262N / V296T; R219Q / S262N / V296W; R219Q / S262N / V296Y; R219Q / K11A / R20A; R219Q / K11A / R20A / K371A; R219Q / R20A / K371A; R219Q / K11A / K371A; S262N / K11A / R20A; S262N / K11A / R20A / K371A; S262N / R20A / K371A; and S262N / K11A / K371A. Examples of these combination mutants containing these replacements: K11A / R20A (SEQ ID NO:55); K11A / R20A / K371A (SEQ ID NO:56); R20A / K371A (SEQ ID NO:57); K11A / K371A (SEQ ID NO:58); S262N / K371D (SEQ ID NO:59); S262N / K371E (SEQ ID NO:60); S262N / R20E (SEQ ID NO:61); S262N / R20E / K371D (SEQ ID NO:62); S262N / R20E / K371E (SEQ ID NO:63); R219Q / K371E (SEQ ID NO:263); R219Q / K371D (SEQ ID NO:264); R219Q / R20E (SEQ ID NO:265); R219Q / K371E / R20E (SEQ ID NO:266); R219Q / K371D / R20E (SEQ ID NO:267); R219Q / S262N / K371E (SEQ ID NO:268); R219Q / S262N / K371D (SEQ ID NO:269); R219Q / S262N / R20E (SEQ ID NO:270); R219Q / S262N / K371E / R20E (SEQ ID NO:271); R219Q / S262N / K371D / R20E (SEQ ID NO:272); R219Q / S262N (SEQ ID NO:273); R219Q / S262N / K11A (SEQ ID NO:659); R219Q / S262N / K11D (SEQ ID NO:660); R219Q / S262N / K11E (SEQ ID NO:661); R219Q / S262N / K13A (SEQ ID NO:662); R219Q / S262N / K13D (SEQ ID NO:663); R219Q / S262N / K13E (SEQ ID NO:682); R219Q / S262N / K371A (SEQ ID NO:683); R219Q / S262N / K372A (SEQ ID NO:684); R219Q / S262N / K372D (SEQ ID NO:685); R219Q / S262N / K372E (SEQ ID NO:686); R219Q / S262N / K452A (SEQ ID [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] BRIEF DESCRIPTION OF THE FIGURES Figures 1A-1F depict exemplary alignments of precursor human adenosine deaminase 2 (ADA2) set forth in SEQ ID NO:2 (residues 30-511 corresponding to mature ADA2 set forth in SEQ ID NO:5) with other ADA2 proteins. A "*" means that the aligned residues are identical, a ":" means that aligned residues are not identical, but are similar and contain conservative amino acids residues at the aligned position, and a "." means that the aligned residues are similar and contain semi- conservative amino acid residues at the aligned position. Residues corresponding to the putative receptor binding domain (PRB) are underlined. Exemplary, non-limiting, corresponding positions for amino acid replacements are indicated by highlighting. For example, Figure 1A depicts the alignment of ADA2 set forth in SEQ ID NO:2 with chimpanzee ADA2 set forth in SEQ ID NO:286. Figure 1B depicts the alignment of a ADA2 set forth in SEQ ID NO:2 with gorilla ADA2 set forth in SEQ ID NO:287. Figure 1C depicts the alignment of a ADA2 set forth in SEQ ID NO:2 with pygmy chimpanzee set forth in SEQ ID NO:288. Figure 1D depicts the alignment of ADA2 set forth in SEQ ID NO:2 with Sumatran orangutan ADA2 set forth in SEQ ID NO:289. Figure 1E depicts the alignment of ADA2 set forth in SEQ ID NO:2 with northern white-cheeked gibbon ADA2 set forth in SEQ ID NO:290. Figure 1F depicts the alignment of ADA2 set forth in SEQ ID NO:2 with crab-eating macaque ADA2 set forth in SEQ ID NO:291. Figure 2 depicts the biosynthesis and catabolism of extracellular adenosine, and adenosine receptor signaling (adapted from Antonioli et al. (2013) Nat Rev Can 13:842-857). Physiological conditions such as hypoxia, ischemia, inflammation, tumor environment or trauma can promote the extracellular accumulation of ATP, which is metabolized to AMP by the cell surface enzyme CD39. AMP is in turn metabolized to adenosine by CD73. Extracellular adenosine can bind to four different G-protein-coupled adenosine receptors (ADRs; i.e. A1, A2A, A2B and A3), expressed on the cell surface of nearby immune, tumor or other cells, to mediate various downstream adenosine-mediated signaling and activities, such as immunosuppression, cancer cell proliferation, cancer cell migration and / or metastasis, angiogenesis, and other effects. Nucleoside transporters (NTs) facilitate uptake of extracellular adenosine into cells. Adenosine deaminase 2 (ADA2), including exogenous ADA2 or variants as provided herein, can breakdown extracellular adenosine by catalyzing the conversion of adenosine to inosine. DETAILED DESCRIPTION Outline A. Definitions B. Adenosine Deaminase 2 (ADA2) and Modulation of Adenosine-Mediated Tumor Immunosuppression 1. Tumor Immunity and Immune Evasion 2. Adenosine Immunomodulation in Cancer and Tumor Microenvironment (TME) 3. Adenosine Deaminase and Targeting Adenosine in Treatment of Cancer C. Adenosine Deaminase 2 (ADA2) and Variants Thereof 1. Structure and Activity of ADA2 a. Structure of ADA2 b. Activities of ADA2 2. ADA2 Variants a. Exemplary Modifications Amino Acid Replacements ii. Modification(s) of PRB Domain iv. Hyperglycosylation D. Nucleic Acid Molecules Production of Variant ADA2 Proteins D. ADA2 Conjugates and Fusion Proteins Half-Life Extending Moieties a. Low Complexity Polypeptides b. C-terminal peptide (CTP) of the $\beta$ Subunit of Human Chorionic Gonadotropin Ξ, C. Immunoglobulin Constant Region (Fc) or Portions . . . · . Thereof d. Albumin or Fragment, or Variant Thereof . * e. Albumin Binding Moiety ſ, PAS Sequences g. HAP Sequences h. XTEN Sequences i. Transferrin or Fragment thereof j. Polymer conjugation Polyethylene Glycol (PEG) ii. Hydroxyethyl Starch (HES) iii. Polysialic Acids (PSA) iv. Other polymers 2. Methods of Producing Conjugates or Fusion Proteins Linkers ı. Peptide Linkers ii. Heterobifunctional linking agents E. Methods of Producing Nucleic Acids Encoding ADA2 and Polypeptides Thereof. Isolation or Preparation of Nucleic Acids Encoding ADA2 Polypeptides Generation of Mutant or Modified Nucleic Acid and Encoding Polypeptides 3. Vectors and Cells Immune cells that encode and express the ADA2 variants provided herein 4. Expression a. Prokaryotic Cells . b. Yeast Cells c. Insect Cells d. Mammalian Cells . . e. Plants 5. Purification Techniques F. Methods of Assessing Activity and Physical Properties of ADA2 1. Adenosine Deaminase Assay 2. Methods of Assessing Heparin Binding a. Affinity Assay b. ELISA Assay C. Dot Blot and other Radiolabeled Heparin Binding Assays 3. Methods for Assessing Stability a. Conditions i. Stability in Plasma ii. Thermal Stability iii. Stability in pH or pH Optima iv. Other Conditions b. Determination of Physical Properties i. Enzymatic Activity ii. Chromatographic Analysis of Protein Purity iii. Differential Scanning Calorimetry iv. Differential Scanning Fluorimetry V. Intrinsic Fluorescence Spectroscopy vi. Circular Dichroism vii. Dynamic Light Scattering viii. Static Light Scattering ix. Turbidity Measurements X. Other Methods to Determine Stability 4. Assay for Therapeutic Activity a. In vitro Tests b. In vivo Animal Models i. Tumor Metabolic Activity ii. Tumor Size and Volume c. Clinical Monitoring 5. Pharmacodynamics / Pharmacokinetics and Tolerability <com:Math><semantics>𝑮<annotation encoding="application / x-tex">\mathbf{G}< / annotation>< / semantics>< / com:Math> Pharmaceutical Compositions and Formulations 1. Formulations – liquids, injectables, emulsions Lyophilized Powders 2. Compositions for Other Routes of Administration 3. Dosages and Administration 4. Packaging and Articles of Manufacture H. Methods of Treatment with an Adenosine Deaminase 2 (ADA2) 1. Exemplary Diseases and Conditions a. Cancers and Tumors b. Non-Cancer Hyperproliferative Diseases c. Fibrotic Diseases d. Infectious Diseases e. Other Diseases and Conditions 2. Methods of Patient Selection a. Adenosine-associated Biomarkers i. Plasma Adenosine Levels ii. Adenosine Receptors (ADRs) iii. Ectonucleotidases CD39 and CD73 b. Patient Selection 3. Dosages and Administration 4 Combination Therapies a. Anticancer Agents i. Anticancer Antibodies ii. Chemotherapeutic Agents iii. Radiation Therapy iv. Anti-angiogenic Agents V. Immune Checkpoint Inhibitors (a) Anti-CTLA4 Therapies (b) Anti-PD-1 and Anti-PD-L1 Therapies b. Other Immunomodulatory Agents c. Hyaluronan-Degrading Enzyme Soluble hyaluronan degrading enzymes (e.g. soluble PH20) d. Antibodies to Treat Infectious Diseases e. Antibiotics and Antifungals I. Examples A. DEFINITIONS Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the invention(s) belong. In the event that there are a plurality of definitions for terms herein, those in this section prevail. Where reference is made to a URL or other such identifier or address, it understood that such identifiers can change and particular information on the internet can come and go, but equivalent information can be found by searching the internet. Reference thereto evidences the availability and public dissemination of such information. As used herein, "adenosine" refers to a purine nucleoside that is composed of a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a β-N<com:Sub>9< / com:Sub>-glycosidic bond. Adenosine can modulate a variety of physiological processes through its interaction with adenosine receptors. As used herein, "Michaelis constant" or <com:Math><semantics>Km<annotation encoding="application / x-tex">K_m< / annotation>< / semantics>< / com:Math> is a measure of the substrate concentration required for effective catalysis to occur. For example, an enzyme with a high <com:Math><semantics>Km<annotation encoding="application / x-tex">K_m< / annotation>< / semantics>< / com:Math> can require a higher substrate concentration to achieve a given reaction velocity than an enzyme with a lower <com:Math><semantics>Km<annotation encoding="application / x-tex">K_m< / annotation>< / semantics>< / com:Math> for the substrate. <com:Math><semantics>Km<annotation encoding="application / x-tex">K_m< / annotation>< / semantics>< / com:Math> can represent the affinity of the enzyme for a substrate. As used herein, "catalytic efficiency" is the efficiency with which an enzyme reacts with a substrate to form a product. It is represented by the <com:Math><semantics>kcat / Km<annotation encoding="application / x-tex">k_{cat} / K_m< / annotation>< / semantics>< / com:Math> (M<com:Sup>-1< / com:Sup>s<com:Sup>-1< / com:Sup> or 1 / Ms). Methods to assess kinetic parameters of catalytic activity, including <com:Math><semantics>kcat / Km<annotation encoding="application / x-tex">k_{cat} / K_m< / annotation>< / semantics>< / com:Math>, are well known to a skilled artisan. Generally, <com:Math><semantics>kcat / Km<annotation encoding="application / x-tex">k_{cat} / K_m< / annotation>< / semantics>< / com:Math> is measured under steady state conditions. As used herein, "adenosine deaminase" or "ADA" refers to an enzyme that catalyzes the hydrolytic deamination of adenosine to form inosine. An ADA also can deaminate 2'deoxyadenosine to 2'deoxyinosine, and hence includes enzymes that have 2'deoxyadenosine deaminase activity. In humans therè are two ADA isozymes, designated ADA1 and ADA2, that differ in their molecular weight, catalytic parameters and other properties. As used herein, "adenosine deaminase 1" or ADA1 refers to an ADA that lacks a signal peptide and is ubiquitously expressed inside cells. It is produced as a monomer. Exemplary of ADA1 is human ADA1 having the sequence of nucleotides set forth in SEQ ID NO:11 and encoding the sequence of amino acids set forth in SEQ ID NO:12. In humans, wild-type ADA1 is characterized by a Km of or of about 5.2 x 10<com:Sup>-5< / com:Sup> M, has a pH optimum of from or from about 7 to 7.5, and exhibits a similar affinity for both adenosine and 2'deoxyadenosine. For example, ADA1 has a 2'deoxyadenosine / adenosine deaminase ratio of at least or at least about 0.70, such at least or at least about 0.75. Reference to ADA1 includes wild-type or native ADA1 present in mammalian, including human and non-human, subjects. For example, reference to ADA1 includes human ADA1 that contains a polypeptide having the sequence of amino acids set forth in SEQ ID NO:12. Reference to ADA1 also 4. includes variants thereof, such as allelic variants, species variants, splice variants and other variants that include a polypeptide having a sequence of amino acids that has at least 65%, 70%, 75%, 80%, 85%, 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:12, and that exhibit adenosine deaminase activity. As used herein, "adenosine deaminase 2," or "ADA2" refers to an ADA that is present in extracellular environments, including in the plasma. ADA2 is produced from a precursor polypeptide that contains a signal peptide (e.g. ADA2 set forth in SEQ ID NO:2), which is removed to yield a mature protein lacking the signal peptide (e.g. ADA2 set forth in SEQ ID NO:5). The secreted ADA2 is a homodimer containing two identical polypeptide chains that interact via non-polar interactions between residues of each subunit. In humans, wild-type ADA2 is characterized with a Km that is or is about 200 x <com:Math><semantics>10−5<annotation encoding="application / x-tex">10^{-5}< / annotation>< / semantics>< / com:Math> M, has a pH optimum of or of about <com:Math><semantics>6.5±0.2<annotation encoding="application / x-tex">6.5 \pm 0.2< / annotation>< / semantics>< / com:Math>, and exhibits a weak affinity for 2'deoxyadenosine. For example, ADA2 has a 2'deoxyadenosine / adenosine deaminase ratio of less than 0.40, such less than or about 0.30 or less than or about 0.25. Reference to ADA2 includes wild-type or native ADA2 present in mammalian, including human and non-human, subjects. For example, reference to ADA2 includes human ADA2 that contains a polypeptide having the sequence of amino acids set forth in SEQ ID NO:2, the mature form set forth in SEQ ID NO:5, catalytically active portions of SEQ ID NO:5, and dimer forms thereof. Reference to ADA2 also includes precursor, mature, catalytically active forms, and dimer forms that are variants thereof, such as allelic variants, species variants, splice variants and other variants that include a polypeptide having a sequence of amino acids that has at least 40%, 50%, 60%, 65%, 70%, 75%, 80%, 85%, 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the precursor polypeptide set forth in SEQ ID NO:2 or the mature form thereof set forth in SEQ ID NO:5, and that, when in active form, exhibit adenosine deaminase activity. Such variants, when in active form, exhibit at least 40%, 50%, 70%, 90%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200% 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000% or more activity than the activity of a native or wildtype ADA2 polypeptide. As used herein, wild-type" or "native" with reference to ADA2 refers to a ADA2 protein containing a polypeptide encoded by a native or naturally occurring ADA2 gene, including allelic variants, that is present in an organism, including a human and other animals, in nature. Reference to wild-type ADA2 without reference to a species is intended to encompass any species of a wild-type ADA2. Included among wild-type ADA2 polypeptides are the encoded precursor polypeptide, fragments thereof, and processed forms thereof, such as a mature form lacking the signal peptide, as well as any pre- or post- translationally processed or modified forms thereof. Also included among native ADA2 proteins are those that are post-translationally modified, including, but not limited to, modification by glycosylation, carboxylation and hydroxylation. Native ADA2 proteins also include the polypeptide monomer as well as dimer forms. For example, humans express native ADA2. Wild-type human ADA2 is set forth in SEQ ID NO:2 (precursor) and SEQ ID NO:5 (mature), and includes catalytically active forms thereof as described herein, and allelic variants (precursor or mature) set forth in any of SEQ ID NOS:376-383, or isoforms of an ADA2 such as ADA2 set forth in SEQ ID NO:68. Wildtype or native ADA2 from non-human species include, but are not limited to, ADA2 from Pan troglodytes (chimpanzee; precursor form SEQ ID NO:286, mature form SEQ ID NO:326; NCBI Acc. No. XP_003317127.1); Gorilla gorilla (gorilla; precursor form SEQ ID NO:287, mature form SEQ ID NO:327; NCBI Acc. No. XP_004063024.1); Pan paniscus (pygmy chimpanzee; precursor form SEQ ID NO:288, mature form SEQ ID NO:328; NCBI Acc. No. XP 003828345.1); Pongo abelii (Sumatran orangutan; precursor form SEQ ID NO:289, mature form SEQ ID NO:329; NCBI Acc. No. NP_001125360.1); Nomascus leucogenys (Northern white-cheeked gibbon; precursor form SEQ ID NO:290, mature form SEQ ID NO:330; NCBI Acc. No. XP 004088517.1); Macaca fascicularis (crab-eating macaque; precursor form SEQ ID NO:291, mature form SEQ ID NO:331; NCBI Acc. No. XP 005568111.1); Chlorocebus sabaeus (green monkey; precursor form SEQ ID NO:292, mature form SEQ ID NO:332; NCBI Acc. No. XP 007972990.1); Macaca mulatta (Rhesus macaque; precursor form SEQ ID NOS:293, 337, mature form SEQ ID NOS:333, 340; GenBank Acc. Nos. AFH32795.1, EHH20002.1); Callithrix jacchus (marmoset; precursor form SEQ ID NOS:294, 374, mature form SEQ ID NO:334, 375; NCBI Acc. No. XP 009004591.1, XP 009004586.1); Xenopus laevis (African clawed frog; precursor form SEQ ID NO:295, mature form SEQ ID NO:335; NCBI Acc. No. NP 001090531.1); Drosophila melanogaster (fruit fly; precursor form SEQ ID NOS:296-300, mature form SEQ ID NOS:336, 338, 339; AAL40913.1, AAL40920.1, AAL40911.1, AAL40912.1, and AAL40910.1); Bombyx mori (silk moth; precursor form SEQ ID NO:301, mature form SEQ ID NO:341; NCBI Acc. No. NP 001098698.1); and Sarcophaga perigrina (flesh fly; precursor form SEQ ID NO:302, mature form SEQ ID NO:342; GenBank Acc. No. BAA11812.1). As used herein, a precursor ADA2 refers to a non-secreted form of an ADA2 that contains an N-terminal signal peptide that targets the protein for secretion. The signal peptide is cleaved off in the endoplasmic reticulum. Exemplary of an ADA2 precursor polypeptide is the polypeptide set forth in SEQ ID NO:2, or an allelic or species variant or other variant thereof such as those set forth in any of SEQ ID NOS:286-302, 337 or 376-379. As used herein, a "mature ADA2" refers to an ADA2 that lacks a signal sequence. An exemplary mature ADA2 is set forth in SEQ ID NO:5, and also includes variants thereof such as species and allelic variants and other variants, such as those set forth in any of SEQ ID NOS:326-336, 338-342, 375, and 380-383. Reference to mature ADA2 includes dimer forms thereof. As used herein, species variants refer to variants in polypeptides among different species, including different mammalian species, such as mouse and human. As used herein, allelic variants refer to variations in proteins among members of the same species. As used herein, domain (typically a sequence of three or more, generally 5 or 7 or more amino acids) refers to a portion of a molecule, such as proteins or the encoding nucleic acids, that is structurally and / or functionally distinct from other portions of the molecule and is identifiable. For example, domains include those portions of a polypeptide chain that can form an independently folded structure within a protein made up of one or more structural motifs and / or that is recognized by virtue of a functional activity, such as proteolytic activity. A protein can have one, or more than one, distinct domains. For example, a domain can be identified, defined or distinguished by homology of the sequence therein to related family members, such as homology to motifs that define a protease domain. In another example, a domain can be distinguished by its function, such as by proteolytic activity, or an ability to interact with a biomolecule, such as DNA binding, ligand binding, and dimerization. A domain independently can exhibit a biological function or activity such that the domain independently or fused to another molecule can perform an activity, such as, for example proteolytic activity or ligand binding. A domain can be a linear sequence of amino acids or a non-linear sequence of amino acids. Many polypeptides contain a plurality of domains. Such domains are known, and can be identified by those of skill in the art. For exemplification herein, definitions are provided, but it is understood that it is well within the skill in the art to recognize particular domains by name. If needed appropriate software can be employed to identify domains. As used herein "catalytic domain" or "ADA domain" refers to the domain that confers adenosine deaminase activity. The catalytic domain of an enzyme contains all of the requisite properties of that protein required for its enzymatic, such as adenosine deaminase activity. The ADA domain is structurally composed of an eight-stranded, parallel <com:Math><semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>< / com:Math>-sheet that closes into a barrel and is surrounded by classical <com:Math><semantics>α / β<annotation encoding="application / x-tex">\alpha / \beta< / annotation>< / semantics>< / com:Math>-TIM barrel motif helices and five additional, located between <com:Math><semantics>β1<annotation encoding="application / x-tex">\beta 1< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>α1<annotation encoding="application / x-tex">\alpha 1< / annotation>< / semantics>< / com:Math> (H1, H2, and H3) and at the C terminus (H4 and H5) (Zavialov et al. (2010) J. Biol. Chem. 285:12367-12377). Loops between <com:Math><semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>< / com:Math>-strands and <com:Math><semantics>α<annotation encoding="application / x-tex">\alpha< / annotation>< / semantics>< / com:Math>-helices contain many of the active site residues required for activity. Active site residues include residues that coordinate zinc binding, active site proton donor and acceptor residues, and substrate binding residues. Exemplary of such residues in human ADA2 are set forth in Table 4. In reference to human ADA2, the ADA domain is contained in the region corresponding to residues 106-502 of the precursor sequence of amino acids set forth in SEQ ID NO:2 (corresponding to residues 77-473 of the mature protein set forth in SEQ ID NO:5), except that residues corresponding to the putative receptor binding (PRB) domain contained therein are not required for catalytic activity. As used herein, "a catalytically active portion thereof" or "a catalytically active fragment thereof" refers to an ADA2 polypeptide that contains less than the full-length sequence of a mature ADA2 polypeptide, but contains a contiguous portion of amino acids of an ADA2, including all or part of the catalytic domain, sufficient for adenosine deaminase activity. For example, a catalytically active portion of ADA2 is one that includes a polypeptide containing a contiguous sequence of amino acids of the mature sequence of an ADA2 polypeptide that includes amino acid residues corresponding to residues 83, 85, 327, 330, 355, and 412 with reference to amino acid residues set forth in SEQ ID NO:5, but does not include the full amino acid sequence of the mature ADA2 polypeptide. For example, a catalytically active portion is one that includes a polypeptide containing a contiguous sequence of amino acids of the mature sequence of ADA2 set forth in SEQ ID NO:5 that includes amino acid residues 83, 85, 327, 330, 355, and 412, but that does not include the full length sequence of amino acids set forth in SEQ ID NO:5. An ADA2 that contains a catalytically active portion of an ADA2 polypeptide, when in active form, exhibits at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more of the activity, such as at least 120%, 130%, 140%, 150%, 200%, 300%, 400%, 500% or more of the activity, compared to the ADA2 containing a full-length mature ADA2 polypeptide. In one example, a catalytically active portion of an ADA2 polypeptide includes a polypeptide that lacks all or a portion of the putative receptor binding (PRB) domain. In another example, a catalytically active portion of an ADA2 polypeptide includes a polypeptide that lacks one or more C- terminal amino acids of the mature polypeptide, i.e. is truncated at the C-terminus, by up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 or more contiguous C-terminal amino acid residues compared to the mature ADA2 polypeptide. It is understood that reference herein to a variant ADA2 or catalytically active portion thereof means that the catalytically active portion contains the modification(s) (e.g. amino acid replacement(s)). As used herein, "putative receptor binding domain" or "PRB domain" refers to a portion of ADA2 that forms an independently folded structure composed of an α- and <com:Math><semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>< / com:Math>-fold containing a three-stranded antiparallel <com:Math><semantics>β<annotation encoding="application / x-tex">\beta< / annotation>< / semantics>< / com:Math>-sheets designated SR1-SR2-SR3, surrounded by the HR and partially H2 α-helices on one side and the proline-rich SR2-SR3 loop on the other side (Zavialov et al. (2010) J. Biol. Chem. 285:12367- 12377). The PRB domain contains conserved cysteine residues that form a disulfide bond between C137 and C159 of precursor ADA2 set forth in SEQ ID NO:2 (positions C108 and C130 of mature ADA2 set forth in SEQ ID NO:5). The PRB domain is reported to be involved in binding of ADA2 to its receptors. It is understood that the particular residues that make up the domain can vary (e.g. longer or shorter), for example, depending on methods used to identify the domain. In reference to human ADA2, the PRB domain is reported to correspond to residues 127-185 or 134- 177 of precursor ADA2 set forth in SEQ ID NO:2 (residues 98-156 or 105-148, respectively, of mature ADA2 set forth in SEQ ID NO:5). As used herein, a protein lacking all or a portion of a domain, such as all or a portion of the PRB domain, refers a polypeptide that has a deletion of one or more amino acids or all of the amino acids of the domain, such as the PRB domain, compared to a reference or unmodified protein. Amino acids deleted in a polypeptide lacking all or part of a domain can be contiguous, but need not be contiguous amino acids within the domain of the cognate polypeptide. Polypeptides that lack all or a part of a domain can include the loss or reduction of an activity of the polypeptide compared to the activity of a reference or unmodified protein. As used herein, "active form" refers to any ADA2 enzyme that exhibits adenosine deaminase activity. An active form of an enzyme can contain a full-length sequence of amino acids or can be a catalytically active portion thereof. An active form of an enzyme can be a monomer or a dimer. Typically, an active enzyme is a dimer. An active enzyme is any form that exhibits a catalytic efficiency <com:Math><semantics>(kcat / KM)<annotation encoding="application / x-tex">(k_{cat} / K_{M})< / annotation>< / semantics>< / com:Math> that is at least or at least about <com:Math><semantics>5×103 M−1s−1<annotation encoding="application / x-tex">5 \times 10^3 \text{ M}^{-1}\text{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>6×103 M−1s−1<annotation encoding="application / x-tex">6 \times 10^3 \text{ M}^{-1}\text{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>7×103 M−1s−1<annotation encoding="application / x-tex">7 \times 10^3 \text{ M}^{-1}\text{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>8×103 M−1s−1<annotation encoding="application / x-tex">8 \times 10^3 \text{ M}^{-1}\text{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>9×103 M−1s−1<annotation encoding="application / x-tex">9 \times 10^{3} \text{ M}^{-1} \text{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>1×104 M−1s−1<annotation encoding="application / x-tex">1 \times 10^{4} \text{ M}^{-1} \text{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>2×104 M−1s−1<annotation encoding="application / x-tex">2 \times 10^{4} \text{ M}^{-1} \text{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>3×104 M−1s−1<annotation encoding="application / x-tex">3 \times 10^{4} \text{ M}^{-1} \text{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>4×104 M−1s−1<annotation encoding="application / x-tex">4 \times 10^{4} \text{ M}^{-1} \text{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>5×104 M−1<annotation encoding="application / x-tex">5 \times 10^{4} \text{ M}^{-1}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>1<annotation encoding="application / x-tex">^{1}< / annotation>< / semantics>< / com:Math>s<com:Math><semantics>−1<annotation encoding="application / x-tex">^{-1}< / annotation>< / semantics>< / com:Math>, 6 x 10<com:Math><semantics>4<annotation encoding="application / x-tex">^{4}< / annotation>< / semantics>< / com:Math> M<com:Math><semantics>−1<annotation encoding="application / x-tex">^{-1}< / annotation>< / semantics>< / com:Math>s<com:Math><semantics>−1<annotation encoding="application / x-tex">^{-1}< / annotation>< / semantics>< / com:Math>, 7 x 10<com:Math><semantics>4<annotation encoding="application / x-tex">^{4}< / annotation>< / semantics>< / com:Math> M<com:Math><semantics>−1<annotation encoding="application / x-tex">^{-1}< / annotation>< / semantics>< / com:Math>s<com:Math><semantics>−1<annotation encoding="application / x-tex">^{-1}< / annotation>< / semantics>< / com:Math>, 8 x 10<com:Math><semantics>4<annotation encoding="application / x-tex">^{4}< / annotation>< / semantics>< / com:Math> M<com:Math><semantics>−1<annotation encoding="application / x-tex">^{-1}< / annotation>< / semantics>< / com:Math>s<com:Math><semantics>−1<annotation encoding="application / x-tex">^{-1}< / annotation>< / semantics>< / com:Math>, 9 x 10<com:Math><semantics>4<annotation encoding="application / x-tex">^{4}< / annotation>< / semantics>< / com:Math> M<com:Math><semantics>−1<annotation encoding="application / x-tex">^{-1}< / annotation>< / semantics>< / com:Math>s<com:Math><semantics>−1<annotation encoding="application / x-tex">^{-1}< / annotation>< / semantics>< / com:Math>, 1 x 10<com:Math><semantics>5<annotation encoding="application / x-tex">^{5}< / annotation>< / semantics>< / com:Math> M<com:Math><semantics>−1<annotation encoding="application / x-tex">^{-1}< / annotation>< / semantics>< / com:Math>s<com:Math><semantics>−1<annotation encoding="application / x-tex">^{-1}< / annotation>< / semantics>< / com:Math>, 2 x 10<com:Math><semantics>5<annotation encoding="application / x-tex">^{5}< / annotation>< / semantics>< / com:Math> <com:Math><semantics>M−1s−1<annotation encoding="application / x-tex">M^{-1}s^{-1}< / annotation>< / semantics>< / com:Math>, 3 x 10<com:Sup>5< / com:Sup> <com:Math><semantics>M−1s−1<annotation encoding="application / x-tex">M^{-1}s^{-1}< / annotation>< / semantics>< / com:Math>, 4 x 10<com:Sup>5< / com:Sup> <com:Math><semantics>M−1s−1<annotation encoding="application / x-tex">M^{-1}s^{-1}< / annotation>< / semantics>< / com:Math>, 5 x 10<com:Sup>5< / com:Sup> <com:Math><semantics>M−1s−1<annotation encoding="application / x-tex">M^{-1}s^{-1}< / annotation>< / semantics>< / com:Math>, 6 x 10<com:Sup>5< / com:Sup> <com:Math><semantics>M−1s−1<annotation encoding="application / x-tex">M^{-1}s^{-1}< / annotation>< / semantics>< / com:Math>, 7 x 10<com:Sup>5< / com:Sup> <com:Math><semantics>M−1s−1<annotation encoding="application / x-tex">M^{-1}s^{-1}< / annotation>< / semantics>< / com:Math>, 8 x <com:Math><semantics>105M−1s−1<annotation encoding="application / x-tex">10^{5} \,\mathrm{M}^{-1} \mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>9×105M−1s−1<annotation encoding="application / x-tex">9 \times 10^{5} \,\mathrm{M}^{-1} \mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>1×106M−1s−1<annotation encoding="application / x-tex">1 \times 10^{6} \,\mathrm{M}^{-1} \mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>2×106M−1s−1<annotation encoding="application / x-tex">2 \times 10^{6} \,\mathrm{M}^{-1} \mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>3×106M−1s−1<annotation encoding="application / x-tex">3 \times 10^{6} \,\mathrm{M}^{-1} \mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>4×106M−1s−1<annotation encoding="application / x-tex">4 \times 10^{6} \,\mathrm{M}^{-1} \mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math>, <Formule mathématique disponible dans le document PDF, Math available in the PDF document>5 \times 10^{6} \,\mathrm{ <com:Math><semantics>×106M−1s−1<annotation encoding="application / x-tex">\times 10^6 \,\mathrm{M}^{-1}\mathrm{s}^{-1}< / annotation>< / semantics>< / com:Math> or greater. As used herein, a "multimer" refers to a molecule composed of several identical or different subunits held together or associated, for example, by non- covalent interactions. As used herein, a "dimer" refers to a molecule that contains two polypeptides linked together. Typically, the polypeptides are non-covalently linked. For example, an ADA2 dimer is formed by nonpolar intersubunit interactions, including hydrophobic interaction, between residues of two polypeptides. As used herein, a "homodimer" refers to a dimer that is formed by two identical polypeptides. As used herein, a "heterodimer" refers to a dimer that is formed by two different polypeptides. As used herein, a "monomer" refers to a single protein or polypeptide unit. A monomer has a relatively low molecular weight compared to dimers or other multimers. A monomer can exist independently, or it can associate with other molecules to form a dimer or other multimer. As used herein a "corresponding form" with reference to an ADA2 protein means that when comparing a property or activity of two ADA2 proteins, the property is compared using the same structural form of the protein. For example, if its stated that an ADA2 protein has less activity compared to the activity of the corresponding form of a first ADA2 protein, that means that a particular form, such as a dimer, has less activity compared to the dimer of the first ADA2 protein. As used herein, a "polypeptide" refers to a linear organic polymer containing a large number of amino acid residues bonded together in a chain, forming part of, or the whole of, a protein molecule. As used herein, a "protein" or "protein molecule" or variations thereof refers to a large molecule composed of one or more polypeptide chains made up of a linear sequence of amino acids. Hence, a protein can be a monomer, or can be a dimer or other multimer. A protein can exhibit structural, mechanical, biochemical or signaling activities. As used herein, a "polypeptide subunit" or "protein subunit" refers to a single polypeptide or monomer that is capable of assembling with other polypeptides or monomers to form a protein molecule that is a multimeric complex. One subunit is made up of one polypeptide chain. As used herein, "variant ADA2 protein" refers to an ADA2 protein, including any form thereof such as a full-length, catalytically active portion, monomer, or dimer, that has one or more amino acid differences compared to an unmodified ADA2 protein. The one or more amino acid differences can be amino acid mutations, such as one or more amino acid replacements (substitutions), insertions or deletions, or can be insertions or deletions of entire domains, and any combination thereof. Typically, a variant ADA2 protein has one or more modifications in primary sequence compared to an unmodified ADA2 protein. For example, a variant ADA2 provided herein can have at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85 or more amino acid differences compared to an unmodified ADA2 protein. Any modification is contemplated as long as the resulting protein exhibits adenosine deaminase activity. As used herein, modification refers to modification of a sequence of amino acid residues of a polypeptide or a sequence of nucleotides in a nucleic acid molecule and includes deletions, insertions, and replacements of amino acids and nucleotides, respectively. Modifications also can include post-translational modifications or other changes to the molecule that can occur due to conjugation or linkage, directly or indirectly, to another moiety. Methods of modifying a polypeptide are routine to those of skill in the art, such as by using recombinant DNA methodologies. As used herein, "deletion," when referring to modification of a nucleic acid or polypeptide sequence, refers to the removal of one or more nucleotides or amino acids compared to a sequence, such as a target polynucleotide or polypeptide or a native or wild-type sequence. Thus, an amino acid sequence or nucleic acid molecule that contains one or more deletions compared to a wild-type sequence, contains one or more fewer amino acids or nucleotides within the linear length of the sequence. As used herein, "insertion" when referring to modification of a nucleic acid or amino acid sequence, describes the inclusion of one or more additional nucleotides or amino acids, within a target, native, wild-type or other related sequence. Thus, an amino acid or nucleic acid molecule that contains one or more insertions compared to a wild-type sequence, contains one or more additional amino acids or nucleotides within the linear length of the sequence. As used herein, "additions" to nucleic acid and amino acid sequences describe addition of nucleotides or amino acids onto either termini compared to another sequence. As used herein, "substitution" or "replacement" with respect to a modification refers to the replacing of one or more nucleotides or amino acids in a native, target, wild-type or other nucleic acid or polypeptide sequence with an alternative nucleotide or amino acid, without changing the length (as described in numbers of residues) of the molecule. Thus, one or more substitutions in a molecule does not change the number of amino acid residues or nucleotides of the molecule. Amino acid replacements compared to a particular polypeptide can be expressed in terms of the number of the amino acid residue along the length of the polypeptide sequence or a reference polypeptide sequence. For example, a modified polypeptide having a modification in the amino acid at the 19<com:Sup>th< / com:Sup> position of the amino acid sequence that is a substitution of Isoleucine (Ile; I) for cysteine (Cys; C) can be expressed as "replacement with Cys or C at a position corresponding to position 19," I19C, Ile19Cys, or simply C19, to indicate that the amino acid at the modified 19<com:Sup>th< / com:Sup> position is a cysteine. In this example, the molecule having the substitution has a modification at Ile 19 of the unmodified polypeptide. As used herein, "unmodified polypeptide" or "unmodified ADA2" and grammatical variations thereof refer to a starting polypeptide that is selected for modification as provided herein. The starting polypeptide can be a naturally- occurring, wild-type form of a polypeptide. Exemplary of an unmodified ADA2 polypeptide is human ADA2 set forth in SEQ ID NO:5, or a catalytically active portion thereof. In addition, the starting polypeptide can be altered or mutated, such that it differs from a native wild type isoform but is nonetheless referred to herein as a starting unmodified polypeptide relative to the subsequently modified polypeptides produced herein. Thus, existing proteins known in the art that have been modified to have a desired increase or decrease in a particular activity or property compared to an unmodified reference protein can be selected and used as the starting unmodified polypeptide. For example, a protein that has been modified from its native form by one or more single amino acid changes and possesses either an increase or decrease in a desired property, such as a change in an amino acid residue or residues to alter glycosylation, can be a target protein, referred to herein as unmodified, for further modification of either the same or a different property. As used herein, "corresponding residues" refers to residues that occur at aligned loci. For purposes herein, the amino acid sequence of a protein is aligned to precursor ADA2 set forth in SEQ ID NO:2 or its mature form set forth in SEQ ID NO:5 (see Figure 1) or to the ADA2 sequence used for Zavialov numbering, the numbering of residues used in Zavialov et al. (2010) J. Biol. Chem. 285:12367-12377 and in PDB accession Nos. 3LGG and 3LGD, set forth in SEQ ID NO:4. Related or variant polypeptides are aligned by any method known to those of skill in the art. Such methods typically maximize matches, and include methods such as using manual alignments and by using the numerous alignment programs available (for example, BLASTP) and others known to those of skill in the art. By aligning the sequences of ADA2 polypeptides, one of skill in the art can identify corresponding residues, using conserved and identical amino acid residues as guides. Generally, recitation that amino acids of a polypeptide correspond to amino acids in a disclosed sequence refers to amino acids identified upon alignment of the polypeptide with the disclosed sequence to maximize identity or homology (where conserved amino acids are aligned) using a standard alignment algorithm, such as the GAP algorithm. As used herein, a "property" of an ADA2 refers to a physical or structural property, such as three-dimensional structure, pI, half-life, conformation and other such physical characteristics. As used herein, an "activity" of an ADA2 or "ADA2 activity" refers to any activity exhibited by the active form of an ADA2 protein, typically the dimer form. Such activities can be tested in vitro and / or in vivo and include, but are not limited to, adenosine deaminase activity, growth factor activity, ability to bind heparin and / or ability to bind to an adenosine receptor (ADR). Activity can be assessed in vitro or in vivo using recognized assays, for example, by measuring adenosine deaminase activity in vitro or in vivo. The results of such assays indicate that a polypeptide exhibits an activity that can be correlated to activity of the polypeptide in vivo, in which in vivo activity can be referred to as biological activity. Assays to determine functionality or activity of modified forms of ADA2 are known to those of skill in the art, and exemplary assays are described herein. As used herein, "adenosine deaminase activity" refers to the ability of an enzyme to catalyze the hydrolytic deamination of adenosine to form inosine. ADA2 activity can be assessed, directly or indirectly, by measuring the rate of production of a product of the enzymatic reaction. For example, the production of inosine or ammonia can be directly or indirectly measured. In other examples, the decrease of the substrate of the enzyme, e.g., adenosine or 2-deoxyadenosine, is measured. Assays to assess adenosine deaminase activity are known to those of skill in the art, and include but are not limited to, assays in which the decrease of the substrate, or the increase of the product, is measured directly by spectrophotometry, or indirectly, by subsequent enzymatic or oxidation-reduction reactions that use chromogenic substrates or change the absorbance spectra of the reaction. As used herein, "increased adenosine deaminase activity" refers to an enhanced ability of an ADA2 protein, for example a variant ADA2 protein, to exhibit adenosine deaminase activity as compared with a reference protein. For example, the ability of a variant ADA2 protein to exhibit adenosine deaminase activity can be greater than the adenosine deaminase activity of the unmodified ADA2 protein. The adenosine dearninase activity can be increased by at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000%, or more compared to the adenosine deaminase activity of reference or an unmodified protein. As used herein, a glycosylation site refers to an amino position in a polypeptide to which a carbohydrate moiety can be attached. Typically, a glycosylated protein contains one or more amino acid residues, such as asparagine or serine, for the attachment of the carbohydrate moieties. As used herein, a native glycosylation site refers to an amino position to which a carbohydrate moiety is attached in a wild-type polypeptide. There are four N-linked native glycosylation sites in ADA2 corresponding to residues N98, N145, N156 and N349 with reference to SEQ ID NO:5. As used herein, a non-native glycosylation site refers to an amino position to which a carbohydrate moiety is attached in a modified polypeptide that is not present in a wild-type polypeptide. Non-native glycosylation sites can be introduced into a ADA2 polypeptide by amino acid replacement. O-glycosylation sites can be created, for example, by amino acid replacement of a native residue with a serine or threonine. N-glycosylation sites can be created, for example, by establishing the motif Asn-Xaa- Ser / Thr / Cys, where Xaa is not proline. Creation of this consensus sequence by amino acid modification can involve, for example, a single amino acid replacement of a native amino acid residue with an asparagine, a single amino acid replacement of a native amino acid residue with a serine, threonine or cysteine, or a double amino acid replacement involving a first amino acid replacement of a native residue with an asparagine and a second amino acid replacement of native residue with a serine, threonine or cysteine, or an insertion of a non-native N-glycosylation motif, such as the motif Asn-Xaa-Ser / Thr / Cys, where Xaa is not proline. As used herein, "level of glycosylation" refers to the number of glycosylation sites capable of being occupied by a glycan, for example, upon expression in a host cell capable of glycosylation. As used herein, increases with reference to the level of glycosylation means that there is a greater number of glycosylation sites capable of being occupied by a glycan with reference to an unmodified or wildtype ADA2. A variant ADA2 that exhibits an increased level of glycosylation can be hyperglycosylated if there is a greater number of glycosylation sites occupied by a glycan compared to the unmodified or wildtype ADA2. As used herein, "protein stability" refers to a measure of the maintenance of one or more physical properties of a protein in response to an environmental condition (e.g. an elevated temperature). In one embodiment, the physical property is the maintenance of the covalent structure of the protein (e.g. the absence of proteolytic cleavage, unwanted oxidation or deamidation). In another embodiment, the physical property is the presence of the protein in a properly folded state (e.g. the absence of soluble or insoluble aggregates or precipitates). In one embodiment, stability of a protein is measured by assaying a biophysical property of the protein, for example thermal stability, pH unfolding profile, stable removal of glycosylation, solubility, biochemical function (e.g., ability to bind to a protein such as a receptor or enzymatic activity) and / or combinations thereof. In another embodiment, biochemical function is demonstrated by the binding affinity of an interaction. Stability can be measured using methods known in the art and / or described herein. As used herein, "half-life" refers to the time that a living body requires to eliminate one half of the quantity of an administered substance through its normal channels of elimination. The normal channels of elimination generally include the kidneys and liver, but can include other excretion pathways. A half-life can be described as the time it takes the concentration of a substance to halve its concentration from steady state or from a certain point on the elimination curve. A half-life typically is measured in the plasma and can be determined by giving a single dose of drug, and then measuring the concentration of the drug in the plasma at times to determine the relationship between time and decline in concentration as the substance is eliminated. As used herein, "increased half-life" refers to a longer half-life of a protein molecule compared to a reference protein. Hence, it means that the time that it takes the concentration of a substance to halve its concentration is longer than for the time it takes the concentration of a reference protein to halve. The half-life can be increased by at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000%, 1100%, 1200%, 1300%, 1400%, 1500%, 1600%, 1700%, 1800%, 1900%, 2000%, 3000%, 4000%, 5000%, 6000%, 7000%, 8000%, 9000%, 10000% or more compared to the half-life of an unmodified polypeptide. Assays to assess half-life are known and standard in the art. As used herein, "thermal stability" refers to the measure of the resistance to denaturation of a protein that occurs upon exposure to high or elevated temperatures, and hence is the ability of a protein to function at a particular temperature. A polypeptide is thermally stable at a temperature if it retains at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more of an activity or a property of the polypeptide at the temperature. Thermal stability can be measured either by known procedures or by the methods described herein. In certain embodiments, thermal stability is evaluated by measuring the melting temperature (Tm) of a protein or by a thermal challenge assay (Tc). As used herein, "increased thermal stability" refers to a higher degree of resistance to denaturation of a protein. For example, it can mean that a protein is thermally stable at a higher temperature than a reference proteins. It also can mean that a protein exhibits greater retained activity at a particular temperature compared to the activity of a reference protein at the same temperature. In some cases, an increased thermal stability means that a protein has a greater melting temperature Tm compared to a reference protein. For example, the thermal stability is increased if the Tm of a protein is at least 0.1°C, 0.2°C, 0.3°C, 0.4°C, 0.5°C, 0.6°C, 0.7°C, 0.8°C, 0.9°C, 1.0°C, 1.5°C, 2.0°C. 2.5°C. 3.0°C, 4.0°C, 5.0°C or more greater than a reference or unmodified protein. As used herein, the melting temperature (Tm; also called transition temperature) is the temperature at the midpoint of a thermal transition curve where 50% of molecules of a composition are in a folded state. Hence, it is the temperature at which 50% of a macromolecule becomes denatured, and is a standard parameter for describing the thermal stability of a protein. Methods to determine Tm are well- known to a skilled artisan and include, for example, analytical spectroscopy methods such as, but are not limited to, differential scanning calorimetry (DSC), circular dichroism (CD) spectroscopy), fluorescence emission spectroscopy or nuclear magnetic resonance (NMR) spectroscopy. As used herein, "pH optima" or "pH optimum" refers to the pH at which any enzymatic reaction, such as adenosine deaminase activity, is most effective under a given set of conditions. With respect to its adenosine deaminase activity, ADA2 exhibits a pH optima that is or is about 6.5. As used herein, "altered pH optima" or "altered pH optimum" refers to a change (increased or decreased) in the pH that is the optimal pH for adenosine deaminase activity. An increased pH optimum occurs if the pH optimum is greater than 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.0, 2.5 or more compared to the pH optimum of a reference or unmodified protein. A decreased pH optimum occurs if the pH optimum is lower than or less than 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.0, 2.5 or more less to the pH optimum of a reference or unmodified protein. As used herein, "bind," "bound" or grammatical variations thereof refers to the participation of a molecule in any attractive interaction with another molecule, resulting in a stable association in which the two molecules are in close proximity to one another. Binding includes, but is not limited to, non-covalent bonds, covalent bonds (such as reversible and irreversible covalent bonds), and includes interactions between molecules such as, but not limited to, proteins, nucleic acids, carbohydrates, lipids, and small molecules, such as chemical compounds including drugs. Typically, bind involves the association of two or more molecules by one or more noncovalent bonds. Binding can be assessed by standard methods known in the art, including but not limited to, equilibrium dialysis, radioimmunoassay radiolabeled target antigen, immunoassays (e.g. enzyme linked immunosorbent assay (ELISA)), surface plasmon resonance (SPR), isothermal titration calorimetry (ITC) and other methods well known to a skilled artisan. As used herein, binding activity refer to characteristics of a molecule, e.g. a polypeptide, relating to whether or not, and how, it binds one or more binding partners. Binding activities include the ability to bind the binding partner(s), the affinity with which it binds to the binding partner (e.g. high affinity), the avidity with which it binds to the binding partner, the strength of the bond with the binding partner and / or specificity for binding with the binding partner. As used herein, "heparin binding" refers to the ability of ADA2 to bind heparin, which is a highly sulfated glycosaminoglycan made up of variably sulfated repeating disaccharide units. Commonly, a heparin disaccharide unit is made up of a 2-O-sulfated iduronic acid and 6-O-sulfated, N-sulfated glucosamine, IdoA(2S)- GlcNS(6S). As used herein, "reduced heparin binding" or "attenuated heparin binding" refers to a lessening or reduced binding activity for heparin. For example, it can mean that the level or degree of binding of an ADA2 protein, such as a variant ADA2, is less than a reference protein. For example, the heparin binding is reduced if the level or degree of binding of an ADA2 protein to heparin is no more than 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the binding of a reference or unmodified ADA2 protein to heparin. In some cases, heparin binding is reduced at least or at least about 0.5-fold, 1-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8- fold, 9-fold, 10-fold or more compared to the heparin binding of a reference or unmodified ADA2 protein. As used herein, "adenosine receptor" or ADR refers to a class of G-protein coupled receptors that bind adenosine. Adenosine receptors also can bind to ADA2. There are four types of adenosine receptors. For example, in humans, the ADRs are designated A<com:Sub>1< / com:Sub> (SEQ ID NO:533), A<com:Sub>2A< / com:Sub> (SEQ ID NO:534), A<com:Sub>2B< / com:Sub> (SEQ ID NO:535) and A<com:Sub>3< / com:Sub> (SEQ ID NOS:536-538). ٠. As used herein, "receptor binding" refers to the ability of ADA2 to bind an adenosine receptor. As used herein, "reduced receptor binding" refers to a lessening or reduced binding activity for an adenosine receptor. For example, it can mean that the level or degree of binding of an ADA2 protein, such as a variant ADA2, is less than the binding of a reference protein for the same adenosine receptor. For example, receptor binding is reduced if the level or degree of an ADA2 protein for an adenosine receptor is no more than 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the binding of a reference or unmodified ADA2 protein for the same adenosine receptor. In some cases, receptor binding is reduced at least or at least about 0.5-fold, 1-fold, 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold or more compared to the receptor binding of a reference or unmodified ADA2 protein for the same adenosine receptor. As used herein, recitation that proteins are "compared under the same conditions" means that different proteins are treated identically or substantially identically such that any one or more conditions that can influence the activity or properties of a protein or agent are not varied or not substantially varied between the test agents. For example, when the adenosine deaminase activity of an ADA2 is compared to an unmodified ADA2 protein any one or more conditions such as the amount or concentration of the protein; presence, including amount, of excipients, carriers or other components in a formulation other than the active agent; temperature; pH and / or other conditions are identical or substantially identical between and among the compared polypeptides. As used herein, "immune checkpoints" refer to inhibitory pathways of the immune system that are responsible for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues in order to minimize collateral tissue damage. Immune checkpoints are regulated by immune checkpoint proteins. An "immune checkpoint protein" is a protein, typically a receptor (e.g., CTLA4 or PD-1) or a ligand (e.g., PD-L1) that regulates or modulates the extent of an immune response. The immune checkpoint proteins can be inhibitory or stimulatory. In particular, the immune checkpoint proteins are inhibitory to the activation of the immune response. Thus, inhibition of an inhibitory immune checkpoint protein acts to stimulate or activate an immune response, such as T cell activation and proliferation. As used herein, an "immune checkpoint inhibitor" or "immune checkpoint" inhibiting agent," or "immune checkpoint blocking agent" refers to an agent that binds an inhibitory immune checkpoint protein and blocks its activity. The inhibition can be competitive or non-competitive inhibition that can be steric or allosteric. In cases where an immune checkpoint protein is an immune stimulating protein, an immune checkpoint inhibitor acts to promote the activity of the immune stimulating protein, such as by binding and activating the stimulatory immune checkpoint protein or by inhibiting by interfering with, such as by binding or deactivating, inhibitors of the stimulatory immune checkpoint protein. An example of an immune checkpoint inhibitor is an anti-immune checkpoint protein antibody. A "target" of an immune checkpoint inhibitor is the immune checkpoint protein to which the immune checkpoint inhibitor or immune checkpoint inhibiting agent binds to block activity. Typically, the immune checkpoint inhibitor specifically binds to the target. For example, the target of the exemplary anti-CTLA4 antibody designated ipilimumab is CTLA4. As used herein, an anti-immune checkpoint protein antibody, refers to any antibody that specifically binds to an immune checkpoint protein or a soluble fragment thereof and blocks. An anti-immune checkpoint protein antibody typically binds an immune checkpoint ligand protein or an immune checkpoint receptor protein and blocks the binding of a receptor to the target immune checkpoint ligand protein or a ligand to the target immune checkpoint receptor protein, thereby preventing the inhibitory signal transduction that suppresses an immune response. Hence, anti- immune checkpoint protein antibodies are immune checkpoint inhibitors. Reference to anti-immune checkpoint protein antibodies herein include full-length antibodies and antigen-binding fragments thereof that specifically bind to an immune checkpoint ligand or receptor protein. Exemplary anti-immune checkpoint protein antibodies include, but are not limited to, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibodies and anti-programmed cell death protein 1 (PD-1) antibodies. As used herein, an antigen-binding fragment of an anti-immune checkpoint protein antibody refers to an antibody derived from an anti-immune checkpoint protein antibody but that is less than the full length sequence of the anti-immune checkpoint protein antibody but contains at least a portion of the variable regions (heavy and light) of the antibody sufficient to form an antigen binding site (e.g., one or more CDRs, and generally all CDRs) and thus retains the binding specificity and / or activity of the anti-immune checkpoint protein antibody. As used herein, anti-CTLA4 antibody refers to any antibody that specifically binds to cytotoxic T-lymphocyte-associated protein 4 (CTLA4) or a soluble fragment thereof and blocks the binding of ligands to CTLA4, thereby resulting in competitive inhibition of CTLA4 and inhibition of CTLA4-mediated inhibition of T cell activation. Hence, anti-CTLA4 antibodies are CTLA4 inhibitors. Reference to anti- CTLA4 antibodies herein include a full-length antibody and derivatives thereof, such as antigen-binding fragments thereof that specifically bind to CTLA4. Exemplary anti-CTLA4 antibodies include, but are not limited to, Ipilimumab or Tremelimumab, or a derivative or antigen-binding fragment thereof. As used herein, anti-PD-1 antibody refers to any antibody that specifically binds to programmed cell death protein 1 (PD-1) or a soluble fragment thereof and blocks the binding of ligands to PD-1, thereby resulting in competitive inhibition of PD-1 and inhibition of PD-1-mediated inhibition of T cell activation. Hence, anti-PD- 1 antibodies are PD-1 inhibitors. Reference to anti-PD-1 antibodies herein include a full-length antibody and derivatives thereof, such as antigen-binding fragments thereof that specifically bind to PD-1. Exemplary anti-PD-1 antibodies include, but are not limited to, Nivolumab, MK-3475, Pidilizumab, or a derivative or antigen- binding fragment thereof. As used herein, anti-PD-L1 antibody refers to an antibody that specifically binds to programed death-ligand 1 (PD-L1) or a soluble fragment thereof and blocking the binding of the ligand to PD-1, thereby resulting in competitive inhibition of PD-1 and inhibition of PD-1-mediated inhibition of T cell activity. Hence, anti-PD- L1 antibodies are PD-1 inhibitors. Reference to anti-PD-L1 antibodies herein include a full-length antibody and derivatives thereof, such as antigen-binding fragments thereof that specifically bind to PD-L1. Exemplary anti-PD-L1 antibodies include, but are not limited to, BMS-936559, MPDL3280A, MEDI4736 or a derivative or antigen-binding fragment thereof. As used herein, "antibody" refers to immunoglobulins and immunoglobulin fragments, whether natural or partially or wholly synthetically, such as recombinantly, produced, including any fragment thereof containing at least a portion of the variable heavy chain and light region of the immunoglobulin molecule that is sufficient to form an antigen binding site and, when assembled, to specifically bind antigen. Hence, an antibody includes any protein having a binding domain that is homologous or substantially homologous to an immunoglobulin antigen-binding domain (antibody combining site). For example, an antibody refers to an antibody that contains two heavy chains (which can be denoted H and H') and two light chains (which can be denoted L and L'), where each heavy chain can be a full-length immunoglobulin heavy chain or a portion thereof sufficient to form an antigen binding site (e.g., heavy chains include, but are not limited to, VH chains, VH-CH1 chains and VH-CH1-CH2- CH3 chains), and each light chain can be a full-length light chain or a portion thereof sufficient to form an antigen binding site (e.g., light chains include, but are not limited to, VL chains and VL-CL chains). Each heavy chain (H and H') pairs with one light chain (L and L', respectively). Typically, antibodies minimally include all or at least a portion of the variable heavy (VH) chain and / or the variable light (VL) chain. The antibody also can include all or a portion of the constant region. For purposes herein, the term antibody includes full-length antibodies and portions thereof including antibody fragments. Antibody fragments, include, but are not limited to, Fab fragments, Fab' fragments, F(ab')<com:Sub>2< / com:Sub> fragments, Fv fragments, disulfide-linked Fvs (dsFv), Fd fragments, Fd' fragments, single-chain Fvs (scFv), single-chain Fabs (scFab), diabodies, anti-idiotypic (anti-Id) antibodies, or antigen- binding fragments of any of the above. Antibody also includes synthetic antibodies, recombinantly produced antibodies, multispecific antibodies (e.g., bispecific antibodies), human antibodies, non-human antibodies, humanized antibodies, chimeric antibodies, and intrabodies. Antibodies provided herein include members of any immunoglobulin type (e.g., IgG, IgM, IgD, IgE, IgA and IgY), any class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass (e.g., IgG2a and IgG2b). As used herein, the phrase "derived from" or "derivative" when referring to antibody fragments derived from another antibody, such as a monoclonal antibody, refers to the engineering of antibody fragments (e.g., Fab, F(ab'), F(ab')<com:Sub>2< / com:Sub>, single-chain Fv (scFv), Fv, dsFv, diabody, Fd and Fd' fragments) that retain the binding specificity of the original or parent antibody. Such fragments can be derived by a variety of methods known in the art, including, but not limited to, enzymatic cleavage, chemical crosslinking, recombinant means or combinations thereof. Generally, the derived antibody fragment shares the identical or substantially identical heavy chain variable region (V<com:Sub>H< / com:Sub>) and light chain variable region (V<com:Sub>L< / com:Sub>) of the parent antibody, such that the antibody fragment and the parent antibody bind the same epitope. As used herein, an anti-hyaluronan agent refers to any agent that modulates hyaluronan (HA) synthesis or degradation, thereby altering hyaluronan levels in a tissue or cell. For purposes herein, anti-hyaluronan agents reduce hyaluronan levels in a tissue or cell compared to the absence of the agent. Such agents include compounds that modulate the expression of genetic material encoding HA synthase (HAS) and other enzymes or receptors involved in hyaluronan metabolism, or that modulate the proteins that synthesize or degrade hyaluronan including HAS function or activity. The agents include small-molecules, nucleic acids, peptides, proteins or other compounds. For example, anti-hyaluronan agents include, but are not limited to, antisense or sense molecules, antibodies, enzymes, small molecule inhibitors and HAS substrate analogs. As used herein, a hyaluronan degrading enzyme refers to an enzyme that catalyzes the cleavage of a hyaluronan polymer (also referred to as hyaluronic acid or HA) into smaller molecular weight fragments. Exemplary hyaluronan degrading enzymes are hyaluronidases, and particular chondroitinases and lyases that have the ability to depolymerize hyaluronan. Exemplary chondroitinases that are hyaluronan degrading enzymes include, but are not limited to, chondroitin ABC lyase (also known as chondroitinase ABC), chondroitin AC lyase (also known as chondroitin sulfate lyase or chondroitin sulfate eliminase) and chondroitin C lyase. As used herein, hyaluronidase refers to a class of hyaluronan degrading enzymes. Hyaluronidases include bacterial hyaluronidases (EC 4.2.2.1 or EC 4.2.99.1), hyaluronidases from leeches, other parasites, and crustaceans (EC 3.2.1.36), and mammalian-type hyaluronidases (EC 3.2.1.35). Hyaluronidases include any of non-human origin including, but not limited to, murine, canine, feline, leporine, avian, bovine, ovine, porcine, equine, piscine, ranine, bacterial, and any from leeches, other parasites, and crustaceans. For example, hyaluronidases include those of human origin. Exemplary human hyaluronidases include HYAL1, HYAL2, HYAL3, HYAL4, and PH20 (SEQ ID NO:480 and 551). Also included amongst hyaluronidases are soluble hyaluronidases, including, ovine and bovine PH20, soluble human PH20 and soluble rHuPH20. Examples of commercially available bovine or ovine soluble hyaluronidases include Vitrase® (ovine hyaluronidase), Amphadase® (bovine hyaluronidase) and Hydase™ (bovine hyaluronidase). Reference to hyaluronan degrading enzymes or hyaluronidase includes precursor hyaluronan degrading enzyme polypeptides and mature hyaluronan degrading enzyme polypeptides (such as those in which a signal sequence has been removed), truncated forms thereof that have activity, and includes allelic variants and species variants, variants encoded by splice variants, and other variants, including polypeptides that have at least 40%, 45%, 50%, 55%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the precursor polypeptides, or the mature forms thereof. Hyaluronan degrading enzymes and hyaluronidase also include those that contain chemical or posttranslational modifications and those that do not contain chemical or posttranslational modifications. Such modifications include, but are not limited to, PEGylation, albumination, glycosylation, farnesylation, carboxylation, hydroxylation, phosphorylation, and other polypeptide modifications known in the art. A truncated PH20 hyaluronidase is any C-terminal shortened form thereof, particularly forms that are truncated and neutral active when N-glycosylated. As used herein, "bovine PH20" refers to a bovine hyaluronidase purified from bovine testicular extracts (see U.S. Patent Nos. 2,488,564, 2,488,565, 2,806,815, 2,808,362, 2,676,139, 2,795,529, 5,747,027 and 5,827,721). Examples of commercially available purified bovine testicular hyaluronidases include Amphadase® and Hydase™, and bovine hyaluronidases, including, but not limited to, those available from Sigma Aldrich, Abnova, EMD Chemicals, GenWay Biotech, Inc., Raybiotech, Inc., and Calzyme. Also included are recombinantly produced bovine hyaluronidases. As used herein, "ovine PH20" refers to an ovine hyaluronidase purified from ovine testicular extracts (see U.S. Patent Nos. 2,488,564, 2,488,565 and 2,806,815 and International PCT Publication No. WO2005 / 118799). Examples of commercially available purified ovine testicular extract include Vitrase®, and ovine hyaluronidases, including, but not limited to, those available from Sigma Aldrich, Cell Sciences, EMD Chemicals, GenWay Biotech, Inc., Mybiosource.com and Raybiotech, Inc. Also included are recombinantly produced ovine hyaluronidases. As used herein, "PH20" refers to a type of hyaluronidase that occurs in sperm and is neutral-active. PH-20 occurs on the sperm surface, and in the lysosome- derived acrosome, where it is bound to the inner acrosomal membrane. PH20 includes those of any origin including, but not limited to, human, chimpanzee, Cynomolgus monkey, Rhesus monkey, murine, bovine, ovine, guinea pig, rabbit and rat origin. Exemplary PH20 polypeptides include those from human (precursor set forth in SEQ ID NO:551 and mature set forth in SEQ ID NO:480). As used herein, a "soluble PH20" refers to any form of PH20 that is soluble under physiologic conditions. A soluble PH20 can be identified, for example, by its partitioning into the aqueous phase of a Triton® X-114 solution at 37 °C (Bordier et al., (1981) J. Biol. Chem., 256:1604-7). Membrane-anchored PH20, such as lipid- anchored PH20, including GPI-anchored PH20, will partition into the detergent-rich phase, but will partition into the detergent-poor or aqueous phase following treatment with Phospholipase-C. Included among soluble PH20 are membrane-anchored PH20 in which one or more regions associated with anchoring of the PH20 to the membrane has been removed or modified, where the soluble form retains hyaluronidase activity. Soluble PH20 also includes recombinant soluble PH20 and those contained in or purified from natural sources, such as, for example, testes extracts from sheep or cows. An example of such soluble PH20 is soluble human PH20. Exemplary soluble human PH20 polypeptides are set forth in any of SEQ ID NOS:481-488, 493-514, or 526-532, or has a sequence of amino acids that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to a sequence of amino acids set forth in any of SEQ ID NOS:481-488, 493-514, or 526- 532 and is soluble and retains hyaluronidase activity. As used herein, "soluble recombinant human PH20 (rHuPH20)" refers to a composition containing soluble form of human PH20 as recombinantly expressed and secreted in Chinese Hamster Ovary (CHO) cells. Soluble rHuPH20 is encoded by nucleic acid molecule that includes the signal sequence and encodes the polypeptide set forth in SEQ ID NO:481. The nucleic acid encoding soluble rHuPH20 is expressed in CHO cells which secrete the mature polypeptide. As produced in the culture medium, there is heterogeneity at the C-terminus so that the product includes a mixture of species that can include any one or more of SEQ ID NO:481-486 in various abundance. As used herein, "hyaluronidase activity" refers to the ability to enzymatically catalyze the cleavage of hyaluronic acid. The United States Pharmacopeia (USP) XXII assay for hyaluronidase determines hyaluronidase activity indirectly by measuring the amount of higher molecular weight hyaluronic acid, or hyaluronan, (HA) substrate remaining after the enzyme is allowed to react with the HA for 30 min at 37°C (USP XXII-NF XVII (1990) 644-645 United States Pharmacopeia Convention, Inc., Rockville, MD). A Reference Standard solution can be used in an assay to ascertain the relative activity, in units, of any hyaluronidase. In vitro assays to determine the hyaluronidase activity of hyaluronidases, such as PH20, including soluble PH20 and esPH20, are known in the art and described herein. Exemplary assays include the microturbidity assay that measures cleavage of hyaluronic acid by hyaluronidase indirectly by detecting the insoluble precipitate formed when the uncleaved hyaluronic acid binds with serum albumin and the biotinylated-hyaluronic acid assay that measures the cleavage of hyaluronic acid indirectly by detecting the remaining biotinylated-hyaluronic acid non-covalently bound to microtiter plate wells with a streptavidin-horseradish peroxidase conjugate and a chromogenic substrate. Reference Standards can be used, for example, to generate a standard curve to determine the activity in Units of the hyaluronidase being tested. As used herein, "neutral active" refers to the ability of a PH20 polypeptide to enzymatically catalyze the cleavage of hyaluronic acid at neutral pH (e.g., at or about pH 7.0). As used herein, an anti-cancer agent or chemotherapeutic agent refers to an agent that is capable of killing cells that divide rapidly, such as cancer cells. One of skill in the art is familiar with anti-cancer agents, including chemotherapeutic agents. Exemplary agents are described herein. As used herein, "biological activity" refers to the in vivo activities of a compound or physiological responses that result upon in vivo administration of a compound, composition or other mixture. Biological activity, thus, encompasses therapeutic effects and pharmaceutical activity of such compounds, compositions and mixtures. Biological activities can be observed in in vitro systems designed to test or use such activities. Thus, for purposes herein a biological activity of a ADA2 encompasses adenosine deaminase activity. As used herein the term "assess", and grammatical variations thereof, is intended to include quantitative and qualitative determination in the sense of obtaining an absolute value for the activity of a polypeptide, and also of obtaining an index, ratio, percentage, visual or other value indicative of the level of the activity. Assessment can be direct or indirect. For example, detection of cleavage of a substrate by a polypeptide can be by direct measurement of the product, or can be indirectly measured by determining the resulting activity of the cleaved substrate. As used herein, "mature numbering" or "standard numbering" refers to the numbering of residues in order based on a mature ADA2 polypeptide. For purposes herein, mature numbering is based on the numbering of residues of mature ADA2 set forth in SEQ ID NO:5. As used herein, "Zavialov numbering" refers to the numbering of residues used in Zavialov et al. (2010) J. Biol. Chem. 285:12367-12377 and in PDB accession Nos. 3LGG and 3LGD. Zavialov numbering is based on the numbering of residues of ADA2 as set forth in SEQ ID NO:4. Hence Zavialov numbering can be determined by alignment with SEQ ID NO:4. Table 1 below sets forth the corresponding position numbers between mature numbering and Zavialov numbering. Table 1 provides the sequence of amino acids set forth in SEQ ID NO:4 (reference sequence for Zavialov numbering), its position numbers and the corresponding position numbers for SEQ ID NO:5 (reference sequence for mature numbering as used herein). [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] As used herein, a "conjugate" refers to a polypeptide linked directly or indirectly to one or more other polypeptides or chemical moieties. Such conjugates include fusion proteins, those produced by chemical conjugates and those produced by any other methods. For example, a conjugate refers to an ADA2 protein linked directly or indirectly to one or more other polypeptides or chemical moieties, whereby at least one ADA2 polypeptide subunit is linked, directly or indirectly to another polypeptide or chemical moiety so long as the conjugate retains adenosine deaminase activity. As used herein, "coupled" or "conjugated" means attached via a covalent or noncovalent interaction. As used herein, a chimeric polypeptide refers to a polypeptide that contains portions from at least two different polypeptides or from two non-contiguous portions of a single polypeptide. Thus, a chimeric polypeptide generally includes a sequence of amino acid residues from all or part of one polypeptide and a sequence of amino acids from all or part of another different polypeptide. The two portions can be linked directly or indirectly and can be linked via peptide bonds, other covalent bonds covalent interactions of sufficient strength to maintain the integrity of a substantial portion of the chimeric polypeptide under equilibrium conditions and physiologic conditions, such as in isotonic pH 7 buffered saline. As used herein, a fusion protein is a polypeptide engineered to contain sequences of amino acids corresponding to two distinct polypeptides, which are joined together, such as by expressing the fusion protein from a vector containing two nucleic acids, encoding the two polypeptides, in close proximity, e.g., adjacent, to one another along the length of the vector. Accordingly, a fusion protein refers to a chimeric protein containing two, or portions from two, or more proteins or peptides that are linked directly or indirectly via peptide bonds. The two molecules can be adjacent in the construct or separated by a linker, or spacer polypeptide. As used herein, "linker" or "spacer" peptide refers to short sequences of amino acids that join two polypeptide sequences (or nucleic acid encoding such an amino acid sequence). "Peptide linker" refers to the short sequence of amino acids joining the two polypeptide sequences. Exemplary of polypeptide linkers are linkers joining a peptide transduction domain to an antibody or linkers joining two antibody chains in a synthetic antibody fragment such as an scFv fragment. Linkers are well-known and any known linkers can be used in the provided methods. Exemplary of polypeptide linkers are (Gly-Ser)<com:Sub>n< / com:Sub> amino acid sequences, with some Glu or Lys residues dispersed throughout to increase solubility. Other exemplary linkers are described herein; any of these and other known linkers can be used with the provided compositions and methods. As used herein, a multimerization domain refers to a sequence of amino acids that promotes stable interaction of a polypeptide molecule with one or more additional polypeptide molecules, each containing a complementary multimerization domain, which can be the same or a different multimerization domain to form a stable multimer with the first domain. Generally, a polypeptide is joined directly or indirectly to the multimerization domain. Exemplary multimerization domains include the immunoglobulin sequences or portions thereof, leucine zippers, hydrophobic regions, hydrophilic regions, and compatible protein-protein interaction domains. The multimerization domain, for example, can be an immunoglobulin constant region or domain, such as, for example, the Fc domain or portions thereof from IgG, including IgG1, IgG2, IgG3 or IgG4 subtypes, IgA, IgE, IgD and IgM and modified forms thereof. As used herein, a "moiety" or "heterologous moiety" refers to a molecule that is capable of associating with another molecule, either directly or indirectly by a covalent or non-covalent interaction. Typically, the molecule is derived from a distinct entity from that of the entity to which it is being associated. In one embodiment, a heterologous moiety can be a polypeptide fused to another polypeptide to produce a fusion polypeptide or protein. In another embodiment, a heterologous moiety can be a non-polypeptide such as a polymer, such as a PEG conjugated to a polypeptide or protein. As used herein, a "half-life extending moiety" is heterologous moiety that facilitates the increased half-life of the molecule to which it is conjugated. As used herein, "Fc" or "Fc region" or "Fc domain" refers to a polypeptide containing the constant region of an antibody heavy chain, excluding the first constant region immunoglobulin domain. Thus, Fc refers to the last two constant region immunoglobulin domains of IgA, IgD, and IgE, or the last three constant region immunoglobulin domains of IgE and IgM. Optionally, an Fc domain can include all or part of the flexible hinge N-terminal to these domains. For IgA and IgM, Fc can include the J chain. For an exemplary Fc domain of IgG, Fc contains immunoglobulin domains Cy2 and Cy3, and optionally, all or part of the hinge between Cy1 and Cy2. The boundaries of the Fc region can vary, but typically, include at least part of the hinge region. In addition, Fc also includes any allelic or species variant or any variant or modified form, such as any variant or modified form that alters the binding to an FcR or alters an Fc-mediated effector function. As used herein, "Fc chimera" refers to a chimeric polypeptide in which one or more polypeptides is linked, directly or indirectly, to an Fc region or a derivative thereof. Typically, an Fc chimera combines the Fc region of an immunoglobulin with another polypeptide. Derivatives of or modified Fc polypeptides are known to those of skill in the art. As used herein, a "polymer" refers to any high molecular weight natural or synthetic moiety that is conjugated to, i.e. stably linked directly or indirectly via a linker, to a polypeptide. Such polymers, typically increase serum half-life, and include, but are not limited to sialic moieties, PEGylation moieties, dextran, and sugar and other moieties, such as for glycosylation. For example, ADA2 proteins, such as a variant ADA2, can be conjugated to a polymer. As used herein, "PEGylated" refers to covalent or other stable attachment of polymeric molecules, such as polyethylene glycol (PEGylation moiety PEG) to proteins, including an ADA2, such as a variant ADA2. PEGylation can increase half- life of the ADA2. As used herein, nucleic acids include DNA, RNA and analogs thereof, including peptide nucleic acids (PNA) and mixtures thereof. Nucleic acids can be single or double-stranded. When referring to probes or primers, which are optionally labeled, such as with a detectable label, such as a fluorescent or radiolabel, single- stranded molecules are contemplated. Such molecules are typically of a length such that their target is statistically unique or of low copy number (typically less than 5, generally less than 3) for probing or priming a library. Generally a probe or primer contains at least 14, 16 or 30 contiguous nucleotides of sequence complementary to or identical to a gene of interest. Probes and primers can be 10, 20, 30, 50, 100 or more nucleotides long. As used herein, a peptide refers to a polypeptide that is from 2 to 40 amino acids in length. As used herein, the amino acids that occur in the various sequences of amino acids provided herein are identified according to their known, three-letter or one-letter abbreviations (Table 2). The nucleotides which occur in the various nucleic acid fragments are designated with the standard single-letter designations used routinely in the art. As used herein, an "amino acid" is an organic compound containing an amino group and a carboxylic acid group. A polypeptide contains two or more amino acids. For purposes herein, amino acids include the twenty naturally-occurring amino acids, non-natural amino acids and amino acid analogs (i.e., amino acids wherein the α- carbon has a side chain). In keeping with standard polypeptide nomenclature described in J. Biol. Chem., 243: 3557-3559 (1968), and adopted in 37 C.F.R. §§ 1.821-1.822, abbreviations for the amino acid residues are shown in Table 2: [Image disponible dans le document PDF, Image available in the PDF document] It should be noted that all amino acid residue sequences represented herein by formulae have a left to right orientation in the conventional direction of amino- terminus to carboxyl-terminus. In addition, the phrase "amino acid residue" is broadly defined to include the amino acids listed in the Table of Correspondence 5 (Table 2) and modified and unusual amino acids, such as those referred to in 37 C.F.R. §§ 1.821-1.822. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino acid residues, to an amino-terminal group such as NH<com:Sub>2< / com:Sub> or to a carboxyl-terminal group such as COOH. As used herein, a "hydrophobic amino acid" includes any one of the amino acids determined to be hydrophobic using the Eisenberg hydrophobicity consensus scale. Exemplary are the naturally occurring hydrophobic amino acids, such as isoleucine, phenylalanine, valine, leucine, tryptophan, methionine, alanine, glycine, cysteine and tyrosine (Eisenberg et al., (1982) Faraday Symp. Chem. Soc. 17:109- 120). Non-naturally-occurring hydrophobic amino acids also are included. As used herein, an "acidic amino acid" includes among the naturally-occurring amino acids aspartic acid and glutamic acid residues. Non-naturally-occurring acidic amino acids also are included. As used herein, a "polar amino acid" refers to an amino acid that is a hydrophile, such that the side chains prefer to reside in an aqueous (i.e. water) environment. Such amino acids generally are located on the surface of a protein. Such amino acids generally are classified if they include those with polar side chains that have a functional group such as an acid, amide, alcohol or amine that contains oxygens or nitrogens that can participate in hydrogen bonding with water. Exemplary of such amino acids are Arg (R), Asn (N), Asp (D), Glu (E), Gln (Q), His (H), Lys (K), Ser (S), Thr (T), and Tyr (Y). Cys (C) and Trp (W), which are also considered to be weakly polar. As used herein, a polar and neutral amino acid is a polar amino acid that contains a neutral side chain. Exemplary of such amino acid residues for replacement are Asn (N), Gln (Q), Ser (S), Thr (T), Cys (C) or Tyr (Y). As used herein, "naturally occurring amino acids" refer to the 20 L-amino acids that occur in polypeptides. As used herein, "non-natural amino acid" refers to an organic compound containing an amino group and a carboxylic acid group that is not one of the naturally-occurring amino acids listed in Table 2. Non-naturally occurring amino acids thus include, for example, amino acids or analogs of amino acids other than the 20 naturally-occurring amino acids and include, but are not limited to, the D- stereoisomer of amino acids. Exemplary non-natural amino acids are known to those of skill in the art and can be included in a modified ADA2 polypeptide. As used herein, suitable conservative substitutions of amino acids are known to those of skill in the art and can be made generally without altering the biological activity of the resulting molecule. Those of skill in the art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity (see, e.g., Watson et al. Molecular Biology of the Gene, 4th Edition, 1987, The Benjamin / Cummings Pub. co., p.224). Such substitutions can be made in accordance with those set forth in Table 3 as follows: [Image disponible dans le document PDF, Image available in the PDF document] Other substitutions also are permissible and can be determined empirically or in accord with known conservative substitutions. As used herein, a DNA construct is a single or double stranded, linear or circular DNA molecule that contains segments of DNA combined and juxtaposed in a manner not found in nature. DNA constructs exist as a result of human manipulation, and include clones and other copies of manipulated molecules. As used herein, a DNA segment is a portion of a larger DNA molecule having specified attributes. For example, a DNA segment encoding a specified polypeptide is a portion of a longer DNA molecule, such as a plasmid or plasmid fragment, which, when read from the 5' to 3' direction, encodes the sequence of amino acids of the specified polypeptide. As used herein, the term polynucleotide means a single- or double-stranded polymer of deoxyribonucleotides or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and can be isolated from natural sources, synthesized in vitro, or prepared from a combination of natural and synthetic molecules. The length of a polynucleotide molecule is given herein in terms of nucleotides (abbreviated "nt") or base pairs (abbreviated "bp"). The term nucleotides is used for single- and double-stranded molecules where the context permits. When the term is applied to double-stranded molecules it is used to denote overall length and will be understood to be equivalent to the term base pairs. It will be recognized by those skilled in the art that the two strands of a double-stranded polynucleotide can differ slightly in length and that the ends thereof can be staggered; thus all nucleotides within a double-stranded polynucleotide molecule cannot be paired. Such unpaired ends will, in general, not exceed 20 nucleotides in length. As used herein, "primary sequence" refers to the sequence of amino acid residues in a polypeptide. As used herein, "similarity" between two proteins or nucleic acids refers to the relatedness between the sequence of amino acids of the proteins or the nucleotide sequences of the nucleic acids. Similarity can be based on the degree of identity and / or homology of sequences of residues and the residues contained therein. Methods for assessing the degree of similarity between proteins or nucleic acids are known to those of skill in the art. For example, in one method of assessing sequence similarity, two amino acid or nucleotide sequences are aligned in a manner that yields a maximal level of identity between the sequences. "Identity" refers to the extent to which the amino acid or nucleotide sequences are invariant. Alignment of amino acid sequences, and to some extent nucleotide sequences, also can take into account conservative differences and / or frequent substitutions in amino acids (or nucleotides). Conservative differences are those that preserve the physico-chemical properties of the residues involved. Alignments can be global (alignment of the compared sequences over the entire length of the sequences and including all residues) or local (the alignment of a portion of the sequences that includes only the most similar region or regions). As used herein, the terms "homology" and "identity" are used interchange- ably, but homology for proteins can include conservative amino acid changes. In general to identify corresponding positions the sequences of amino acids are aligned so that the highest order match is obtained (see, e.g.: Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; Carrillo et al. (1988) SIAM J Applied Math 48:1073). As use herein, "sequence identity" refers to the number of identical amino acids (or nucleotide bases) in a comparison between a test and a reference polypeptide or polynucleotide. Homologous polypeptides refer to a pre-determined number of identical or homologous amino acid residues. Homology includes conservative amino acid substitutions as well as identical residues. Sequence identity can be determined by standard alignment algorithm programs used with default gap penalties established by each supplier. Homologous nucleic acid molecules refer to a pre-determined number of identical or homologous nucleotides. Homology includes substitutions that do not change the encoded amino acid (i.e., "silent substitutions") as well identical residues. Substantially homologous nucleic acid molecules hybridize typically at moderate stringency or at high stringency all along the length of the nucleic acid or along at least about 70%, 80% or 90% of the full-length nucleic acid molecule of interest. Also contemplated are nucleic acid molecules that contain degenerate codons in place of codons in the hybridizing nucleic acid molecule. (For determination of homology of proteins, conservative amino acids can be aligned as well as identical amino acids; in this case, percentage of identity and percentage homology varies). Whether any two nucleic acid molecules have nucleotide sequences (or any two polypeptides have amino acid sequences) that are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% "identical" can be determined using known computer algorithms such as the "FAST A" program, using for example, the default parameters as in Pearson et al. Proc. Natl. Acad. Sci. USA 85: 2444 (1988) (other programs include the GCG program package (Devereux, J., et al., Nucleic Acids Research 12(I): 387 (1984)), BLASTP, BLASTN, FASTA (Altschul, S.F., et al., J. Molec. Biol. 215:403 (1990); Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego (1994), and Carrillo et al. SIAM J Applied Math 48: 1073 (1988)). For example, the BLAST function of the National Center for Biotechnology Information database can be used to determine identity. Other commercially or publicly available programs include DNAStar "MegAlign" program (Madison, WI) and the University of Wisconsin Genetics Computer Group (UWG) "Gap" program (Madison WI)). Percent homology or identity of proteins and / or nucleic acid molecules can be determined, for example, by comparing sequence information using a GAP computer program (e.g., Needleman et al. J. Mol. Biol. 48: 443 (1970), as revised by Smith and Waterman (Adv. Appl. Math. 2: 482 (1981)). Briefly, a GAP program defines similarity as the number of aligned symbols (i.e., nucleotides or amino acids) that are similar, divided by the total number of symbols in the shorter of the two sequences. Default parameters for the GAP program can include: (1) a unary comparison matrix (containing a value of 1 for identities and 0 for non identities) and the weighted comparison matrix of Gribskov et al. Nucl. Acids Res. 14: 6745 (1986), as described by Schwartz and Dayhoff, eds., Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, pp. 353-358 (1979); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps. Therefore, as used herein, the term "identity" represents a comparison between a test and a reference polypeptide or polynucleotide. In one non-limiting example, "at least 90% identical to" refers to percent identities from 90 to 100% relative to the reference polypeptides. Identity at a level of 90% or more is indicative of the fact that, assuming for exemplification purposes a test and reference polynucleotide length of 100 amino acids are compared, no more than 10% (i.e., 10 out of 100) of amino acids in the test polypeptide differs from that of the reference polypeptides. Similar comparisons can be made between a test and reference polynucleotides. Such differences can be represented as point mutations randomly distributed over the entire length of an amino acid sequence or they can be clustered in one or more locations of varying length up to the maximum allowable, e.g., 10 / 100 amino acid difference (approximately 90% identity). Differences are defined as nucleic acid or amino acid substitutions, insertions or deletions. At the level of homologies or identities above about 85-90%, the result should be independent of the program and gap parameters set; such high levels of identity can be assessed readily, often without relying on software. As used herein, it also is understood that the terms "substantially identical" or "similar" varies with the context as understood by those skilled in the relevant art, but that those of skill can assess such. As used herein, an aligned sequence refers to the use of homology (similarity and / or identity) to align corresponding positions in a sequence of nucleotides or amino acids. Typically, two or more sequences that are related by 50% or more identity are aligned. An aligned set of sequences refers to 2 or more sequences that are aligned at corresponding positions and can include aligning sequences derived from RNAs, such as ESTs and other cDNAs, aligned with genomic DNA sequence. As used herein, "specifically hybridizes" refers to annealing, by complementary base-pairing, of a nucleic acid molecule (e.g. an oligonucleotide) to a target nucleic acid molecule. Those of skill in the art are familiar with in vitro and in vivo parameters that affect specific hybridization, such as length and composition of the particular molecule. Parameters particularly relevant to in vitro hybridization further include annealing and washing temperature, buffer composition and salt concentration. Exemplary washing conditions for removing non-specifically bound nucleic acid molecules at high stringency are 0.1 x SSPE, 0.1% SDS, 65°C, and at medium stringency are 0.2 x SSPE, 0.1% SDS, 50°C. Equivalent stringency conditions are known in the art. The skilled person can readily adjust these parameters to achieve specific hybridization of a nucleic acid molecule to a target nucleic acid molecule appropriate for a particular application. As used herein, isolated or purified polypeptide or protein or biologically- active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue from which the protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. Preparations can be determined to be substantially free if they appear free of readily detectable impurities as determined by standard methods of analysis, such as thin layer chromatography (TLC), gel electrophoresis and high performance liquid chromatography (HPLC), used by those of skill in the art to assess such purity, or sufficiently pure such that further purification would not detectably alter the physical and chemical properties, such as enzymatic and biological activities, of the substance. Methods for purification of the compounds to produce substantially chemically pure compounds are known to those of skill in the art. A substantially chemically pure compound, however, can be a mixture of stereoisomers. In such instances, further purification might increase the specific activity of the compound. Hence, reference to an isolated or purified protein or catalytically active protein thereof means that it is substantially free of cellular material or other contaminating proteins from the cell of tissue from which the protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. Preparations can be determined to be substantially free if they appear free of readily detectable impurities as determined by standard methods of analysis, such as thin layer chromatography (TLC), gel electrophoresis and high performance liquid chromatography (HPLC), used by those of skill in the art to assess such purity, or sufficiently pure such that further purification would not detectably alter the physical and chemical properties, such as proteolytic and biological activities, of the substance. Methods for purification of the proteins to produce substantially pure polypeptides are known to those of skill in the art. The term substantially free of cellular material includes preparations of proteins in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the term substantially free of cellular material includes preparations of protease proteins having less than about 30% (by dry weight) of non-protease proteins (also referred to herein as a contaminating protein), generally less than about 20% of non-protease proteins or 10% of non-protease proteins or less that about 5% of non-protease proteins. When the protease protein or active portion thereof is recombinantly produced, it also is substantially free of culture medium, i.e., culture medium represents less than, about, or equal to 20%, 10% or 5% of the volume of the protease protein preparation. As used herein, the term substantially free of chemical precursors or other chemicals includes preparations of protease proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. The term includes preparations of protease proteins having less than about 30% (by dry weight), 20%, 10%, 5% or less of chemical precursors or non-protease chemicals or components. As used herein, production by recombinant methods by using recombinant DNA methods refers to the use of the well-known methods of molecular biology for expressing proteins encoded by cloned DNA. As used herein, vector (or plasmid) refers to discrete elements that are used to introduce heterologous nucleic acid into cells for either expression or replication thereof. The vectors typically remain episomal, but can be designed to effect integration of a gene or portion thereof into a chromosome of the genome. Also contemplated are vectors that are artificial chromosomes, such as bacterial artificial chromosomes, yeast artificial chromosomes and mammalian artificial chromosomes. Selection and use of such vehicles are well known to those of skill in the art. As used herein, expression refers to the process by which nucleic acid is transcribed into mRNA and translated into peptides, polypeptides, or proteins. If the nucleic acid is derived from genomic DNA, expression can, if an appropriate eukaryotic host cell or organism is selected, include processing, such as splicing of the mRNA. As used herein, an expression vector includes vectors capable of expressing DNA that is operatively linked with regulatory sequences, such as promoter regions, that are capable of effecting expression of such DNA fragments. Such additional segments can include promoter and terminator sequences, and optionally can include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal, and the like. Expression vectors are generally derived from plasmid or viral DNA, or can contain elements of both. Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into an appropriate host cell, results in expression of the cloned DNA. Appropriate expression vectors are well known to those of skill in the art and include those that are replicable in eukaryotic cells and / or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome. As used herein, vector also includes "virus vectors" or "viral vectors." Viral vectors are engineered viruses that are operatively linked to exogenous genes to transfer (as vehicles or shuttles) the exogenous genes into cells. As used herein, "operably" or "operatively linked" when referring to DNA segments means that the segments are arranged so that they function in concert for their intended purposes, e.g., transcription initiates downstream of the promoter and upstream of any transcribed sequences. The promoter is usually the domain to which the transcriptional machinery binds to initiate transcription and proceeds through the coding segment to the terminator. As used herein, a human protein is one encoded by a nucleic acid molecule, such as DNA, present in the genome of a human, including all allelic variants and conservative variations thereof. A variant or modification of a protein is a human protein if the modification is based on the wildtype or prominent sequence of a human protein. As used herein, a "composition" refers to any mixture of two or more products or compounds. It can be a solution, a suspension, liquid, powder, a paste, aqueous, non-aqueous, or any combination thereof. As used herein, "a combination" refers to any association between two or among more items or elements, for example, two or more items that can be used together. For example, a combination can include an ADA2 protein and another therapeutic agent. Such combinations can be packaged as kits. As used herein, a kit is a packaged combination, optionally, including instructions for use of the combination and / or other reactions and components for such use. As used herein, an "article of manufacture" is a product that is made and sold. As used throughout this application, the term is intended to encompass ADA2 proteins, for example variant ADA2 proteins contained in articles of packaging. As used herein, direct administration refers to a composition that is administered without dilution. As used herein, a single dosage formulation refers to a formulation for use only once. Typically, a single dosage formulation is for direct administration. As used herein, a multiple dosage formulation refers to a formulation for use in repeat administrations. As used herein, when referencing dosage based on mg / kg of the subject, an average human subject is considered to have a mass of about 70 kg-75 kg, such as 70 kg and a body surface area (BSA) of 1.73 m<com:Sup>2< / com:Sup>. As used herein, "disease or disorder" refers to a pathological condition in an organism resulting from cause or condition including, but not limited to, infections, acquired conditions, genetic conditions, and characterized by identifiable symptoms. Diseases and disorders of interest herein are any associated with aberrant or high adenosine levels. As used herein, a tumor, also known as a neoplasm, is an abnormal mass of tissue that results when cells proliferate at an abnormally high rate. Tumors can show partial or total lack of structural organization and functional coordination with normal tissue. Tumors can be benign (not cancerous), or malignant (cancerous). As used herein, a tumor is intended to encompass hematopoietic tumors as well as solid tumors. Malignant tumors can be broadly classified into three major types. Carcinomas are malignant tumors arising from epithelial structures (e.g. breast, prostate, lung, colon, pancreas). Sarcomas are malignant tumors that originate from connective tissues, or mesenchymal cells, such as muscle, cartilage, fat or bone. Leukemias and lymphomas are malignant tumors affecting hematopoietic structures (structures pertaining to the formation of blood cells) including components of the immune system. Other malignant tumors include, but are not limited to, tumors of the nervous system (e.g. neurofibromatomas), germ cell tumors, and blastic tumors. As used herein, neoplastic disease refers to any disorder involving cancer, including tumor development, growth, metastasis and progression. As used herein, cancer is a term for diseases caused by or characterized by any type of malignant tumor, including metastatic cancers, lymphatic tumors, and blood cancers. Exemplary cancers include, but are not limited to, cancers of the bladder, brain, breast, bone marrow, cervix, colon / rectum, kidney, liver, lung / bronchus, ovary, pancreas, prostate, skin, stomach, thyroid, or uterus. As used herein, "intravenous administration" refers to delivery of a therapeutic directly into a vein. As used herein, a control refers to a sample that is substantially identical to the test sample, except that it is not treated with a test parameter, or, if it is a plasma sample, it can be from a normal volunteer not affected with the condition of interest. A control also can be an internal control. As used herein, normal levels or values can be defined in a variety of ways known to one of skill in the art. Typically, normal levels refer to the expression levels of a marker (e.g. adenosine, ADR or nucleosidase) across a healthy population. The normal levels (or reference levels) are based on measurements of healthy subjects, such as from a specified source (i.e., blood, serum, tissue, or other source). Often, a normal level will be specified as a "normal range", which typically refers to the range of values of the median 95% of the healthy population. Reference value is used interchangeably herein with normal level but can be different from normal levels depending on the subjects or the source. Reference levels are typically dependent on the normal levels of a particular segment of the population. Thus, for purposes herein, ٠ a normal or reference level is a predetermined standard or control by which a test patient can be compared. As used herein, elevated level refers to the any level of amount or expression of a marker above a recited or normal threshold. As used herein, biological sample refers to any sample obtained from a living or viral source or other source of macromolecules and biomolecules, and includes any cell type or tissue of a subject from which nucleic acid or protein or other macromolecule can be obtained. The biological sample can be a sample obtained directly from a biological source or to sample that is processed. For example, isolated nucleic acids that are amplified constitute a biological sample. Biological samples include, but are not limited to, body fluids, such as blood, plasma, serum, cerebrospinal fluid, synovial fluid, urine and sweat, and tissue and organ samples from animals, including biopsied tumor samples. As used herein, detection includes methods that permit visualization (by eye or equipment) of a protein or marker. A protein can be visualized using an antibody specific to the protein. Detection of a protein can also be facilitated by fusion of a protein with a tag including an epitope tag or label. As used herein, "treating" a subject with a disease or condition means that the subject's symptoms are partially or totally alleviated, or remain static following treatment. Hence treatment encompasses prophylaxis, therapy and / or cure. Prophylaxis refers to prevention of a potential disease and / or a prevention of worsening of symptoms or progression of a disease. As used herein, a pharmaceutically effective agent includes any therapeutic agent or bioactive agents, including, but not limited to, for example, chemotherapeutics, anesthetics, vasoconstrictors, dispersing agents, conventional therapeutic drugs, including small molecule drugs and therapeutic proteins. As used herein, treatment means any manner in which the symptoms of a condition, disorder or disease or other indication, are ameliorated or otherwise beneficially altered. As used herein, therapeutic effect means an effect resulting from treatment of a subject that alters, typically improves or ameliorates the symptoms of a disease or condition or that cures a disease or condition. A therapeutically effective amount refers to the amount of a composition, molecule or compound which results in a therapeutic effect following administration to a subject. As used herein, amelioration of the symptoms of a particular disease or disorder by a treatment, such as by administration of a pharmaceutical composition or other therapeutic, refers to any lessening, whether permanent or temporary, lasting or transient, of the symptoms or, adverse effects of a condition, such as, for example, reduction of adverse effects associated with or that occur upon administration of an ADA2, such as a variant ADA2. As used herein, prevention or prophylaxis refers to reduction in the risk of developing a disease or condition. As used herein, a "therapeutically effective amount" or a "therapeutically effective dose" refers to the quantity of an agent, compound, material, or composition containing a compound that is at least sufficient to produce a therapeutic effect. Hence, it is the quantity necessary for preventing, curing, ameliorating, arresting or partially arresting a symptom of a disease or disorder. As used herein, unit dose form refers to physically discrete units suitable for human and animal subjects and packaged individually as is known in the art. As used herein, the term "subject" refers to an animal, including a mammal, such as a human being. The subject can include any animal, such as, but are not limited to primates including humans, gorillas and monkeys; rodents, such as mice and rats; fowl, such as chickens; ruminants, such as goats, cows, deer, sheep; pigs and other animals. Non-human animals exclude humans as the contemplated animal. As used herein, a patient refers to a human subject exhibiting symptoms of a disease or disorder. As used herein, about the same means within an amount that one of skill in the art would consider to be the same or to be within an acceptable range of error. For example, typically, for pharmaceutical compositions, within at least 1%, 2%, 3%, 4%, 5% or 10% is considered about the same. Such amount can vary depending upon the tolerance for variation in the particular composition by subjects. As used herein, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a compound comprising or containing "an extracellular domain" includes compounds with one or a plurality of extracellular domains. As used herein, ranges and amounts can be expressed as "about" a particular value or range. About also includes the exact amount. Hence "about 5 bases" means "about 5 bases" and also "5 bases." As used herein, "optional" or "optionally" means that the subsequently described event or circumstance does or does not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. For example, an optionally substituted group means that the group is unsubstituted or is substituted. As used herein, the abbreviations for any protective groups, amino acids and other compounds, are, unless indicated otherwise, in accord with their common usage, recognized abbreviations, or the IUPAC-IUB Commission on Biochemical Nomenclature (see, (1972) Biochem. 11:1726). B. ADENOSINE DEAMINASE 2 (ADA2) AND MODULATION OF ADENOSINE-MEDIATED TUMOR IMMUNOSUPPRESSION Provided herein are methods of treating diseases or conditions such as a cancer or a tumor by administering any Adenosine Deaminase 2 (ADA2) protein, including variants or conjugates thereof, to a subject. Extracellular adenosine is responsible for the regulation of critical biological processes, such as immunomodulation (Blay, J. (2012) Encyclopedia of Cancer pp.49-52). In pathophysiological conditions such as the tumor microenvironment (TME), extracellular adenosine concentration rapidly increases in certain parts of the TME, generating an immunosuppressive niche that promotes tumor growth. ADA2 modulates adenosine levels in the extracellular environment, thereby affecting adenosine signaling and adenosine-dependent immunosuppression. ADA2 can decrease the extracellular adenosine levels by converting adenosine to inosine, to overcome the immunosuppressive effects in the TME. For example, as shown herein, administration of ADA2 can reverse the adenosine-dependent immunosuppression and can reduce tumor growth in vivo. 1. Tumor Immunity and Immune Evasion Cancerous cells contain tumor-specific antigens that are recognized by the immune system. In tumor immunity, the goal of the immune system is to attack and eradicate these cancerous cells through the actions of immune cells, including cytotoxic T cells, Natural Killer (NK) cells and macrophages. For example, CD4+ and CD8+ T cells can become activated upon recognition of antigenic peptides presented on antigen-presenting cells on major histocompatibility complex (MHC) class I or class II molecules, respectively. Activated CD8+ cells, or cytotoxic T cells, can kill tumor cells expressing the antigen, which can be helped by the presence of CD4+ T cells. In addition to the direct killing effects of cytotoxic T cells, T cells also produce various cytokines and chemokines that can recruit other effector immune cells, such as neutrophils, macrophages or NK cells to the tumor microenvironment. NK cells also can directly kill cancer cells. Studies have demonstrated that the immune system can prevent tumor growth. For example, immunodeficient mice develop more cancers than wild-type mice (Dunn et al. (2004) Immunity, 21:137-48). Lymphocytes and IFN-gamma have been shown to collaborate to prevent the formation of carcinogen-induced sarcoma and spontaneous epithelial carcinomas (Shankaran et al. (2001) Nature, 410:1107-1111). Further, gene-targeted and lymphocyte subset-depleted mice have demonstrated a role for NK cells in tumor rejection. For example, mice depleted for both NK and NK1.1+ T cells were found to have increased susceptibility to tumor formation compared to control mice, and a similar result was observed upon treatment of mice with antisialo- GM1, which selectively eliminates NK cells (Smyth et al. (2001) Int Immunol., 13;459-63). In addition, the number, type and location of tumor immune infiltrates in primary tumors are prognostic factors for survival of cancer in human patients (Pages et al. (2005) N Engl J Med, 353:2654-2666). Most tumors, however, can evade the immune system. The tumor microenvironment is complex, and includes a variety of immunosuppressive mechanisms that can be intrinsic to tumor cells or mediated by other cells or molecules. Through these mechanisms, alone or in combination, the immune system can promote tumor progression. These mechanisms include, but are not limited to, eliminating tumor cell antigens that elicit immune response; preventing or downregulating the expression of ligands required for immune activation, such as major histocompatibility complex class I (MHC I); production of immunosuppressive mediators, such as interleukin-10 (IL-10), transforming growth factor-β or adenosine; recruitment of immune cell subsets that suppress effector immune cell function, such as T regulatory cells (Tregs) or myeloid-derived suppressor cell (MDSC); or the upregulation of checkpoint inhibitors, such as cytotoxic T-lymphocyte antigen 4 (CTLA4), that can attenuate effector T-cell function. For example, adenosine is a prominent immunosuppressive agent in the tumor microenvironment. 2. Adenosine Immunomodulation in Cancer and Tumor Microenvironment (TME) Adenosine (adenine-9-β-D-ribofuranoside; Ado) is a nucleoside that exists as a part of adenine nucleotides (AMP, ADP, and ATP) which participate widely in cellular energy metabolism and act as precursor molecules in many processes. Adenosine can exist in the free form both inside and outside of cells. Adenosine is an important in vivo signaling molecule, especially for the immune system. In particular, adenosine is a well-known effector of immune function. In T-cells, adenosine decreases T-cell receptor induced activation of NF-kB, and inhibits IL-2, IL-4, and IFN-γ. Adenosine decreases T-cell cytotoxicity, increases T-cell anergy, and increases T-cell differentiation to Foxp3<com:Sup>+< / com:Sup> or Lag-3<com:Sup>+< / com:Sup> regulatory T cells. Adenosine decreases IFN-y production by NK cells and suppresses NK cell cytotoxicity. Adenosine blocks neutrophil adhesion and extravasation, decreases phagocytosis, and attenuates levels of superoxide and nitric oxide. Adenosine also decreases the expression of TNF-<com:Math><semantics>α<annotation encoding="application / x-tex">\alpha< / annotation>< / semantics>< / com:Math>, IL-12, and MIP-1<com:Math><semantics>α<annotation encoding="application / x-tex">\alpha< / annotation>< / semantics>< / com:Math> on macrophages, attenuates MHC Class II expression, and increases levels of IL-10 and IL-6. In addition, adenosine decreases phagocytosis and superoxide and nitric oxide levels on macrophages (Stagg and Smyth (2010) Oncogene 29:5346-5358). Figure 2 sets forth the biosynthesis and catabolism of adenosine. Extracellular adenosine is produced by the sequential activities of membrane associated ectoenzymes, CD39 and CD73, which together produce adenosine by phosphohydrolysis of ATP or ADP produced from dead or dying cells. CD39 (also called ectonucleoside triphosphate diphosphohydrolase; SEQ ID NO:542) converts extracellular ATP (or ADP) to 5'AMP. Then, CD73 (also called 5'nucleotidase; SEQ ID NO:543) converts 5'AMP to adenosine. The activity of CD39 is reversible by the actions of NDP kinase and adenylate kinase, whereas the activity of CD73 is irreversible. CD39 and CD73 are expressed on tumor stromal cells, including endothelial cells and Tregs, and also on many cancer cells. For example, the expression of CD39 and CD73 on endothelial cells is increased under the hypoxic conditions of the tumor microenvironment. Tumor hypoxia can result from inadequate blood supply and disorganized tumor vasculature, impairing delivery of oxygen (Carroll and Ashcroft (2005), Expert. Rev. Mol. Med. 7(6):1-16). Hypoxia also inhibits adenylate kinase (AK), which converts adenosine to AMP, leading to very high extracellular adenosine concentration. Thus, adenosine is released at high concentrations in response to hypoxia, which is a condition that frequently occurs the tumor microenvironment (TME), in or around solid tumors. Thus, while the concentration of adenosine is typically low in the tissues and blood, the local adenosine concentration can increase significantly as a result of damage or stress, e.g., inflammation, ischemia, and hypoxia. For example, the extracellular concentration of adenosine in the hypoxic tumor microenvironment can be up to 10 µM adenosine, which is up to about 100-fold higher than the typical extracellular adenosine concentration of approximately 0.1 µM (Antonioli et al. (2013) Nat Rev Can 13:842-857). Since the hypoxic regions in tumors are centered around the microvessels, the local concentration of adenosine in regions of the tumor can actually be higher. Adenosine immunomodulation activity occurs after its release into the extracellular space of the tumor and activation of adenosine receptors (ADRs) on the surface of target immune cells, cancer cells or endothelial cells. There are four types of ADRs, A<com:Sub>1< / com:Sub> (SEQ ID NO:533), A<com:Sub>2A< / com:Sub> (SEQ ID NO:534), A<com:Sub>2B< / com:Sub> (SEQ ID NO:535) and A<com:Sub>3< / com:Sub> (SEQ ID NOS:536-538), which are each G-protein coupled receptors with different affinity for adenosine and different downstream signaling pathways. Activation of the A<com:Sub>1< / com:Sub> and A<com:Sub>3< / com:Sub> receptors decrease intracellular cyclic AMP (cAMP) levels, and the activation of A<com:Sub>2A< / com:Sub> and A<com:Sub>2B< / com:Sub> receptors increase cAMP levels through the activation of adenylyl cyclase. Each of the <com:Math><semantics>A1<annotation encoding="application / x-tex">A_1< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>A2A<annotation encoding="application / x-tex">A_{2A}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>A3<annotation encoding="application / x-tex">A_3< / annotation>< / semantics>< / com:Math> can be activated at physiological concentrations of adenosine (e.g. 30-300 nM), but A<com:Sub>2B< / com:Sub> has a lower affinity for adenosine and requires higher levels of adenosine for activation (Stagg et al. (2010) Oncogene, 29:5346-5358). The result of activation of the ADRs differs depending on the cell type and the receptor type: it can lead to activation or suppression of cell function and cell death (Antonioli et al. (2013) Nat Rev Can 13:842-857). All four types of receptors can exist on cells in the tumor microenvironment, including on cancer cells, stromal cells, endothelial cells, and inflammatory and immune cells, and all can be activated at adenosine concentrations present in the tumor microenvironment. The high adenosine levels in the tumor microenvironment results in local immunosuppression, which limits the capacity of the immune system to eliminate cancer cells. For example, adenosine can suppress various functions of T lymphocytes, natural killer (NK) cells, polymorphonuclear granulocytes, and phagocytic cells such as tissue macrophages. In particular, the <com:Math><semantics>A2A<annotation encoding="application / x-tex">A_{2A}< / annotation>< / semantics>< / com:Math> receptor is known to be expressed on monocytes, macrophages, mast cells, granulocytes, lymphocytes, dendritic cells (DCs), NK cells and endothelial cells, and its expression on many cell types is induced by hypoxia (Stagg and Smyth (2010) Oncogene, 29:5346-5358). Activation of A<com:Sub>2A< / com:Sub> has been shown to suppress NK cell functions, inhibit T-cell proliferation, inhibit T cell cytotoxicity and cytokine production, and inhibit macrophage activation (Stagg and Smyth (2010); Antonioli et al. (2013)). Activation of A<com:Sub>2B< / com:Sub> has been shown to suppress DC differentiation to limit T cell activation and to promote expansion and accumulation of MSDC (Stagg and Smyth (2010); Antonioli et al. (2013)). In addition to direct effects to inhibit the immune system, adenosine also can control cancer cell growth and dissemination by effects on cancer cell proliferation, apoptosis and angiogenesis. For example, adenosine can promote angiogenesis, primarily through the stimulation of <com:Math><semantics>A2A<annotation encoding="application / x-tex">A_{2A}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>A2B<annotation encoding="application / x-tex">A_{2B}< / annotation>< / semantics>< / com:Math> receptors. Stimulation of the receptors on endothelial cells can regulate the expression of intercellular adhesion molecule 1 (ICAM-1) and E-selectin on endothelial cells, maintain vascular integrity, and promote vessel growth (Antonioli et al. (2013)). In addition, activation of one or more of A<com:Sub>2A< / com:Sub>, A<com:Sub>2B< / com:Sub> or A<com:Sub>3< / com:Sub> on various cells by adenosine can stimulate the production of the pro-angiogenic factors, such as vascular endothelial growth factor (VEGF), interleukin-8 (IL-8) or angiopoietin 2 (Antonioli et al. (2013)). • Adenosine also can directly regulate tumor cell proliferation, apoptosis and metastasis through interaction with receptors on cancer cells. For example, studies have shown that the activation of <com:Math><semantics>A1<annotation encoding="application / x-tex">A_1< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>A2A<annotation encoding="application / x-tex">A_{2A}< / annotation>< / semantics>< / com:Math> receptors promote tumor cell proliferation in some breast cancer cell lines, and activation of A<com:Sub>2B< / com:Sub> receptors have cancer growth-promoting properties in colonic carcinoma cells (Antonioli et al. (2013)). Adenosine also can trigger apoptosis of cancer cells, and various studies have correlated this activity to activation of the extrinsic apoptotic pathway through <com:Math><semantics>A3<annotation encoding="application / x-tex">A_3< / annotation>< / semantics>< / com:Math> or the intrinsic apoptotic pathway through <com:Math><semantics>A2A<annotation encoding="application / x-tex">A_{2A}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>A2B<annotation encoding="application / x-tex">A_{2B}< / annotation>< / semantics>< / com:Math> (Antonioli et al. (2013)). In addition, adenosine can promote tumor cell migration and metastasis, by increasing cell motility, adhesion to the extracellular matrix, and expression of cell attachment proteins and receptors to promote cell movement motility. 3. Adenosine Deaminase and Targeting Adenosine in Treatment of Cancer The levels of adenosine can be regulated by the actions of adenosine deaminase (ADA), which is an enzyme that converts adenosine to inosine or 2'- deoxyadenosine to 2'-deoxyinosine. In particular, ADA converts either adenosine or deoxyadenosine, in the presence or water, into inosine or dexoyinosine and ammonia as follows: adenosine <com:Math><semantics>+H2O=inosine+NH3<annotation encoding="application / x-tex">+ H_2O = inosine + NH_3< / annotation>< / semantics>< / com:Math> or 2'-deoxyadenosine <com:Math><semantics>+H2O=2<annotation encoding="application / x-tex">+ H_2O = 2< / annotation>< / semantics>< / com:Math>'- deoxyinosine + NH<com:Sub>3< / com:Sub>. The increase in ammonia in the local tumor microenvironment can increase the pH. There are two types of ADA in humans, ADA1 and ADA2. ADA1 is ubiquitously present inside cells, and exhibits a similar binding affinity for adenosine and 2'deoxyadenosine with a Km of about 5.2 x 10<com:Sup>-5< / com:Sup> M. ADA1 principally functions intracellularly, to reduce the levels of adenosine that can be toxic to cells, such as lymphocytes. For example, deficiency of adenosine deaminase 1 (ADA1) is associated with mild immunodeficiency to severe combi...

Claims

CLAIMS:

1. A wild-type Adenosine Deaminase 2 (ADA2) protein or a catalytically active portion thereof for use for treating a tumor, a cancer, a non-cancer hyperproliferative disease, a fibrotic disease, an infectious disease, a vasculopathy, or an immunodeficiency disease, wherein the ADA2 protein or catalytically active portion thereof comprises a sequence of amino acids selected from the group consisting of: a) the sequence of amino acids set forth in any one of SEQ ID NOS: 326-336, 338-342, and 375; b) the sequence of amino acids set forth in any one of SEQ ID NOS: 326-336, 338-342, and 375, with all or a part of the ADA2 putative receptor binding domain (PRB domain) deleted; c) the sequence of amino acids set forth in any one of SEQ ID NOS: 326-336, 338-342, and 375, with all or a part of the ADA2 putative receptor binding domain (PRB domain) deleted and a linker in place of the deleted residues; d) the ADA2 catalytic domain of any one of SEQ ID NOS: 326-336, 338-342, and 375; e) the ADA2 catalytic domain of any one of SEQ ID NOS: 326-336, 338-342, and 375, with all or a part of the PRB domain deleted; f) the ADA2 catalytic domain of any one of SEQ ID NOS: 326-336, 338-342, and 375, with all or a part of the PRB domain deleted and a linker in place of the deleted residues; g) the ADA2 catalytic domain of any one of SEQ ID NOS: 326-336, 338-342, and 375; h) the ADA2 catalytic domain of any one of SEQ ID NOS: 326-336, 338-342, and 375, with all or a part of the PRB domain deleted; and i) the ADA2 catalytic domain of any one of SEQ ID NOS: 326-336, 338-342, and 375, with all or a part of the PRB domain deleted and a linker in place of the deleted residues, wherein the PRB domain consists of residues corresponding to residues 98-156 of SEQ ID NO:5, wherein the linker is <com:Math><semantics>(GGGGS)n<annotation encoding="application / x-tex">(GGGGS)_n< / annotation>< / semantics>< / com:Math>, where <com:Math><semantics>n=1−5<annotation encoding="application / x-tex">n = 1-5< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>(Gly)n<annotation encoding="application / x-tex">(Gly)_n< / annotation>< / semantics>< / com:Math>, where <com:Math><semantics>n=2−20<annotation encoding="application / x-tex">n = 2-20< / annotation>< / semantics>< / com:Math>, and wherein the ADA2 catalytic domain consists of residues corresponding to residues 77- 473 of the sequence of amino acids set forth in SEQ ID NO:

5.

2. The ADA2 protein or catalytically active portion thereof for use of claim 1 comprising the sequence of amino acids set forth in any one of SEQ ID NOS: 326-336, 338-342, and 375.

3. The ADA2 protein or catalytically active portion thereof for use of any one of claims 1-2 with all or a portion of the PRB domain deleted.

4. The ADA2 protein or catalytically active portion thereof for use of any one of claims 1-3 with all or a portion of the PRB domain deleted and the linker in place of the deleted residues.

5. The ADA2 protein or catalytically active portion thereof for use of any one of claims 1-4, wherein the ADA2 protein or a catalytically active portion thereof comprises: a) the sequence of amino acids set forth in any one of SEQ ID NOs: 326-336, 338-342, and 375 with all or a part of the PRB domain deleted; b) the ADA2 catalytic domain of any one of SEQ ID NOs: 326-336, 338-342, and 375, with all or a part of the PRB domain deleted; or c) the ADA2 catalytic domain of any one of SEQ ID NOs: 326-336, 338-342, and 375 with all or a part of the PRB domain deleted.

6. The ADA2 protein or catalytically active portion thereof of any one of claims 1-5, wherein the ADA2 protein or catalytically active portion thereof lacks residues N98-N156, C105-E148, C105-T147, or V99-Q144, and optionally, includes the linker in place thereof.

7. The ADA2 protein or the catalytically active portion thereof for use of any one of claims 1-6, wherein the ADA2 protein comprises the sequence of amino acids set forth in any one of SEQ ID NOs: 326-336, 338-342, and 375, or is the catalytically active portion of the ADA2 protein.

8. The ADA2 protein for use of any one of claims 1-7, wherein the ADA2 protein consists of the sequence of amino acids set forth in any one of SEQ ID NOs: 326-336, 338-342, and 375, or is the catalytically active portion of the ADA2 protein.

9. The ADA2 protein or the catalytically active portion thereof for use of any one of claims 1-8, wherein the ADA2 protein or the catalytically active portion thereof is PEGylated.

10. The ADA2 protein or the catalytically active portion thereof for use of any one of claims 1-9, wherein the catalytically active portion of the ADA2 protein comprises the ADA2 catalytic domain that corresponds to residues 77-473 of the sequence of amino acids set forth in SEQ ID NO:

5.

11. An ADA2 multimer, comprising a plurality of ADA2 proteins or the catalytically active portions thereof for use of any one of claims 1-10, wherein the ADA2 proteins or the catalytically active portions thereof are the same or different.

12. An ADA2 dimer, comprising the ADA2 protein or the catalytically active portion thereof for use of any one of claims 1-10.

13. The ADA2 dimer for use of claim 12, wherein the ADA2 dimer is a homodimer comprising two ADA2 proteins or catalytically active portions thereof that are the same.

14. The ADA2 dimer for use of claim 12, wherein the ADA2 dimer is a homodimer comprising two ADA2 proteins or catalytically active portions thereof that are different.

15. A conjugate, comprising the ADA2 protein or the catalytically active portion thereof for use of any one of claims 1-10, or the multimer for use of claim 11, or the dimer for use of any one of claims 12-14, wherein the ADA2 protein or the catalytically active portion thereof is linked directly or indirectly via a linker to a heterologous moiety.

16. The ADA2 protein or the catalytically active portion thereof for use of any one of claims 1-10, or the multimer for use of claim 11, or the dimer for use of any one of claims 12-14, or the conjugate for use of claim 15 for treating cancer.

17. A cell or cells comprising a vector comprising nucleic acid encoding the ADA2 protein or the catalytically active portion thereof for use of any one of claims 1-10, or the multimer for use of claim 11, or the dimer for use of any one of claims 12-14, or the conjugate for use of claim 15 for treating cancer.

18. The cell or cells for use of claim 17, wherein the cell is a tumor-infiltrating lymphocyte (TIL), a cytotoxic T lymphocyte (CTL), a natural killer (NK) cell, or a lymphokine- activated killer (LAK) cell.

19. The cell or cells for use of claim 18, that is / are a T cell(s) that encode(s) and express(es): a chimeric antigen receptor (CAR) that is specific for a tumor cell antigen; and the ADA2 protein or the catalytically active portion thereof, or the ADA2 multimer, or the ADA2 dimer.

20. A pharmaceutical composition, comprising the ADA2 protein or the catalytically active portion thereof for use of any one of claims 1-10, or the multimer for use of claim 11, or the dimer for use of any one of claims 12-14, or the conjugate for use of claim 15, in a pharmaceutically acceptable vehicle.

21. A kit for use for treating cancer, comprising: (a) the ADA2 protein or the catalytically active portion thereof for use of any one of claims 1-10, or the multimer for use of claim 11, or the dimer for use of any one of claims 12-14, or the conjugate for use of claim 15; and (b) optionally including instructions for use.

Citation Information

Patent Citations

  • Cytokine which is a ligand for OX40

    US5457035A

  • Thomas blancharjq

    US5A

  • Human monoclonal antibodies to programmed death ligand 1 (PD-L1)

    US7943743B2

  • Adenosine deaminase anticancer therapy

    US8741283B2